<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2489936</PMID><DateCompleted><Year>1989</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>10</Issue><PubDate><Year>1989</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Thought disorder in the relatives of psychotic patients.</ArticleTitle><Pagination><MedlinePgn>897-901</MedlinePgn></Pagination><Abstract><AbstractText>Using the Holzman-Johnston Thought Disorder Index, thought disorder was examined in the first-degree relatives of schizophrenic, manic, and schizoaffective patients. In all three groups, there was a tendency for probands with higher thought disorder to have first-degree relatives with higher thought disorder. Furthermore, the quality of thought disorder in the groups of relatives was similar to that in the groups of probands, although it was clear that the relatives of schizoaffective-manic patients showed the highest amount of thought disorder, which was not found in the proband sample. Although based on a small sample, these findings suggest that amount and type of thought disorder differ not only among medicated patient groups but also among their unmedicated relatives.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shenton</LastName><ForeName>M E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans Administration Medical Center, Brockton, Mass.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solovay</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Holzman</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gale</LastName><ForeName>H J</ForeName><Initials>HJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 31154</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH31340</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Gen Psychiatry. 1991 Mar;48(3):280-2</RefSource><PMID Version="1">1996923</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="Y">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2489936</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1989.01810100039007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17445513</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0010-440X</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>3</Issue><PubDate><MedlineDate>2007 May-Jun</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Is unipolar mania a distinct subtype?</ArticleTitle><Pagination><MedlinePgn>213-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Some recent reports raised the question whether unipolar mania, without severe or mild depression, really exists and whether it defines a distinct disorder. Literature on this topic is still scarce, although this was a matter of debate since several decades.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Eighty-seven inpatients with Diagnostic and Statistical Manual of Mental Disorder, Revised Third Edition, manic episode and at least 3 major affective episodes, in 10 years of illness duration, were systematically evaluated to collect demographic and clinical information. The symptomatological evaluation was conducted by means of the Comprehensive Psychopathological Rating Scale. Clinical features, social disability, first-degree family history, and temperaments were compared between unipolar and bipolar manics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nineteen (21.8%) of 87 patients presented a course of illness characterized by recurrent unipolar manic episodes without history of major or mild depression (MAN). When this group was compared with 68 (78.2%) manic patients with a previous history of depressive episodes (BIP), we found substantial similarities in most demographic, familial, and clinical characteristics. MAN group reported more congruent psychotic symptoms and more frequent chronic course of the current episode in comparison to BIP group. In the MAN patients, we also observed a high percentage of hyperthymic temperament and a complete absence of depressive temperament. This latter difference was statistically significant. MAN patients compared with BIP ones also reported lower severity scores in social, familial, and work disability, and they showed less depressive features, hostility, and anxiety.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The numerous demographic, clinical, and psychopathological overlapping characteristics in unipolar and bipolar mania raise questions about the general nosographic utility of this categorization. Nonetheless, our data suggest a clinical and prognostic validity of keeping unipolar manic patients as a separate subgroup, in particular, as social adjustment and disability are concerned.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perugi</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pisa, 56100 Pisa, Italy. g.perugi@psico.med.unipi.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passino</LastName><ForeName>M Chiara Sanna</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Toni</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Maremmani</LastName><ForeName>Icro</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>Jules</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012494" MajorTopicYN="N">Sampling Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="N">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>09</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>12</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>01</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17445513</ArticleId><ArticleId IdType="pii">S0010-440X(07)00012-0</ArticleId><ArticleId IdType="doi">10.1016/j.comppsych.2007.01.004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8401957</PMID><DateCompleted><Year>1993</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>163</Volume><PubDate><Year>1993</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Genotypes, phenotypes, and the brain. A search for connections in schizophrenia.</ArticleTitle><Pagination><MedlinePgn>299-307</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>M T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Harvard Department of Psychiatry, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1 R37MH43518-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1 RO1MH41874-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="Y">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>60</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8401957</ArticleId><ArticleId IdType="pii">S0007125000049175</ArticleId><ArticleId IdType="doi">10.1192/bjp.163.3.299</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3884739</PMID><DateCompleted><Year>1985</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>173</Volume><Issue>4</Issue><PubDate><Year>1985</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>A clinically relevant guide to the differential diagnosis of depression.</ArticleTitle><Pagination><MedlinePgn>199-211</MedlinePgn></Pagination><Abstract><AbstractText>Reviewing the current literature on affective disorders reveals controversy and confusion at the most fundamental levels of terminology and description. A valid, etiologically and pathophysiologically grounded nosology has not as yet emerged. To the practicing clinician, the therapeutic and prognostic significance of the various diagnostic categories is of greatest interest. In this paper, those diagnostic categories with the most clearly demonstrated and empirically supported therapeutic and prognostic significance are outlined in a flow sheet format with accompanying text. Areas of diagnostic overlap and terminological confusion are delineated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sinaikin</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006117" MajorTopicYN="N">Grief</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008370" MajorTopicYN="N">Manuals as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>131</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3884739</ArticleId><ArticleId IdType="doi">10.1097/00005053-198504000-00001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19222987</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Overdiagnosis and underdiagnosis of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>143; author reply 144</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ej701letters</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manning</LastName><ForeName>Sloan J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Kane</LastName><ForeName>Michelle E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Clin Psychiatry. 2008 Jun;69(6):935-40</RefSource><PMID Version="1">18466044</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19222987</ArticleId><ArticleId IdType="pii">ej701letters</ArticleId><ArticleId IdType="doi">10.4088/jcp.08lr04522</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24855890</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1601-5215</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Acta neuropsychiatrica</Title><ISOAbbreviation>Acta Neuropsychiatr</ISOAbbreviation></Journal><ArticleTitle>Are oxidative stress markers useful to distinguish schizoaffective disorder from schizophrenia and bipolar disorder?</ArticleTitle><Pagination><MedlinePgn>120-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/neu.2013.44</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Schizoaffective disorder is a disease with both affective and psychotic symptoms. In this study, we aimed to compare oxidative metabolism markers of schizoaffective disorder, bipolar disorder and schizophrenic patients. Furthermore, we also aimed to investigate whether schizoaffective disorder could be differentiated from schizophrenia and bipolar disorder in terms of oxidative metabolism.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Total oxidant status (TOS) and total antioxidant status (TAS) were measured in the blood samples that were collected from schizoaffective patients (n = 30), bipolar disorder patients (n = 30) and schizophrenic patients (n = 30). Oxidative stress index (OSI) was calculated by dividing TOS by TAS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">TOS and OSI were found to be higher in patients with schizoaffective disorder compared with those in schizophrenia and bipolar disorder patients. TAS was not significantly different between the groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Schizoaffective disorder was found to be different from bipolar disorder and schizophrenia in terms of oxidative parameters. This result may indicate that schizoaffective disorder could differ from bipolar disorder and schizophrenia in terms of biochemical parameters. Increased TOS levels observed in schizoaffective disorder may suggest poor clinical course and may be an indicator of poor prognosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bulbul</LastName><ForeName>Feridun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>1 Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Virit</LastName><ForeName>Osman</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>1 Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alpak</LastName><ForeName>Gokay</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1 Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unal</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1 Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bulut</LastName><ForeName>Mahmut</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>2 Department of Psychiatry, School of Medicine, Dicle University, Dicle, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaya</LastName><ForeName>Mehmet Cemal</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>2 Department of Psychiatry, School of Medicine, Dicle University, Dicle, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altindag</LastName><ForeName>Abdurrahman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>3 Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celik</LastName><ForeName>Hakim</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>4 Department of Biochemistry, School of Medicine, Harran University, Harran, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savas</LastName><ForeName>Haluk A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>3 Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropsychiatr</MedlineTA><NlmUniqueID>9612501</NlmUniqueID><ISSNLinking>0924-2708</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24855890</ArticleId><ArticleId IdType="pii">S0924270813000446</ArticleId><ArticleId IdType="doi">10.1017/neu.2013.44</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28612649</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1089-4098</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>10</Month></PubDate></JournalIssue><Title>The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry</Title><ISOAbbreviation>Neuroscientist</ISOAbbreviation></Journal><ArticleTitle>A Brain on a Roller Coaster: Can the Dopamine Reward System Act as a Protagonist to Subdue the Ups and Downs of Bipolar Disorder?</ArticleTitle><Pagination><MedlinePgn>423-439</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1073858417714226</ELocationID><Abstract><AbstractText>One of the most interesting but tenebrous parts of the bipolar disorder (BD) story is the switch between (hypo)mania and depression, which can give bipolar patients a thrilling, but somewhat perilous, 'ride'. Numerous studies have pointed out that there are some recognizable differences (either state-dependent or state-independent) in several brain regions of people with BD, including components of the brain's reward system. Understanding the underpinning mechanisms of high and low mood statuses in BD has potential, not only for the development of highly specific and selective pharmaceutical agents, but also for better treatment approaches and psychological interventions to manage BD and, thus, give patients a safer ride. Herein, we review evidence that supports involvement of the reward system in the pathophysiology of mood swings, with the main focus on the mesocorticolimbic dopaminergic neural circuitry. Principally using findings from neuroimaging studies, we aim to signpost readers as to how mood alterations may affect different areas of the reward system and how antipsychotic drugs can influence the activity of these brain areas. Finally, we critically evaluate the hypothesis that the mesocorticolimbic dopamine reward system may act as a functional rheostat for different mood states.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arjmand</LastName><ForeName>Shokouh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 Kerman Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behzadi</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1 Kerman Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>Gary J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>2 School of Pharmacy, Reading University, Whiteknights, Reading, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezzatabadipour</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 Kerman Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seifaddini</LastName><ForeName>Rostam</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>3 Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arjmand</LastName><ForeName>Shahrad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>4 Department of Psychology, Shahid Bahonar University of Kerman, Kerman, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shabani</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1 Kerman Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuroscientist</MedlineTA><NlmUniqueID>9504819</NlmUniqueID><ISSNLinking>1073-8584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">(hypo)mania</Keyword><Keyword MajorTopicYN="Y">antipsychotics</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">depression</Keyword><Keyword MajorTopicYN="Y">dopamine reward system</Keyword><Keyword MajorTopicYN="Y">structural and functional neuroimaging studies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28612649</ArticleId><ArticleId IdType="doi">10.1177/1073858417714226</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2282885</PMID><DateCompleted><Year>1991</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0412-4057</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>5</Issue><PubDate><Year>1990</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry</Title><ISOAbbreviation>Zhonghua Shen Jing Jing Shen Ke Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Melatonin in seasonal affective disorder].</ArticleTitle><Pagination><MedlinePgn>306-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>N F</ForeName><Initials>NF</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>B H</ForeName><Initials>BH</Initials></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Z Y</ForeName><Initials>ZY</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Shen Jing Jing Shen Ke Za Zhi</MedlineTA><NlmUniqueID>16210510R</NlmUniqueID><ISSNLinking>0412-4057</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>JL5DK93RCL</RegistryNumber><NameOfSubstance UI="D008550">Melatonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008550" MajorTopicYN="N">Melatonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010789" MajorTopicYN="N">Phototherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>17</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2282885</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10609101</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>25 Spec No 4</Volume><PubDate><Year>1999</Year><Month>Nov</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Epidemiology of humor perception disorders in schizophrenia].</ArticleTitle><Pagination><MedlinePgn>2-3</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Canceil</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Service Hospitalo-Universitaire de Santé Mentale et Thérapeutique, Hôpital Sainte-Anne, Paris.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouillon</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Epidémiologie des troubles de l'humeur dans la schizophrénie.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>12</Month><Day>28</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>12</Month><Day>28</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10609101</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10710967</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2941</ISSN><JournalIssue CitedMedium="Print"><Volume>85</Volume><Issue>3 Pt 2</Issue><PubDate><Year>1999</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Psychological reports</Title><ISOAbbreviation>Psychol Rep</ISOAbbreviation></Journal><ArticleTitle>Depressive and manic tendencies in high school and college students.</ArticleTitle><Pagination><MedlinePgn>1118</MedlinePgn></Pagination><Abstract><AbstractText>A sample of 101 high school students obtained higher mania scores than, but did not differ in depression scores from, a sample of 504 college students.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burge</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Richard Stockton College of New Jersey, Pomona 08240-0195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lester</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychol Rep</MedlineTA><NlmUniqueID>0376475</NlmUniqueID><ISSNLinking>0033-2941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Psychol Rep. 1994 Oct;75(2):984</RefSource><PMID Version="1">7862811</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013334" MajorTopicYN="N">Students</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10710967</ArticleId><ArticleId IdType="doi">10.2466/pr0.1999.85.3f.1118</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10401516</PMID><DateCompleted><Year>1999</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>7</Issue><PubDate><Year>1999</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Factor analysis of mania.</ArticleTitle><Pagination><MedlinePgn>671-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rietschel</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lattuada</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Krauss</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Held</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Nöthen</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Smeraldi</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>7</Month><Day>13</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>7</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10401516</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.56.7.671</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6867235</PMID><DateCompleted><Year>1983</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0048-5764</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>1983</Year><Season>Spring</Season></PubDate></JournalIssue><Title>Psychopharmacology bulletin</Title><ISOAbbreviation>Psychopharmacol Bull</ISOAbbreviation></Journal><ArticleTitle>Lithium-induced behavior changes in children with symptoms suggesting manic-depressive illness.</ArticleTitle><Pagination><MedlinePgn>258-65</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeLong</LastName><ForeName>G R</ForeName><Initials>GR</Initials></Author><Author ValidYN="Y"><LastName>Nieman</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychopharmacol Bull</MedlineTA><NlmUniqueID>0101123</NlmUniqueID><ISSNLinking>0048-5764</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002653" MajorTopicYN="N">Child Behavior Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1983</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1983</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1983</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6867235</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12888852</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0327-6139</ISSN><JournalIssue CitedMedium="Print"><Volume>14 Suppl Spec</Volume><PubDate><Year>2003</Year></PubDate></JournalIssue><Title>Vertex (Buenos Aires, Argentina)</Title><ISOAbbreviation>Vertex</ISOAbbreviation></Journal><ArticleTitle>[A likely course of bipolar disorder: restituto ad integrum or defect. Second part].</ArticleTitle><Pagination><MedlinePgn>13-5</MedlinePgn></Pagination><Abstract><AbstractText>Although the more favorable prognosis was essential to bipolar disorder, persisting alterations concerning psychosocial functioning and psychopathology are not rare. A number of patients develops persistent impairment, a fact that refers to the initial 25% of patients shown in the literature (through naturalistic and long-term studies) as having poor recovery. Present studies intend to correlate with a neuroanatomy and a neuropsychology of bipolar disorder. It has been suggested that neuropsychological impairment persists during the euthymic state but has been confounded partly by mild affective symptoms in remitted patients (we emphasize the importance of treating bipolar depression).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Epstein</LastName><ForeName>Ana Judit</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>La evolución cierta del trastorno bipolar: restitutio ad integrum o defecto. Segunda parte.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Vertex</MedlineTA><NlmUniqueID>9440528</NlmUniqueID><ISSNLinking>0327-6139</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12888852</ArticleId><ArticleId IdType="pii">040579197</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17476362</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1180-4882</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of psychiatry &amp; neuroscience : JPN</Title><ISOAbbreviation>J Psychiatry Neurosci</ISOAbbreviation></Journal><ArticleTitle>Is bipolar disorder a mitochondrial disease?</ArticleTitle><Pagination><MedlinePgn>160-1</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young</LastName><ForeName>L Trevor</ForeName><Initials>LT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Psychiatry Neurosci</MedlineTA><NlmUniqueID>9107859</NlmUniqueID><ISSNLinking>1180-4882</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical><Chemical><RegistryNumber>020IUV4N33</RegistryNumber><NameOfSubstance UI="D010725">Phosphocreatine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028361" MajorTopicYN="N">Mitochondrial Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010725" MajorTopicYN="N">Phosphocreatine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17476362</ArticleId><ArticleId IdType="pmc">PMC1863554</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hum Mol Genet. 2005 Jan 15;14(2):241-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15563509</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bioenerg Biomembr. 1997 Apr;29(2):131-49</Citation><ArticleIdList><ArticleId IdType="pubmed">9239539</ArticleId></ArticleIdList></Reference><Reference><Citation>NeuroRx. 2006 Jan;3(1):22-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16490411</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2006 May;31(3):189-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16699605</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jun 1;59(11):1006-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16487491</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2006 Sep;79(3):586-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16909399</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2007 Feb 23;144(4):1447-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17184924</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2001 Feb;27(2):181-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11175786</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 1):180-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11256685</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2001;15(4):287-310</Citation><ArticleIdList><ArticleId IdType="pubmed">11463134</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2003 Feb;111(3):303-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12569152</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2003 Jul-Aug;37(4):287-95</Citation><ArticleIdList><ArticleId IdType="pubmed">12765851</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Mar;61(3):300-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14993118</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2004 Mar;88(6):1477-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15009649</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Neurobiol. 2005;63:21-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15797464</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3535545</PMID><DateCompleted><Year>1986</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>143</Volume><Issue>11</Issue><PubDate><Year>1986</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Sedative or antimanic effects of carbamazepine and treatment of behavioral dyscontrol.</ArticleTitle><Pagination><MedlinePgn>1486-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>W M</ForeName><Initials>WM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="Y">Sleep</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3535545</ArticleId><ArticleId IdType="doi">10.1176/ajp.143.11.aj143111486</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25937504</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>66-67</Volume><PubDate><MedlineDate>2015 Jul-Aug</MedlineDate></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Predictors of switch from depression to mania in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>45-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2015.04.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3956(15)00117-X</ELocationID><Abstract><AbstractText>Manic switch is a relevant issue when treating bipolar depression. Some risk factors have been suggested, but unequivocal findings are lacking. We therefore investigated predictors of switch from depression to mania in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) sample. Manic switch was defined as a depressive episode followed by a (hypo)manic or mixed episode within the following 12 weeks. We assessed possible predictors of switch using generalized linear mixed models (GLMM). 8403 episodes without switch and 512 episodes with switch (1720 subjects) were included in the analysis. Several baseline variables were associated with a higher risk of switch. They were younger age, previous history of: rapid cycling, severe manic symptoms, suicide attempts, amphetamine use and some pharmacological and psychotherapeutic treatments. During the current depressive episode, the identified risk factors were: any possible mood elevation, multiple mania-associated symptoms with at least moderate severity, and comorbid panic attacks. In conclusion, our study suggests that both characteristics of the disease history and clinical features of the current depressive episode may be risk factors for manic switch. </AbstractText><CopyrightInformation>Copyright © 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Niitsu</LastName><ForeName>Tomihisa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy; Research Center for Child Mental Development, Chiba University Graduate School of Medicine, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabbri</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy. Electronic address: alessandro.serretti@unibo.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2N01MH080001-001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016584" MajorTopicYN="N">Panic Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amphetamine use</Keyword><Keyword MajorTopicYN="N">Bipolar depression</Keyword><Keyword MajorTopicYN="N">Manic switch</Keyword><Keyword MajorTopicYN="N">Manic symptom</Keyword><Keyword MajorTopicYN="N">Onset</Keyword><Keyword MajorTopicYN="N">Panic attack</Keyword><Keyword MajorTopicYN="N">Rapid-cycling</Keyword><Keyword MajorTopicYN="N">Suicide</Keyword><Keyword MajorTopicYN="N">Venlafaxine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>04</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>04</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25937504</ArticleId><ArticleId IdType="pii">S0022-3956(15)00117-X</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2015.04.014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8464576</PMID><DateCompleted><Year>1993</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-842X</ISSN><JournalIssue CitedMedium="Print"><Volume>90</Volume><Issue>2</Issue><PubDate><Year>1993</Year><Month>Feb</Month></PubDate></JournalIssue><Title>New Jersey medicine : the journal of the Medical Society of New Jersey</Title><ISOAbbreviation>N J Med</ISOAbbreviation></Journal><ArticleTitle>Mood disorders: diagnosis and treatment in the 1990s.</ArticleTitle><Pagination><MedlinePgn>124-7</MedlinePgn></Pagination><Abstract><AbstractText>We all experience fluctuations in mood. There are some persons who experience severe, persistent, or cyclical changes of mood. When this interferes with functioning, it may be a manifestation of those psychiatric illnesses known as mood disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reiter</LastName><ForeName>S R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Summit Psychiatric and Counseling Associates, NJ 07901.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N J Med</MedlineTA><NlmUniqueID>8511653</NlmUniqueID><ISSNLinking>0885-842X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8464576</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19339914</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2009</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5873</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychiatric genetics</Title><ISOAbbreviation>Psychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>First evidence of association between G72 and bipolar disorder in the Chinese Han population.</ArticleTitle><Pagination><MedlinePgn>151-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YPG.0b013e32832a50f1</ELocationID><Abstract><AbstractText>The G72/G30 (D-amino-acid oxidase activator) complex was the first gene to be associated with bipolar disorder (BPD) in European populations, but until now no such association has been identified in Asian populations. To investigate possible association in the Chinese Han population, we carried out a study involving 475 BPD patients and 588 healthy controls. The results provide first evidence for the single nucleotide polymorphism rs778293 in G72 as a potential candidate in altering risk for BPD in the Chinese Han population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Changing Institute of Mental Health, Institute of Neuropsychiatric Science and Systems Biological Medicine, Xiehe Road 299, Bio-X Center Hospital, Bio-X Center, Shanghai Jiao Tong University, Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>You</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Qian</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ke</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Peng</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Sheng</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Guoyin</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Lindpaintner</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yongyong</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychiatr Genet</MedlineTA><NlmUniqueID>9106748</NlmUniqueID><ISSNLinking>0955-8829</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="Y">Ethnic Groups</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19339914</ArticleId><ArticleId IdType="doi">10.1097/YPG.0b013e32832a50f1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1479134</PMID><DateCompleted><Year>1993</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>1992</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy.</ArticleTitle><Pagination><MedlinePgn>223-30</MedlinePgn></Pagination><Abstract><AbstractText>Brain phosphorus metabolism was measured in 22 patients with depressive disorders. Ten of them had DSM-III-R bipolar disorder, and 12 had major depression. In bipolar patients, phosphomonoester (PME) and intracellular pH were significantly increased in the depressive state than in the euthymic state, while those values in the euthymic state were significantly low as compared to age-matched normal controls. Phosphocreatine (PCr) was significantly decreased in severely depressed patients compared to mild depressives. These findings suggest that high energy phosphate metabolism, intracellular pH and membrane phospholipid metabolism are altered in depressive disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Shiga University of Medical Science, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Shioiri</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Inubushi</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>020IUV4N33</RegistryNumber><NameOfSubstance UI="D010725">Phosphocreatine</NameOfSubstance></Chemical><Chemical><RegistryNumber>27YLU75U4W</RegistryNumber><NameOfSubstance UI="D010758">Phosphorus</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="Y">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010725" MajorTopicYN="N">Phosphocreatine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010758" MajorTopicYN="N">Phosphorus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1479134</ArticleId><ArticleId IdType="pii">0165-0327(92)90099-R</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(92)90099-r</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11559864</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0010-440X</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>5</Issue><PubDate><MedlineDate>2001 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Bipolar II and unipolar comorbidity in 153 outpatients with social phobia.</ArticleTitle><Pagination><MedlinePgn>375-81</MedlinePgn></Pagination><Abstract><AbstractText>Previous studies on social phobia (SP) have focused largely on comorbidity between SP and major depression. Less attention has been devoted to the comorbidity between SP and bipolar disorder. In this retrospective study, we investigated family history, lifetime comorbidity, and demographic and clinical characteristics among 153 outpatients who met DSM-III-R diagnostic criteria for SP. Information regarding axis I diagnoses was obtained using the Structured Clinical Interview for DSM III-R (SCID-UP-R). Social phobic symptoms and the severity of the illness were assessed by the Liebowitz Social Anxiety Scale (LSAS) and the Liebowitz Social Phobic Disorders Rating Scale, Severity (LSPDRS). Patients completed the Hopkins Symptom Checklist (HSCL 90). Fourteen patients (9.1%) satisfied DSM-III-R criteria for lifetime bipolar disorder not otherwise specified (NOS) (bipolar II), while 71 (46.4%) had unipolar major depression and 68 (44.4%) had no lifetime history of major mood disorders. Comorbid panic disorder/agoraphobia (PDA), obsessive-compulsive disorder (OCD), and alcohol abuse were reported more frequently in the bipolar group than in the other two subgroups. Unipolar patients showed higher rates of comordid PDA and OCD compared with SP patients without mood disorders. Severity and generalization of the SP symptoms, prevalent interactional anxiety, multiple comorbidity, and alcohol abuse appeared to be the most relevant consequences of SP-bipolar coexistence. In a significant minority of cases, protracted social anxiety may hypothetically have represented, along with inhibited depression, the dimensional opposite of gregarious hypomania.</AbstractText><CopyrightInformation>Copyright 2001 by W.B. Saunders Company</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perugi</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pisa, Via Roma 67, 56100 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frare</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Toni</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mata</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>H S</ForeName><Initials>HS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010698" MajorTopicYN="N">Phobic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11559864</ArticleId><ArticleId IdType="pii">S0010-440X(01)24652-5</ArticleId><ArticleId IdType="doi">10.1053/comp.2001.26270</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10335547</PMID><DateCompleted><Year>1999</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0955-8829</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>1999</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Psychiatric genetics</Title><ISOAbbreviation>Psychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>MAOA: association and linkage studies with lithium responsive bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>13-6</MedlinePgn></Pagination><Abstract><AbstractText>A number of association studies have investigated the role of the monoamine oxidase A (MAOA) gene in the susceptibility to bipolar disorder. Although some studies have reported positive findings, there remains some controversy, because results from different studies have not been consistent. A common explanation for inconsistencies between studies is genetic heterogeneity. We have focused on lithium responsive bipolar disorder as a way to reduce heterogeneity. In this study, we investigated the role of MAOA in lithium responsive bipolar patients using association and linkage study designs. The investigation used 138 patients and 108 normal controls. In addition, 25 families were also studied. Our results were not supportive of a major role of MAOA in the predisposition to bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turecki</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Research in Neuroscience, Montreal General Hospital, McGill University, Canada. gustavo@bagel.epi.mcgill.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grof</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Cavazzoni</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Duffy</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Grof</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ahrens</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Berghöfer</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Müller-Oerlinghausen</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Dvoráková</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Libigerová</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Vojtechovsky</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zvolsky</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Joober</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Prochazka</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Licht</LastName><ForeName>R W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>N A</ForeName><Initials>NA</Initials></Author><Author ValidYN="Y"><LastName>Schou</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vestergaard</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Holzinger</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schumann</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Thau</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>G A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Alda</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychiatr Genet</MedlineTA><NlmUniqueID>9106748</NlmUniqueID><ISSNLinking>0955-8829</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.4.3.4</RegistryNumber><NameOfSubstance UI="D008995">Monoamine Oxidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008995" MajorTopicYN="N">Monoamine Oxidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>5</Month><Day>21</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>5</Month><Day>21</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10335547</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29579760</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0795</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Pharmacopsychiatry</Title><ISOAbbreviation>Pharmacopsychiatry</ISOAbbreviation></Journal><ArticleTitle>Genetics of Lithium Response in Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>206-211</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/a-0590-4992</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Lithium remains the best-established long-term treatment for bipolar disorder because of its efficacy in maintaining periods of remission and reducing the risk of suicide. Not all patients successfully respond to lithium treatment, and the individual response, including the occurrence of side effects, is highly variable and not easy to predict. The genetic basis of lithium response is supported by the fact that the response clusters in families. Likewise, recent high-throughput genomic analyses have shed light on its genetic architecture.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This nonsystematic review summarizes the main results obtained in genetic association studies using lithium response as target trait.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">These studies suggest that several genetic loci might modulate the way a patient responds to lithium maintenance treatment. Further studies to fully characterize the genetic architecture of lithium response are warranted.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The identification of genetic factors associated with lithium response will be important for (1) better understanding of lithium's mode of action and (2) development of a predictive model for optimization of long-term treatment of bipolar disorder.</AbstractText><CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="N"><LastName>Papiol</LastName><ForeName>Sergi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, Ludwig Maximilian University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="N"><LastName>Schulze</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, Ludwig Maximilian University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="N"><LastName>Alda</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Pharmacopsychiatry</MedlineTA><NlmUniqueID>8402938</NlmUniqueID><ISSNLinking>0176-3679</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010597" MajorTopicYN="Y">Pharmacogenetics</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29579760</ArticleId><ArticleId IdType="doi">10.1055/a-0590-4992</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8818383</PMID><DateCompleted><Year>1996</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>169</Volume><Issue>1</Issue><PubDate><Year>1996</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Ultra-rapid mood cycling.</ArticleTitle><Pagination><MedlinePgn>115</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Littlejohns</LastName><ForeName>C S</ForeName><Initials>CS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Br J Psychiatry. 1996 Mar;168(3):314-23</RefSource><PMID Version="1">8833685</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="N">Awareness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002650" MajorTopicYN="N">Child Abuse, Sexual</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8818383</ArticleId><ArticleId IdType="pii">S0007125000145015</ArticleId><ArticleId IdType="doi">10.1192/bjp.169.1.115a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8349491</PMID><DateCompleted><Year>1993</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0090-3604</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>1993</Year><Season>Summer</Season></PubDate></JournalIssue><Title>The Journal of the American Academy of Psychoanalysis</Title><ISOAbbreviation>J Am Acad Psychoanal</ISOAbbreviation></Journal><ArticleTitle>Separation-individuation issues in sister transference.</ArticleTitle><Pagination><MedlinePgn>273-89</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Des Rosiers</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>McGill University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Psychoanal</MedlineTA><NlmUniqueID>7505570</NlmUniqueID><ISSNLinking>0090-3604</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003379" MajorTopicYN="N">Countertransference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005783" MajorTopicYN="Y">Gender Identity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007207" MajorTopicYN="Y">Individuation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010553" MajorTopicYN="N">Personality Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011574" MajorTopicYN="Y">Psychoanalytic Theory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011575" MajorTopicYN="N">Psychoanalytic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012801" MajorTopicYN="Y">Sibling Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014167" MajorTopicYN="Y">Transference, Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8349491</ArticleId><ArticleId IdType="doi">10.1521/jaap.1.1993.21.2.273</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19673090</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1562-2975</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</Title><ISOAbbreviation>World J Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Adjunctive topiramate treatment for a refractory familial adolescent mania.</ArticleTitle><Pagination><MedlinePgn>74-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15622970701268864</ELocationID><Abstract><AbstractText>Adolescent mania is often misdiagnosed. This case study describes the clinical course and diagnostic reclassification from schizophrenia to bipolar disorder in a 15-year-old girl. This case study also describes the pedigree of the siblings, familial aggregation, and anticipation of mood disorders. In addition, we present the successful use of topiramate, a new antiepileptic drug, which is increasingly being used as a mood stabilizer in paediatric bipolar disorder. The efficacy of topiramate in this case supports its role as a promising agent in treatment-resistant adolescent mania associated with familial aggregation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lung</LastName><ForeName>For-Wey</ForeName><Initials>FW</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chun-Lin</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chien-Shu</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Tzeng</LastName><ForeName>Dong-Sheng</ForeName><Initials>DS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Biol Psychiatry</MedlineTA><NlmUniqueID>101120023</NlmUniqueID><ISSNLinking>1562-2975</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0H73WJJ391</RegistryNumber><NameOfSubstance UI="D000077236">Topiramate</NameOfSubstance></Chemical><Chemical><RegistryNumber>30237-26-4</RegistryNumber><NameOfSubstance UI="D005632">Fructose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020132" MajorTopicYN="N">Anticipation, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005632" MajorTopicYN="N">Fructose</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077236" MajorTopicYN="N">Topiramate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19673090</ArticleId><ArticleId IdType="pii">778365673</ArticleId><ArticleId IdType="doi">10.1080/15622970701268864</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32054361</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8352</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>03</Month></PubDate></JournalIssue><Title>Expert review of molecular diagnostics</Title><ISOAbbreviation>Expert Rev Mol Diagn</ISOAbbreviation></Journal><ArticleTitle>Clinical, genetic, and brain imaging predictors of risk for bipolar disorder in high-risk individuals.</ArticleTitle><Pagination><MedlinePgn>327-333</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14737159.2020.1727743</ELocationID><Abstract><AbstractText><b>Introduction</b>: Early detection and intervention in bipolar disorder (BD) might reduce illness severity, slow its progression, and, in specific cases, even ward off the full-blown disorder. Therefore, identifying at-risk individuals and targeting them promptly before the illness onset is of the utmost importance. In the last decades, there has been a significant effort aimed at identifying genetic and molecular factors able to modulate risk and pharmacological outcomes.<b>Areas covered</b>: We performed a narrative review of articles aimed at identifying clinical, genetics, molecular, and brain imaging markers of BD specifically focusing on samples of individuals at high-risk for BD. Special emphasis was put on studies applying an integrative design, e.g. studies combining different markers such as genetic and brain imaging.<b>Expert opinion</b>: Findings from studies in risk individuals are still too sparse to allow drawing definite conclusions. However, the high potentiality of longitudinal studies in individuals considered at risk to develop BD supports the need for more efforts. Future investigations should focus on more homogeneous subpopulations and evaluate the cross-linking between clinical, genetic, and brain morphostructural/functional neuroimaging characteristics as predictors of risk for BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steardo</LastName><ForeName>Luca</ForeName><Initials>L</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Psychiatric Unit, Department of Health Sciences, University Magna Graecia, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manchia</LastName><ForeName>Mirko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carpiniello</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisanu</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steardo</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Squassina</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Mol Diagn</MedlineTA><NlmUniqueID>101120777</NlmUniqueID><ISSNLinking>1473-7159</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="Y">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="Y">Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Biomarker</Keyword><Keyword MajorTopicYN="Y">early intervention</Keyword><Keyword MajorTopicYN="Y">genetics</Keyword><Keyword MajorTopicYN="Y">longitudinal</Keyword><Keyword MajorTopicYN="Y">mood disorders</Keyword><Keyword MajorTopicYN="Y">neuroimaging</Keyword><Keyword MajorTopicYN="Y">offspring</Keyword><Keyword MajorTopicYN="Y">staging</Keyword><Keyword MajorTopicYN="Y">ultra-high risk</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32054361</ArticleId><ArticleId IdType="doi">10.1080/14737159.2020.1727743</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1770968</PMID><DateCompleted><Year>1992</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2804</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>11</Issue><PubDate><Year>1991</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Personality profile in bipolar schizoaffective psychoses. A comparison with bipolar affective psychoses].</ArticleTitle><Pagination><MedlinePgn>682-8</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this study was to investigate personality profiles in patients with bipolar affective and schizoaffective disorder, classified according to ICD-9 criteria using objective psychological tests (Personal Research Form, Objective Analytical Test Battery, IPC-Query Form). The bipolar schizoaffective patients were further subtyped according to Research Diagnostic Criteria (RDC) into schizoaffective-affective and schizoaffective-schizophrenic patients. 81 patients took part in the study (29 bipolar affective and 52 bipolar schizoaffective patients; the latter were subtyped into 23 schizoaffective-schizophrenic and 29 schizoaffective-affective patients). We showed that the personality profiles are quite similar in schizoaffective-affective and schizoaffective-schizophrenic patients if compared to purely affective patients. But indeed there are pronounced differences between the schizoaffective-affective and the schizoaffective-schizophrenic subtypes, so that subtyping schizoaffective disorder like done in Research Diagnostic Criteria (RDC) seems to show that schizoaffective disorders are not a homogenous group.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thau</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Psychiatrische Universitätsklinik Wien.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenz</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rieder</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kubinger</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Grisar</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Persönlichkeitsprofile bei bipolar schizoaffektiven Psychosen. Ein Vergleich zu bipolar affektiven Psychosen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010556" MajorTopicYN="N">Personality Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1770968</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17064435</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0954-5794</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Season>Fall</Season></PubDate></JournalIssue><Title>Development and psychopathology</Title><ISOAbbreviation>Dev Psychopathol</ISOAbbreviation></Journal><ArticleTitle>Bipolar depression: diagnostic and treatment considerations.</ArticleTitle><Pagination><MedlinePgn>1213-30</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar affective disorder is a recurrent, disabling, and potentially lethal illness that typically begins early in life. Although the disorder is defined by the manic and hypomanic episodes, for most people the depression episodes are the more virulent aspect of the illness. Specifically, the depressive episodes are more numerous, last longer, and are more difficult to treat than the manias, and depression is the principal cause of the illness's increased mortality due to suicide. For people with early-onset depression, predictors of subsequent bipolarity include a family history, psychotic features, and reverse neurovegetative features. Initial episodes of depression are commonly misdiagnosed, which often delays initiation of appropriate therapy and increases the likelihood of treatment with antidepressants alone. Unfortunately, the correct diagnosis is often not made until there has been a treatment-emergent affective switch. There are no treatments specifically approved for bipolar disorder in youth and, among antidepressants, only fluoxetine has received approved. When bipolarity is suspected, treatment with mood stabilizers, both conventional (i.e., lithium, valproate, and carbamazapine) and more recently classified (lamotrigine) and atypical antipsychotics should be prioritized. When antidepressants are indicated in combination with mood stabilizers, first choice options include bupropion and the selective serotonin reuptake inhibitors. Studies of adults indicate that several forms of focused psychotherapy may improve longer term outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, PA 15123-2593, USA. thaseme@upmc.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dev Psychopathol</MedlineTA><NlmUniqueID>8910645</NlmUniqueID><ISSNLinking>0954-5794</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018682">GABA Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018682" MajorTopicYN="N">GABA Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>108</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17064435</ArticleId><ArticleId IdType="pii">S0954579406060585</ArticleId><ArticleId IdType="doi">10.1017/S0954579406060585</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22000157</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2012</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7862</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title><ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>339-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.euroneuro.2011.09.008</ELocationID><Abstract><AbstractText>Over one half of bipolar patients have been reported to be more prone to either depressive or manic relapses. This study aimed to define profiles of drugs used for maintenance treatment of bipolar disorder (BD) by the means of Polarity Index. Polarity Index is a new metric indicating the relative antimanic versus antidepressive preventive efficacy of drugs. Polarity Index was retrieved by calculating Number Needed to Treat (NNT) for prevention of depression and NNT for prevention of mania ratio, as emerging from the results of randomized placebo-controlled trials. Included trials were randomized and double blind, with a minimal duration of 24 weeks, assessing effectiveness of a mood stabilizer or antipsychotic drug alone or in combination with a mood stabilizing agent versus a placebo comparator in BD maintenance treatment. Polarity Index value above 1.0 indicates a relative greater antimanic prophylactic efficacy, number below 1.0 a relative greater antidepressive efficacy. The polarity index for the drugs used in maintenance therapy for bipolar disorder was 12.09 for risperidone, 4.38 for aripiprazole, 3.91 for ziprasidone, 2.98 for olanzapine, 1.39 for lithium, 1.14 for quetiapine, and 0.40 for lamotrigine. Polarity index of valproate and oxcarbazepine may not be reliable due to the failure of their maintenance trials. The polarity index provides a measure of how much antidepressant versus antimanic a drug is in bipolar disorder prophylaxis, and may guide the choice of maintenance therapy in bipolar patients.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier B.V. and ECNP. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Popovic</LastName><ForeName>Dina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinares</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Goikolea</LastName><ForeName>Jose Manuel</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Bonnin</LastName><ForeName>Caterina Mar</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Gonzalez-Pinto</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Neuropsychopharmacol</MedlineTA><NlmUniqueID>9111390</NlmUniqueID><ISSNLinking>0924-977X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>07</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>09</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>09</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22000157</ArticleId><ArticleId IdType="pii">S0924-977X(11)00261-6</ArticleId><ArticleId IdType="doi">10.1016/j.euroneuro.2011.09.008</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12944339</PMID><DateCompleted><Year>2003</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>160</Volume><Issue>9</Issue><PubDate><Year>2003</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Relationship of birth cohort and early age at onset of illness in a bipolar disorder case registry.</ArticleTitle><Pagination><MedlinePgn>1636-42</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Utilizing data from a previously characterized registry of subjects with bipolar illness, the authors examined age at onset of the first illness episode in cohorts of subjects born from 1900 through 1939 and from 1940 through 1959.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Demographic and clinical characteristics at the first full episode of bipolar disorder of subjects in a diagnostically validated voluntary bipolar disorder registry (N=1,218) were reviewed and subjected to statistical analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age at onset of the first episode of bipolar illness was lower by 4.5 years in subjects born during or after 1940 (median age=19 years), compared with subjects born before 1940 (median age=23.5 years). The proportion of subjects with bipolar disorder presenting with a prepubertal onset was significantly higher in the later birth-year cohort than in the earlier birth-year cohort. More than 50% of male and female subjects in both cohorts had a depressive episode as the first episode of bipolar illness. Subjects in each cohort who had a parent with major depression, bipolar disorder, or schizophrenia experienced their first episode nearly 4 to 5 years earlier than the other subjects in the cohort.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Prospective epidemiological studies conducted with bipolar disorder subjects are needed to either affirm or refute these data on age at illness onset. If the results are affirmed, the early recognition of prepubertal bipolar disorder will be important, so that the condition can be treated with appropriate medications and medications that could potentially worsen the illness course can be avoided. Similarly, early recognition of bipolar illness is important, especially in women, to minimize use of antidepressant monotherapy for patients with bipolar illness. Among young people presenting with major depression as the first illness episode, a parental history of major depression, bipolar disorder, or psychosis may be a useful pointer to future bipolar disorder. Early recognition and appropriate treatment of bipolar illness may prevent the development of chronicity and serious functional impairment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chengappa</LastName><ForeName>K N Roy</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, 3811 O'Hara Street, Pittsburgh, PA 15213-2593, USA. chengappakn@msx.upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Houck</LastName><ForeName>Patricia R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Grochocinski</LastName><ForeName>Victoria J</ForeName><Initials>VJ</Initials></Author><Author ValidYN="Y"><LastName>Cluss</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Stapf</LastName><ForeName>Debra A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 29618</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 30915</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="N">Child of Impaired Parents</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>12</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12944339</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.160.9.1636</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12792837</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1300-2163</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Season>Spring</Season></PubDate></JournalIssue><Title>Turk psikiyatri dergisi = Turkish journal of psychiatry</Title><ISOAbbreviation>Turk Psikiyatri Derg</ISOAbbreviation></Journal><ArticleTitle>[Phenomenological differences between adolescent and adult onset mania: a comparative study].</ArticleTitle><Pagination><MedlinePgn>21-30</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study is to determine the relationship between age of onset and phenomenology of bipolar affective disorder (mania).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The current and retrospective diagnoses of the patients were made according to DSM-IV Bipolar Affective Disorder (mania) criteria. Sociodemographic features, clinical features, type of episode, number and length of hospitalizations were investigated in three groups which were consisted of adolescent-onset adolescents (n=60), adolescent-onset adults (n=60) and adult-onset adults (n=60). The groups were determined according to age of onset and current age categories. All patients have been assessed by Structured Clinical Interview for DSM-IV-Clinical Version (SCID-I), Young Mania Rating Scale (YMRS), Hamilton Depression Rating Scale (HAM-D) and Scale for the Assessment of Positive Symptoms (SAPS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The groups were consisted of equal numbers of women and men. Rate of single (%51.7) and divorced patients (%21.7), rate of unemployment status (%70) were higher in adolescent-onset patients than adult-onsets. Adolescent-onset adolescents and adolescent-onset adults were different from adult-onset patients with respect to mixt episodes (%26.7, %15) and mood congruent or incongruent psychotic features (%35/%50, %31.7/%66.7) and length of hospitalization (23.9+/-4.8, 23.8+/-3.9).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Adolescent-onset of illness causes higher probability of mixt episodes, psychotic features such as mood congruent or incongruent hallucinations and delusions. This study supports the hypothesis that adolescent-onset mania may be a different subtype than adult-onset mania with respect to type of episode, phenomenology, and clinical features.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erkiran</LastName><ForeName>Murat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Uzm., Bakirköy Prof. Mazhar Osman Ruh Sağliği ve Hastaliklari Eğitim ve Araştirma Hastanesi, Istanbul.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karamustafalioğlu</LastName><ForeName>Nesrin</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Tomruk</LastName><ForeName>Nesrin</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kahraman</LastName><ForeName>Erdem</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Alpay</LastName><ForeName>Nihat</ForeName><Initials>N</Initials></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Ergen ve erişkin başlangiçli maninin fenomenolojik farkliliklari: karşilaştirmali bir calişma.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk Psikiyatri Derg</MedlineTA><NlmUniqueID>9425936</NlmUniqueID><ISSNLinking>1300-2163</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008499" MajorTopicYN="N">Medical Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>6</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>6</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12792837</ArticleId><ArticleId IdType="pii">420</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7365494</PMID><DateCompleted><Year>1980</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>168</Volume><Issue>5</Issue><PubDate><Year>1980</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Halstead-Reitan Category Test in bipolar and unipolar affective disorders. Relationship to age and phase of illness.</ArticleTitle><Pagination><MedlinePgn>297-304</MedlinePgn></Pagination><Abstract><AbstractText>Unipolar and bipolar affectively disturbed patients were administered the Halstead-Reitan category test when in an unmedicated acutely depressed phase and during recovery. Controls consisted of normal volunteers and spouses. Spouse controls were tested at intervals similar to those of the patients and were utilized to control for age, sex, education, and socioeconomic status. Results showed that depressives in the acute depressed state made significantly more errors did controls. Older bipolar patients made significantly more errors than did controls. Older bipolar patients made significantly more errors than younger bipolar or younger unipolar patients. In the recovered state the order remained the same. In spite of a decrease in error scores the older bipolar group remained in the abnormal range, whereas the younger groups scored in the normal range with few exceptions. These data suggest that impaired cognitive functioning may be a factor in the disability associated with the major affective disorders in addition to the distorted affective component usually emphasized. Furthermore, in the case of older bipolar patients, the deficit is more severe and may persist beyond the disappearance of affective signs, suggesting that factors associated with age may play an important role in conjunction with other factors associated with bipolar illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savard</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Rey</LastName><ForeName>A C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Post</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004193" MajorTopicYN="N">Discrimination Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="Y">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1980</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1980</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1980</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7365494</ArticleId><ArticleId IdType="doi">10.1097/00005053-198005000-00010</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21918448</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2011</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Current opinion in psychiatry</Title><ISOAbbreviation>Curr Opin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychotherapy for bipolar disorder:  a review of the most recent studies.</ArticleTitle><Pagination><MedlinePgn>549-55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YCO.0b013e32834b7c5f</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">The aim of this review is to give an update on recent randomized controlled trials (RCTs) evaluating psychotherapy for bipolar disorder.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Methodological issues like the inclusion of differing patient populations, differences in who (patients, family members, caregivers) received psychotherapy, and varying follow-up periods make it difficult to compare RCTs. Despite heterogeneous results, the majority of the studies showed relevant positive results in terms of reduced relapse rates, increased quality of life, better functioning or more favorable symptomatic outcome.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Recent RCTs evaluating psychosocial interventions for bipolar disorder have added to the evidence, thereby broadening existing therapeutic options. These promising results should encourage future studies leading to a better understanding of what kind of patient or caregiver will benefit from what kind of therapy, and how efficient psychosocial interventions can be under routine conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schöttle</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Psychosis Early Detection and Intervention Centre, Department of Psychiatry and Psychotherapy, Centre for Psychosocial Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. d.schoettle@uke.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Bock</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Psychiatry</MedlineTA><NlmUniqueID>8809880</NlmUniqueID><ISSNLinking>0951-7367</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="Y">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21918448</ArticleId><ArticleId IdType="doi">10.1097/YCO.0b013e32834b7c5f</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2690170</PMID><DateCompleted><Year>1990</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-4962</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>1989</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>Psychopathology, temperament, and past course in primary major depressions. 1. Review of evidence for a bipolar spectrum.</ArticleTitle><Pagination><MedlinePgn>268-77</MedlinePgn></Pagination><Abstract><AbstractText>In reviewing recent findings on affective conditions in the interface of unipolar and bipolar disorders, we find evidence favoring a partial return to Kraepelin's broad concept of manic-depressive illness, which included many recurrent depressives and temperamental variants. This review addresses methodologic, clinical, and familial considerations in the definition and characterization of a proposed spectrum of bipolar disorders which subsumes episodic and chronic forms. Episodic bipolar disorders are subclassified into bipolar schizoaffective, and bipolar I and II, and bipolar III or pseudo-unipolar forms. Chronic bipolar disorders could be either intermittent or persistent, and are subclassified into chronic mania, protracted mixed states, and rapid-cycling forms, as well as the classical temperaments (cyclothymic, hyperthymic, irritable and dysthymic).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>H S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>University of Tennessee, Department of Psychiatry, Memphis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cassano</LastName><ForeName>G B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Musetti</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Perugi</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Tundo</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mignani</LastName><ForeName>V</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="Y">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="Y">Temperament</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>71</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2690170</ArticleId><ArticleId IdType="doi">10.1159/000284607</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21692606</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1614</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>10</Issue><PubDate><Year>2011</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mirtazapine induced mania in a woman with major depression in the absence of features of bipolarity.</ArticleTitle><Pagination><MedlinePgn>901</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/00048674.2011.589369</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Basavraj</LastName><ForeName>Vinay</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Nanjundappa</LastName><ForeName>Girish B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Chandra</LastName><ForeName>Prabha S</ForeName><Initials>PS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>250PJI13LM</RegistryNumber><NameOfSubstance UI="D008803">Mianserin</NameOfSubstance></Chemical><Chemical><RegistryNumber>A051Q2099Q</RegistryNumber><NameOfSubstance UI="D000078785">Mirtazapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008803" MajorTopicYN="N">Mianserin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078785" MajorTopicYN="N">Mirtazapine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21692606</ArticleId><ArticleId IdType="doi">10.3109/00048674.2011.589369</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10404708</PMID><DateCompleted><Year>1999</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>3</Issue><PubDate><Year>1999</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The effect of episodes on recurrence in affective disorder: a case register study.</ArticleTitle><Pagination><MedlinePgn>225-31</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The risk of recurrence has been found to increase with the number of episodes in both unipolar and bipolar affective disorder. The present study compared the effect of the number of episodes on the risk of recurrence in the two disorders.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A case register study including all hospital admissions with primary affective disorder in Denmark during 1971-1993. The effect of the number of prior episodes on the rate of recurrence following the first discharge after 1984 was estimated. A total of 7925 unipolar patients and 2011 bipolar patients were included in the study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The rate of recurrence was, on average, 1.6 times greater for bipolar patients than for unipolar patients. Nevertheless, the effect of the number of episodes was greatest for unipolar patients. Thus, the rate of recurrence increased, on average, 15% with every episode for unipolar patients and 9% with every episode for bipolar patients, when adjusted for differences in age and gender.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The risk of recurrence increases with every new episode in affective disorder. The effect of episodes is greater for unipolar disorder than for bipolar disorder.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The data relate to re-admissions rather than recurrence.</AbstractText><AbstractText Label="CLINICAL RELEVANCE" NlmCategory="CONCLUSIONS">The study shows that the prognosis worsens more for unipolar than for bipolar patients with each new episode and suggests the relevance of earlier and more sustained intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>L V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Copenhagen, Rigshospitalet, Denmark. lars.kessing@dadlnet.dk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>P K</ForeName><Initials>PK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>7</Month><Day>15</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>7</Month><Day>15</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10404708</ArticleId><ArticleId IdType="pii">S0165032798001256</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(98)00125-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15995798</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0940-1334</ISSN><JournalIssue CitedMedium="Print"><Volume>256</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European archives of psychiatry and clinical neuroscience</Title><ISOAbbreviation>Eur Arch Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Gender differences in bipolar-II disorder.</ArticleTitle><Pagination><MedlinePgn>67-71</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Gender differences in bipolar-II disorder (BP-II) are understudied.</AbstractText><AbstractText Label="STUDY AIM" NlmCategory="OBJECTIVE">was to test if there were gender differences in the clinical and family history features of BP-II.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Consecutive 374 BP-II private practice outpatients were interviewed by a senior psychiatrist using the Structured Clinical Interview for DSM-IV, modified to improve the detection of BP-II (by Benazzi and Akiskal 2003, J Affect Disord 73:33-38), the Montgomery Asberg Depression Rating Scale (MADRS), the Hypomania Interview Guide, and the Family History Screen. Logistic regression was used to study associations and control for confounding. Alpha level was set at 0.05; P was two-tailed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Females represented 67.3% of the group. The female to male ratio was independent of age. Females were more common in younger onset BP-II. Females, versus males, had significantly lower age at onset, more axis I comorbidity, atypical depressions, intra-depression hypomanic symptoms (i. e., mixed depression), and family history of suicidal behavior. On the MADRS, females had more sadness, loss of energy, loss of interest, and suicidal ideas. The symptom structure of hypomanic episodes was similar between females and males.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Single interviewer, outpatient sample, private practice study setting.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Clinical differences were found between BP-II females and males. Differences were found only on the depressive pole of the disorder. However, the magnitude of the differences had not a strong clinical significance, suggesting that at present, on the basis of the variables and the population studied, there is little ground to support a female BP-II depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>FrancoBenazzi@FBenazzi.it</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Arch Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9103030</NlmUniqueID><ISSNLinking>0940-1334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15995798</ArticleId><ArticleId IdType="doi">10.1007/s00406-005-0599-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Compr Psychiatry. 2000 Mar-Apr;41(2):106-10</Citation><ArticleIdList><ArticleId IdType="pubmed">10741888</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1977 Nov;134(11):1227-33</Citation><ArticleIdList><ArticleId IdType="pubmed">910973</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1999 Sep;22(3):667-73, ix-x</Citation><ArticleIdList><ArticleId IdType="pubmed">10550861</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):133-46</Citation><ArticleIdList><ArticleId IdType="pubmed">12507746</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Sep;59 Suppl 1:S5-S30</Citation><ArticleIdList><ArticleId IdType="pubmed">11121824</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1993 Sep-Oct;34(5):303-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2003 Oct 15;120(3):273-82</Citation><ArticleIdList><ArticleId IdType="pubmed">14561439</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Aug;152(8):1130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7625459</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):49-57</Citation><ArticleIdList><ArticleId IdType="pubmed">12507737</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2003 Aug;253(4):203-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12910352</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):33-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12507735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Oct;6(5):395-405</Citation><ArticleIdList><ArticleId IdType="pubmed">15383132</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1999 Jun 30;86(3):259-65</Citation><ArticleIdList><ArticleId IdType="pubmed">10482345</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Sep;50(2-3):163-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9858076</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):113-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12507744</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1999 Sep;22(3):517-34, vii</Citation><ArticleIdList><ArticleId IdType="pubmed">10550853</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1999 Sep;22(3):547-64</Citation><ArticleIdList><ArticleId IdType="pubmed">10550855</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1979 Apr;134:382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2000;250(1):53-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10738866</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Nov;72(2):125-38</Citation><ArticleIdList><ArticleId IdType="pubmed">12200203</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):199-205</Citation><ArticleIdList><ArticleId IdType="pubmed">12507752</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2004 Aug;9(8 Suppl 7):5-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15303076</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Aug;59(8):736-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12150650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 1999 Jun;11(2):55-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10440521</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1999 Sep;22(3):689-703, x</Citation><ArticleIdList><ArticleId IdType="pubmed">10550863</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Feb;78(2):149-52</Citation><ArticleIdList><ArticleId IdType="pubmed">14706725</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2004 Apr;254(2):61-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15146334</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2003 Apr;107(4):268-74</Citation><ArticleIdList><ArticleId IdType="pubmed">12662249</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2005 May-Jun;46(3):159-66</Citation><ArticleIdList><ArticleId IdType="pubmed">16021584</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2003 Sep;27(6):985-91</Citation><ArticleIdList><ArticleId IdType="pubmed">14499315</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Jul;57(7):675-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10891038</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2004 Apr;254(2):92-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15146338</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17391349</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1-2</Issue><PubDate><MedlineDate>2007 Feb-Mar</MedlineDate></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Functional impairment in patients with mania: baseline results of the EMBLEM study.</ArticleTitle><Pagination><MedlinePgn>45-52</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) is a large-scale prospective observational multicentre study to evaluate the longitudinal course of bipolar disorder and its associations with pharmacological treatment following an acute manic or mixed episode. We present an overview of the study design and patient characteristics at baseline while focusing on factors influencing work performance in the year prior to enrollment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 530 investigators across 14 European countries enrolled 3,681 patients with acute mania between December 2002 and June 2004. Longitudinal observations are ongoing until July 2006. Socio-demographic variables, psychiatric history, clinical status and information on pharmacological treatment for bipolar disorder were recorded. Items from the SLICE of LIFE were applied, including a measure of work impairment during the previous year. The distribution of the baseline characteristics was analysed with descriptive statistics. Eighteen variables were investigated as hypothesized risk factors for work impairment applying logistic regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the previous year, 28 and 68% of patients were classified as having 'low' and 'high' work impairment, respectively. Clinical Global Impression - Bipolar Disorder (CGI-BP) overall, CGI-BP depression at baseline, rapid cycling during the previous 12 months, age between 35 and 64 years, substance abuse other than alcohol and cannabis and living without a partner or as dependent household member were significantly associated with work impairment during the previous year.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">EMBLEM is to our knowledge the largest prospective observational study assessing patients during and after an acute episode of mania. Work impairment is significant in the year prior to an acute episode of mania.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>European Health Outcomes, Lilly Research Centre, Windlesham, Surrey, UK. goetzi@lilly.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lorenzo</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><CollectiveName>EMBLEM Advisory Board</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000275" MajorTopicYN="N">Adjustment Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="Y">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17391349</ArticleId><ArticleId IdType="pii">BDI325</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2007.00325.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4711760</PMID><DateCompleted><Year>1973</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-8673</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>13</Issue><PubDate><Year>1973</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Zeitschrift fur Allgemeinmedizin</Title><ISOAbbreviation>Z Allgemeinmed</ISOAbbreviation></Journal><ArticleTitle>[For lithium].</ArticleTitle><Pagination><MedlinePgn>626-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>W</ForeName><Initials>W</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Pro lithio.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Z Allgemeinmed</MedlineTA><NlmUniqueID>7700691</NlmUniqueID><ISSNLinking>0300-8673</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1973</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1973</Year><Month>5</Month><Day>10</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1973</Year><Month>5</Month><Day>10</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4711760</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4515947</PMID><DateCompleted><Year>1973</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0044-166X</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>1</Issue><PubDate><Year>1973</Year></PubDate></JournalIssue><Title>ZWR</Title><ISOAbbreviation>ZWR</ISOAbbreviation></Journal><ArticleTitle>[Relationship between psychopathology and genetics in so-called late schizophrenias].</ArticleTitle><Pagination><MedlinePgn>1-11</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berner</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Beziehungen zwischen Psychopathologie und Genetik sogenannter Spätschizophrenien.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>ZWR</MedlineTA><NlmUniqueID>0233767</NlmUniqueID><ISSNLinking>0044-166X</ISSNLinking></MedlineJournalInfo><CitationSubset>D</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004777" MajorTopicYN="N">Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1973</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1973</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1973</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4515947</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8271632</PMID><DateCompleted><Year>1994</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0912-2036</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>2</Issue><PubDate><Year>1993</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Japanese journal of psychiatry and neurology</Title><ISOAbbreviation>Jpn J Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Clinical EEG study of biological rhythm on manic state and remission state in MDI case (compared to monopolar depression case).</ArticleTitle><Pagination><MedlinePgn>449-51</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Nippon Medical School, Tokyo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamadera</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Endo</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kajimura</LastName><ForeName>N</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Jpn J Psychiatry Neurol</MedlineTA><NlmUniqueID>8610886</NlmUniqueID><ISSNLinking>0912-2036</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="Y">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017286" MajorTopicYN="N">Polysomnography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012894" MajorTopicYN="N">Sleep Stages</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012895" MajorTopicYN="N">Sleep, REM</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014851" MajorTopicYN="N">Wakefulness</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8271632</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1819.1993.tb02145.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">444016</PMID><DateCompleted><Year>1979</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>6</Issue><PubDate><Year>1979</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>'Schizoaffective disorder': dead or alive?</ArticleTitle><Pagination><MedlinePgn>633-4</MedlinePgn></Pagination><Abstract><AbstractText>Schizoaffective disorder, traditionally classified under schizophrenia, recently tends to be subsumed under affective disorder. This article reports a study of 35 sib pairs, where each six was independently diagnosed as having schizophrenia (SC), affective disorder (AD), or schizoaffective disorder (SA). The observed numbers of same-diagnosis pairs (ADAD, SASA, SCSC) were compared with the numbers expected if the three disorders are genetically independent. The results showed a significant deficiency only in the observed number of SASA pairs, which suggests that schizophrenia and affective disorder are genetically distinct whereas schizoaffective disorder is not. To test whether schizoaffective disorder is a variant of affective disorder or schizophrenia, the observed number of ADSA and SASC pairs were compared against the expected numbers. No significant differences were found, which suggests that schizoaffective disorder is genetically heterogeneous, with at least two subtypes, one a variant of affective disorder, the other a variant of schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">444016</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1979.01780060023001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12890305</PMID><DateCompleted><Year>2004</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1461-1457</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The international journal of neuropsychopharmacology</Title><ISOAbbreviation>Int J Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Introduction to the Special Section. New advances in the understanding and treatment of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>123-5</MedlinePgn></Pagination><Abstract><AbstractText>The current renewed interest in the field of bipolar disorders can be attributed to various factors which are reviewed in this Special Section of the International Journal of Neuropsychopharmacology. Bipolar disorders are one of the most frequent disorders in psychiatry and this Special Section presents papers on recent advances in the clinical course, epidemiology, biological models and neurobiology of bipolar disorders. Novel therapeutic approaches will be covered in a second part in Volume 6, Number 3 (September 2003).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Souery</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Erasme Hospital, Department of Psychiatry, Universit Libre de Bruxelles, Brussels. dsouery@arcadis.be</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendlewicz</LastName><ForeName>Julien</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Neuropsychopharmacol</MedlineTA><NlmUniqueID>9815893</NlmUniqueID><ISSNLinking>1461-1457</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12890305</ArticleId><ArticleId IdType="doi">10.1017/S1461145703003444</ArticleId><ArticleId IdType="pii">S1461145703003444</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5286329</PMID><DateCompleted><Year>1971</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-1591</ISSN><JournalIssue CitedMedium="Print"><Volume>221</Volume><PubDate><Year>1971</Year></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica. Supplementum</Title><ISOAbbreviation>Acta Psychiatr Scand Suppl</ISOAbbreviation></Journal><ArticleTitle>The Capgras syndrome: a case report.</ArticleTitle><Pagination><MedlinePgn>53-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Perris</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Acta Psychiatr Scand Suppl</MedlineTA><NlmUniqueID>0370365</NlmUniqueID><ISSNLinking>0065-1591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011011" MajorTopicYN="N">Pneumoencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1971</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1971</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1971</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5286329</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1971.tb02137.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15208783</PMID><DateCompleted><Year>2004</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0002-9297</ISSN><JournalIssue CitedMedium="Print"><Volume>75</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Month>Aug</Month></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Genomewide linkage scan for bipolar-disorder susceptibility loci among Ashkenazi Jewish families.</ArticleTitle><Pagination><MedlinePgn>204-19</MedlinePgn></Pagination><Abstract><AbstractText>The relatively short history of linkage studies in bipolar disorders (BPs) has produced inconsistent findings. Implicated regions have been large, with reduced levels of significance and modest effect sizes. Both phenotypic and genetic heterogeneity may have contributed to the failure to define risk loci. BP is part of a spectrum of apparently familial affective disorders, which have been organized by severity. Heterogeneity may arise because of insufficient data to define the spectrum boundaries, and, in general, the less-severe disorders are more difficult to diagnose reliably. To address the inherent complexities in detecting BP susceptibility loci, we have used restricted diagnostic classifications and a genetically more homogeneous (Ashkenazi Jewish) family collection to perform a 9-cM autosomal genomewide linkage scan. Although they are genetically more homogeneous, there are no data to suggest that the rate of illness in the Ashkenazim differs from that in other populations. In a genome scan of 41 Ashkenazi pedigrees with a proband affected with bipolar I disorder (BPI) and at least one other member affected with BPI or bipolar II disorder (BPII), we identified four regions suggestive of linkage on chromosomes 1, 3, 11, and 18. Follow-up genotyping showed that the regions on chromosomes 1, 3, and 18 are also suggestive of linkage in a subset of pedigrees limited to relative pairs affected with BPI. Furthermore, our chromosome 18q22 signal (D18S541 and D18S477) overlaps with previous BP findings. This research is being conducted in parallel with our companion study of schizophrenia, in which, by use of an identical approach, we recently reported significant evidence for a schizophrenia susceptibility locus in the Ashkenazim on chromosome 10q22.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fallin</LastName><ForeName>M Daniele</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasseter</LastName><ForeName>Virginia K</ForeName><Initials>VK</Initials></Author><Author ValidYN="Y"><LastName>Wolyniec</LastName><ForeName>Paula S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>John A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Nestadt</LastName><ForeName>Gerald</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Valle</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Kung-Yee</ForeName><Initials>KY</Initials></Author><Author ValidYN="Y"><LastName>Pulver</LastName><ForeName>Ann E</ForeName><Initials>AE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 RR003655</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH058153</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH58153</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR03655</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002887" MajorTopicYN="N">Chromosomes, Human, Pair 18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="Y">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007585" MajorTopicYN="N">Jews</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>02</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>05</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15208783</ArticleId><ArticleId IdType="doi">10.1086/422474</ArticleId><ArticleId IdType="pii">S0002-9297(07)62403-3</ArticleId><ArticleId IdType="pmc">PMC1216055</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Hum Genet. 2001 Nov;69(5):1095-112</Citation><ArticleIdList><ArticleId IdType="pubmed">11573163</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2001 Nov;6(6):684-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11673797</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 Nov;58(11):1025-31</Citation><ArticleIdList><ArticleId IdType="pubmed">11695948</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Genet. 2003 Sep;13(3):143-50</Citation><ArticleIdList><ArticleId IdType="pubmed">12960745</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2004 Feb 11;291(6):718-24</Citation><ArticleIdList><ArticleId IdType="pubmed">14871915</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Feb;9(2):213-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14699422</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2004 May;74(5):886-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15060841</ArticleId></ArticleIdList></Reference><Reference><Citation>Isr J Med Sci. 1973 Sep-Oct;9(9):1276-84</Citation><ArticleIdList><ArticleId IdType="pubmed">4775110</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1981 Apr;38(4):400-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7212970</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1984 Jul;141(7):892-3</Citation><ArticleIdList><ArticleId IdType="pubmed">6731641</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1987 Feb 26-Mar 4;325(6107):783-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2881209</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1989 Aug;155:220-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2597918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1990 Jul 7;336(8706):13-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1973210</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1991 Jan;48(1):129-36</Citation><ArticleIdList><ArticleId IdType="pubmed">1670749</ArticleId></ArticleIdList></Reference><Reference><Citation>Jpn J Psychiatry Neurol. 1992 Mar;46(1):155-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1635305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Hum Genet. 1993 Jan;57(Pt 1):55-64</Citation><ArticleIdList><ArticleId IdType="pubmed">8101437</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5918-21</Citation><ArticleIdList><ArticleId IdType="pubmed">8016089</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1995 Jun;56(6):1277-86</Citation><ArticleIdList><ArticleId IdType="pubmed">7762550</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1995 Nov;11(3):241-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7581446</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1996 Feb;153(2):271-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8561212</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1996 Jun;58(6):1347-63</Citation><ArticleIdList><ArticleId IdType="pubmed">8651312</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1996 Apr;12(4):427-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8630499</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2003 Dec;5(6):469-76</Citation><ArticleIdList><ArticleId IdType="pubmed">14609502</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Dec 1;54(11):1265-73</Citation><ArticleIdList><ArticleId IdType="pubmed">14643094</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2004 Feb 15;125B(1):69-78</Citation><ArticleIdList><ArticleId IdType="pubmed">14755448</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1995 Dec;57(6):1384-94</Citation><ArticleIdList><ArticleId IdType="pubmed">8533768</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1996 Apr;12(4):436-41</Citation><ArticleIdList><ArticleId IdType="pubmed">8630501</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1996 Sep 13;273(5281):1516-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8801636</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1995 Dec 18;60(6):522-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8825888</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1997 May 15;336(20):1401-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9145676</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Genet. 1997 Spring;7(1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">9264132</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 Dec;73(6):1250-60</Citation><ArticleIdList><ArticleId IdType="pubmed">14624392</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2003;48(4):186-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14673216</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1997 Dec;61(6):1397-404</Citation><ArticleIdList><ArticleId IdType="pubmed">9399888</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1998 Jun;62(6):1381-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9585613</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1998 Sep 7;81(5):364-76</Citation><ArticleIdList><ArticleId IdType="pubmed">9754621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1999 Jan;4(1):76-84</Citation><ArticleIdList><ArticleId IdType="pubmed">10089014</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1999 May 11;96(10):5604-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10318931</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 1999 Aug;36(8):585-94</Citation><ArticleIdList><ArticleId IdType="pubmed">10465107</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1999 Aug;54(3):319-28</Citation><ArticleIdList><ArticleId IdType="pubmed">10467978</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1999 Oct 15;88(5):567-87</Citation><ArticleIdList><ArticleId IdType="pubmed">10490718</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2001 Nov-Dec;42(6):461-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11704936</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Genet. 2001 Nov;2(11):891-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11715044</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2002 Jan;30(1):97-101</Citation><ArticleIdList><ArticleId IdType="pubmed">11731797</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2001 Dec 8;105(8):765-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11803528</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2002 Feb;4(1):1-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11814388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Dec;3(6):299-317</Citation><ArticleIdList><ArticleId IdType="pubmed">11843780</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):79-88</Citation><ArticleIdList><ArticleId IdType="pubmed">11869754</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2002 Apr;4(2):141-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11914176</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(4):405-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11986984</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2002 Jun 1;11(12):1373-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12023979</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Genet. 2002 Mar;32(2):135-44</Citation><ArticleIdList><ArticleId IdType="pubmed">12036111</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(6):579-93</Citation><ArticleIdList><ArticleId IdType="pubmed">12140781</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2002 Aug 8;114(6):679-86</Citation><ArticleIdList><ArticleId IdType="pubmed">12210287</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2002 Dec;71(6):1395-412</Citation><ArticleIdList><ArticleId IdType="pubmed">12454801</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2003 Jan 1;116B(1):90-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12497621</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Feb 1;53(3):239-43</Citation><ArticleIdList><ArticleId IdType="pubmed">12559657</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2003 Mar;8(3):288-98</Citation><ArticleIdList><ArticleId IdType="pubmed">12660801</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2003 Mar;8(3):333-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12660806</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2003 May 15;119B(1):69-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12707942</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2003 Apr;8(4):445-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12740602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Hered. 2002;54(4):199-209</Citation><ArticleIdList><ArticleId IdType="pubmed">12771552</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 Jul;73(1):107-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12772088</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 Jul;73(1):49-62</Citation><ArticleIdList><ArticleId IdType="pubmed">12802785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2003 Aug 1;12(15):1907-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12874110</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 Sep;73(3):601-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12929083</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2000 Jan;49(1):126-30</Citation><ArticleIdList><ArticleId IdType="pubmed">10615960</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Apr;58(1):51-61</Citation><ArticleIdList><ArticleId IdType="pubmed">10760558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2000 Apr 12;9(7):1049-57</Citation><ArticleIdList><ArticleId IdType="pubmed">10767329</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2000 Apr 28;288(5466):678-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10784452</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6769-74</Citation><ArticleIdList><ArticleId IdType="pubmed">10801975</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2000 Sep;67(3):727-36</Citation><ArticleIdList><ArticleId IdType="pubmed">10924406</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):531-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11018225</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Hered. 2001;51(1-2):64-78</Citation><ArticleIdList><ArticleId IdType="pubmed">11096273</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Genet. 2000 Dec;107(6):630-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11153918</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2000 Jun;66(6):1945-57</Citation><ArticleIdList><ArticleId IdType="pubmed">10796874</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2001 Mar;68(3):661-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11179014</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):585-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11149935</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2001 Apr;68(4):1061-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11222106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2001 May;6(3):293-301</Citation><ArticleIdList><ArticleId IdType="pubmed">11326297</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2001 Aug;69(2):428-33</Citation><ArticleIdList><ArticleId IdType="pubmed">11443544</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Aug;158(8):1258-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11481160</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11485-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11572994</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31529809</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2155-7780</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>The primary care companion for CNS disorders</Title><ISOAbbreviation>Prim Care Companion CNS Disord</ISOAbbreviation></Journal><ArticleTitle>Hereditary Features of Bipolar Disorder.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4088/PCC.18l02423</ELocationID><ELocationID EIdType="pii" ValidYN="Y">18l02423</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Côrte-Real</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Mental Health, Centro Hospitalar Universitário Lisboa Norte, Av Prof Egas Moniz, 1649-035 Lisboa, Lisbon, Portugal. beatriz.corte-real@chln.min-saude.pt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Mental Health, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrade</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Mental Health, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pestana</LastName><ForeName>Pedro Câmara</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Mental Health, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte</LastName><ForeName>Tiago A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Mental Health, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Paulo T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Mental Health, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prim Care Companion CNS Disord</MedlineTA><NlmUniqueID>101547532</NlmUniqueID><ISSNLinking>2155-7780</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31529809</ArticleId><ArticleId IdType="doi">10.4088/PCC.18l02423</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12842302</PMID><DateCompleted><Year>2003</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Can adults with attention-deficit/hyperactivity disorder be distinguished from those with comorbid bipolar disorder? Findings from a sample of clinically referred adults.</ArticleTitle><Pagination><MedlinePgn>1-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite data describing the overlap of attention deficit hyperactivity disorder (ADHD) and bipolar disorder (BPD) in youth, little is known about adults with these co-occurring disorders. We now evaluate the clinical characteristics of referred adults with (n = 24) and without BPD (n = 27).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Referred adults to clinical trials of ADHD were evaluated by psychiatric evaluation using DSM-IV criteria. Structured psychiatric interviews were used to systematically assess adult and childhood disorders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The vast majority of patients with ADHD plus BPD had bipolar II disorder (88%). Adults with ADHD plus BPD had higher rates of the combined subtype of ADHD compared to ADHD without BPD (chi(2) = 8.7, p =.003), a greater number of DSM-IV ADHD symptoms (14.8 +/- 2.9 and 11.4 +/- 4.0; t = -3.4, p &lt;.01), more attentional symptoms of ADHD (8.1 +/- 1.4 and 6.8 +/- 2.1; t = -2.5, p &lt;.02; trend), poorer global functioning (47 +/- 5.9 and 52 +/- 7.4, t = 2.6, p &lt;.02; trend), and additional comorbid psychiatric disorders (3.7 +/- 2.5 and 2.0 +/- 1.9; t = -2.9, p &lt;.01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results suggest that adults with ADHD plus BPD have prototypic symptoms of both disorders, suggesting that both disorders are present and are distinguishable clinically.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilens</LastName><ForeName>Timothy E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biederman</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gunawardene</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Jocelyn</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Monuteaux</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DA12945</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12842302</ArticleId><ArticleId IdType="pii">S0006322302016669</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(02)01666-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21270973</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2016</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0327-6139</ISSN><JournalIssue CitedMedium="Print"><Volume>21 Suppl II Consenso</Volume><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Vertex (Buenos Aires, Argentina)</Title><ISOAbbreviation>Vertex</ISOAbbreviation></Journal><ArticleTitle>[2nd Argentine consensus on the treatment of bipolar disorders 2010].</ArticleTitle><Pagination><MedlinePgn>3-55</MedlinePgn></Pagination><Abstract><AbstractText>The consensus guidelines of Argentine experts in the treatment of bipolar disorders are the result of three days of work of the 9 main local experts under the organization of the Argentine Association of Mood Disorders (ASATHU). This work is an update of the guidelines published on this journal in 2006. It was adopted a mixed criterion for its preparation: all the recent data of the evidence medicine based published until now were discussed and were balanced with the knowledge acquired from clinical experience of the local experts on the bipolar field. It presents general recommendations and suggested therapeutic sequences for maintenance, manic/hypomanic or mixed episode and depressive episode treatments. Bipolar disorders have been divided according to the international classifications in type I and II; with or without rapid cycling. This work also includes a series of recommendations for early and differential diagnosis of bipolar disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strejilevich</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Programa de Trastornos Bipolares, Instituto de Neurociencias, Universidad Favaloro. sstrejilevich@ffavaloro.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vázquez</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>García Boneto</LastName><ForeName>Gerardo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Zaratiegui</LastName><ForeName>Rodolfo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Vilapriño</LastName><ForeName>Juan J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Herbst</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lupo</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Cetkovich-Bakmas</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><VernacularTitle>II Consenso argentino sobre el tratamiento de los trastornos bipolares 2010.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Vertex</MedlineTA><NlmUniqueID>9440528</NlmUniqueID><ISSNLinking>0327-6139</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21270973</ArticleId><ArticleId IdType="pii">040579197</ArticleId><ArticleId IdType="doi">10.1267/science.040579197</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">33620723</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-7339</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Tijdschrift voor psychiatrie</Title><ISOAbbreviation>Tijdschr Psychiatr</ISOAbbreviation></Journal><ArticleTitle>[Proactive cognitive psychiatry while aging].</ArticleTitle><Pagination><MedlinePgn>120-124</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COGNITIVE SYMPTOMS ARE COMMONLY REPORTED IN PATIENTS WITH UNIPOLAR OR BIPOLAR MOOD DISORDER. THE PREVALENCE OF COGNITIVE SYMPTOMS INCREASES WITH AGEING. THE PRESENCE AND EXTENT OF COGNITIVE SYMPTOMS HAS A DIRECT NEGATIVE IMPACT ON RECOVERY OF THE PSYCHIATRIC ILLNESS AND QUALITY OF LIFE. &lt;br/&gt; AIM: IMPROVING OUTCOME OF OLDER PATIENTS WITH A UNIPOLAR OR BIPOLAR MOOD DISORDER.&lt;br/&gt; METHOD: REVIEW OF AVAILABLE INTERVENTIONS TO IMPROVE COGNITIVE FUNCTIONING DIRECT OR INDIRECT.&lt;br/&gt; RESULTS: STRATEGY TRAINING, TRAINING OF COGNITIVE FUNCTIONS AND PHYSICAL EXERCISE HAVE SHOWN TO BE EFFECTIVE TO IMPROVE COGNITIVE FUNCTIONING AND ITS POSSIBLE ADVANTAGES FOR PSYCHIATRIC POPULATIONS ARE CURRENTLY STUDIED IN THE NETHERLANDS. TREATMENT OF COMORBID INSOMNIA BY COGNITIVE BEHAVIORAL THERAPY MAY IMPROVE COGNITIVE FUNCTIONING INDIRECTLY BY DISCONTINUATION OF SLEEP MEDICATION, IMPROVEMENT OF SLEEP AND MOOD RELATED COGNITIVE SYMPTOMS.&lt;br/&gt; CONCLUSION: A PROACTIVE APPROACH, INCLUDING SCREENING AND TREATMENT OF COGNITIVE SYMPTOMS BEFORE IMPAIRMENT OCCURS, IS WARRANTED TO OPTIMIZE OUTCOME OF THE AGEING PSYCHIATRIC PATIENT. TIJDSCHRIFT VOOR PSYCHIATRIE 63(2021)2, 120-124.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dols</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Oudega</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Korten</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Vijverberg</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Schouws</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>dut</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Proactieve cognitieve psychiatrie bij het ouder worden.</VernacularTitle></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Tijdschr Psychiatr</MedlineTA><NlmUniqueID>0423731</NlmUniqueID><ISSNLinking>0303-7339</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="Y">Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>23</Day><Hour>12</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33620723</ArticleId><ArticleId IdType="pii">TVPart_12471</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6814397</PMID><DateCompleted><Year>1982</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>11</Issue><PubDate><Year>1982</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Prophylaxis with lithium carbonate: an update.</ArticleTitle><Pagination><MedlinePgn>1344-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dunner</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Stallone</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Fieve</LastName><ForeName>R R</ForeName><Initials>RR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6814397</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1982.04290110092017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">30920970</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>05</Month></PubDate></JournalIssue><Title>Current opinion in psychiatry</Title><ISOAbbreviation>Curr Opin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Dysregulation of the gut-brain axis in schizophrenia and bipolar disorder: probiotic supplementation as a supportive treatment in psychiatric disorders.</ArticleTitle><Pagination><MedlinePgn>185-195</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YCO.0000000000000499</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">Schizophrenia (SCZ) and bipolar disorder are severe mental disorders, both placing a significant burden on individuals' wellbeing and global health generally. The complex interaction of multiple mechanisms, underlying these disorders, still needs further elucidation. Increased activation of components of the immune system may be involved, including alterations in intestinal permeability and gut microbiome. Probiotics, defined as living microorganisms conferring health benefits to the host when administered in adequate amounts, seem to have supportive therapeutic effect in psychiatric disorders. The authors in this review provide an overview of this emerging research field and summarize both the publicated microbiome studies in SCZ and bipolar disorder and the current clinical research using probiotic supplementation in patients diagnosed with these disorders.</AbstractText><AbstractText Label="RECENT FINDINGS">The current data indicate that there are differences in the microbiome in SCZ and bipolar disorder patients as compared with healthy controls. Part of these differences may be induced by medication use, others by smoking and other lifestyle factors. Correlations between microbiome quantification and symptom severity have been observed in cross-sectional studies, but unfortunately, no replicated findings so far. Probiotic supplementation was shown not only to alleviate gastrointestinal complaints but also reduce symptom severity, rehospitalization rates and cognitive improvement. Replication of improvement of cognition is needed.</AbstractText><AbstractText Label="SUMMARY">Differences in microbiome have been shown in both SCZ and bipolar disorder in comparison to healthy controls. Evidence that probiotics can improve psychiatric functioning is still very limited.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Genedi</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Cells &amp; Systems.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janmaat</LastName><ForeName>Isabel E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Cells &amp; Systems.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haarman</LastName><ForeName>Bartholomeus Benno C M</ForeName><Initials>BBCM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sommer</LastName><ForeName>Iris E C</ForeName><Initials>IEC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Cells &amp; Systems.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Psychiatry</MedlineTA><NlmUniqueID>8809880</NlmUniqueID><ISSNLinking>0951-7367</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078331" MajorTopicYN="N">Correlation of Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="Y">Dysbiosis</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30920970</ArticleId><ArticleId IdType="doi">10.1097/YCO.0000000000000499</ArticleId><ArticleId IdType="pii">00001504-201905000-00008</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19766321</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2010</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>123</Volume><Issue>1-3</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Gray matter reduction of the superior temporal gyrus in patients with established bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>276-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2009.08.022</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Functional abnormalities of the superior temporal gyrus (STG) have been implicated in the pathophysiology of bipolar disorder, but magnetic resonance imaging (MRI) studies of this region have yielded inconsistent findings.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We used MRI to examine the volumes of the STG and its gray matter subregions [planum polare (PP), Heschl gyrus (HG), planum temporale (PT), and lateral STG (rostral and caudal regions)] in 26 patients with established bipolar I disorder (8 males and 18 females, mean age=38.4 years) and 24 age and gender-matched healthy controls (7 males and 17 females, mean age=38.7 years).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar patients had significantly smaller volumes of the PT and caudal STG compared with controls in the left hemisphere. The STG white matter volume did not differ between the groups. There was no association between the STG volume and number of manic/depressive episodes, family history, or clinical subtype (i.e., psychotic and nonpsychotic), but daily dosage of lithium treatment at the time of scanning was positively correlated with right PP and right rostral STG volumes.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Entire clinical data (e.g., lifetime medication, symptomatology) were not available.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings implicate a role for the STG gray matter, especially its left posterior regions, in the neurobiology of bipolar disorder. Our findings may also support the notion of lithium-induced gray matter expansion.</AbstractText><CopyrightInformation>Copyright 2009 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Tsutomu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Victoria, Australia. tsutomu@med.u-toyama.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhi</LastName><ForeName>Gin S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Yücel</LastName><ForeName>Murat</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Walterfang</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kawasaki</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Michio</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pantelis</LastName><ForeName>Christos</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="Y">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="Y">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>08</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19766321</ArticleId><ArticleId IdType="pii">S0165-0327(09)00405-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2009.08.022</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3971001</PMID><DateCompleted><Year>1985</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>1985</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lithium in prophylactic therapy of manic-depressive illness: biochemical correlates of response.</ArticleTitle><Pagination><MedlinePgn>202-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Upadhyaya</LastName><ForeName>A K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Varma</LastName><ForeName>V K</ForeName><Initials>VK</Initials></Author><Author ValidYN="Y"><LastName>Sankaranarayanan</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Goel</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NEZ333N27</RegistryNumber><NameOfSubstance UI="D012964">Sodium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012964" MajorTopicYN="N">Sodium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3971001</ArticleId><ArticleId IdType="pii">0006-3223(85)90083-6</ArticleId><ArticleId IdType="doi">10.1016/0006-3223(85)90083-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4849730</PMID><DateCompleted><Year>1974</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2015</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><JournalIssue CitedMedium="Print"><Volume>219</Volume><Issue>2</Issue><PubDate><Year>1974</Year></PubDate></JournalIssue><Title>Archiv fur Psychiatrie und Nervenkrankheiten</Title><ISOAbbreviation>Arch Psychiatr Nervenkr (1970)</ISOAbbreviation></Journal><ArticleTitle>[Social and other exogenous factors in case history of involutional depressions. A statistical investigation (author's transl)].</ArticleTitle><Pagination><MedlinePgn>187-96</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lungershausen</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Soziale und andere exogene Faktoren im Vorfeld depressiver Psychosen des Involutionsalters. Statistische Untersuchungen</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Arch Psychiatr Nervenkr (1970)</MedlineTA><NlmUniqueID>1270313</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005860" MajorTopicYN="N" Type="Geographic">Germany, West</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012924" MajorTopicYN="N">Social Conditions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1974</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1974</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1974</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4849730</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3602337</PMID><DateCompleted><Year>1987</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-3190</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>1-2</Issue><PubDate><Year>1986</Year></PubDate></JournalIssue><Title>Psychotherapy and psychosomatics</Title><ISOAbbreviation>Psychother Psychosom</ISOAbbreviation></Journal><ArticleTitle>Different treatment modalities for recurrent bipolar affective disorders: an integrative approach.</ArticleTitle><Pagination><MedlinePgn>13-22</MedlinePgn></Pagination><Abstract><AbstractText>Pharmacological, behavioural and psychotherapeutic procedures for the acute and prophylactic treatment of mania and depression are considered in outline. It is argued that the manic state is the primary disorder, with depression being a secondary homeostatic response to mania: the prophylaxis of depression thus depends upon the successful long-term control of mania. Suggestions are made regarding ways in which nonpharmacological techniques may be developed to achieve the prophylactic effectiveness against recurrent bipolar affective disorders which is, at the present time, to be found only among pharmacological treatment procedures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>F N</ForeName><Initials>FN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychother Psychosom</MedlineTA><NlmUniqueID>0024046</NlmUniqueID><ISSNLinking>0033-3190</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001521" MajorTopicYN="N">Behavior Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3602337</ArticleId><ArticleId IdType="doi">10.1159/000287958</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1545043</PMID><DateCompleted><Year>1992</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>1992</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Course of bipolar disorder in eastern India.</ArticleTitle><Pagination><MedlinePgn>35-41</MedlinePgn></Pagination><Abstract><AbstractText>The life course of affective episodes was determined for 95 consecutively admitted patients from eastern India fulfilling RDC criteria for definite mania during the current episode, using SADS-L interviews. There was a significantly greater frequency of manic compared to depressive relapses. Presentation as recurrent mania was very common. The total numbers of affective and manic episodes were significantly higher among those with recurrent mania and in cases where the first illness episode was manic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khanna</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Central Institute of Psychiatry, Kanke, Ranchi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Shanker</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="Y">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003906" MajorTopicYN="Y">Developing Countries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1545043</ArticleId><ArticleId IdType="pii">0165-0327(92)90058-E</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(92)90058-e</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24844980</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>218</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Evidence of weekly cyclicity in mood and functional impairment in those with a bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>290-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2014.04.047</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(14)00361-8</ELocationID><Abstract><AbstractText>A key characteristic of bipolar disorder is fluctuation in mood symptoms and functional capacity, yet assessment of bipolar symptomatology often relies heavily on interval measurement that is unable to capture the full range of daily symptom variability and severity. The current study provides a detailed analysis of the variability in mood symptoms, functional impairment and medication compliance in a large sample of individuals newly diagnosed with bipolar disorder. Individuals diagnosed with bipolar disorder in the previous 12 months (n=192) rated their mood, functional impairment, medication compliance and symptom triggers daily over 10 consecutive weeks. High mood, low mood and functional impairment were found to vary on a weekly cycle, independently of medication compliance. Low mood and functional impairment were worse on weekdays, particularly Mondays and Tuesdays, whereas mood was most elevated on Saturdays. Work-related stressors were the most common symptom triggers on weekdays, whereas sleep-related problems and positive social events were the most common triggers on weekends. This study provides evidence that individuals newly diagnosed with bipolar disorder experience fluctuations in mood and functioning that vary according to a weekly cycle. This finding has implications for the assessment and treatment of patients, and for future research. </AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Proudfoot</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of NSW and Black Dog Institute, Hospital Road, Randwick, Sydney, NSW 2031, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitton</LastName><ForeName>Alexis E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of NSW and Black Dog Institute, Hospital Road, Randwick, Sydney, NSW 2031, Australia. Electronic address: alexis.e.whitton@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of NSW and Black Dog Institute, Hospital Road, Randwick, Sydney, NSW 2031, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manicavasagar</LastName><ForeName>Vijaya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of NSW and Black Dog Institute, Hospital Road, Randwick, Sydney, NSW 2031, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of NSW and Black Dog Institute, Hospital Road, Randwick, Sydney, NSW 2031, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Meg</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Social Sciences, University of Western Sydney, Penrith South DC, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="Y">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010507" MajorTopicYN="N">Periodicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="N">Temperament</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Functional impairment</Keyword><Keyword MajorTopicYN="N">Hypomania</Keyword><Keyword MajorTopicYN="N">Mania</Keyword><Keyword MajorTopicYN="N">Medication compliance</Keyword><Keyword MajorTopicYN="N">Mood monitoring</Keyword><Keyword MajorTopicYN="N">Weekly cycle</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>04</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24844980</ArticleId><ArticleId IdType="pii">S0165-1781(14)00361-8</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2014.04.047</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29488889</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1105-2333</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>4</Issue><PubDate><MedlineDate>2017 Oct-Dec</MedlineDate></PubDate></JournalIssue><Title>Psychiatrike = Psychiatriki</Title><ISOAbbreviation>Psychiatriki</ISOAbbreviation></Journal><ArticleTitle>[Perceptions regarding pharmacotherapy and effective treatment disease in people diagnosed with bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>291-300</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.22365/jpsych.2017.284.291</ELocationID><Abstract><AbstractText>Bipolar disorder (BD) encompasses neuro-cognitive disturbances leading to psychological and social consequences affecting the quality of life of those suffering from it. However, the number of studies on the lived experience of people with BD about the treatment provided is relatively scant. The aim of this study is to investigate the lived experience of people with BD, focused on their perceptions and meanings about the treatment provided for their disorder. A qualitative, phenomenological design was applied. Following informed consent, thirteen people agreed to participate in the study, according to purposeful sampling and thematic saturation. Data collection was achieved through individual, semistructural interviews with open-ended questions, of a 30 minutes to an hour. The rigor of the analysis was validated according to Munhall's and van Manen's criteria. With regard to the main themes emerged, those revolved mainly around the social stigmatization following psychotropic medication. Further, the participants described anguish, fear and insecurity about the winding road nature of the disease, a condition that seemed to be worsened mainly due to discontinuation of medication, or alterations of the therapeutic schema. Interestingly, some of the participants described medication as a nutrient ingredient that kept them alive, thus revealing the importance they attached to psychotropic medication. Participants highlighted the importance of psychotropic medication, along with psychotherapy and personal effort, as well as education on topics related to psychopathology and treatment interventions for BD. Control over the clinical outcome of the disorder and self-management of the symptoms seem to be the ultimate need of people suffering from BD, with a core association to the effective medication and psycho-education. Based on that, interventions aiming to patients' education in self-management skills are suggested. Furthermore, interventions towards the sensitization of the community on the biological aspects of mental disorders are proposed, tackling issues as stigma and medication concerns.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ηatzioannou</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cyprus Mental Health Services, Nicosia, Cyprus.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nursing, Cyprus University of Technology, Limassol, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karanikola</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nursing, Cyprus University of Technology, Limassol, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papathanasoglou</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaikoushi</LastName><ForeName>Aik</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nursing, Cyprus University of Technology, Limassol, Cyprus.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Health Services, Famagusta, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nystazaki</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Athens, "Agioi Anargyroi" Hospital, Athens.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alevizopoulos</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Athens, "Agioi Anargyroi" Hospital, Athens.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nursing, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>gre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Psychiatriki</MedlineTA><NlmUniqueID>101534363</NlmUniqueID><ISSNLinking>1105-2333</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29488889</ArticleId><ArticleId IdType="doi">10.22365/jpsych.2017.284.291</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2049022</PMID><DateCompleted><Year>1991</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>1991</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Depression sub-typing: unitary, binary or arbitrary?</ArticleTitle><Pagination><MedlinePgn>63-76</MedlinePgn></Pagination><Abstract><AbstractText>The strongest statistical support for the binary view of depression has been provided by factor (principal components) analytic studies which delineate a bipolar factor with features interpreted as reflecting "endogenous depression" and "neurotic depression" at opposing poles. We review the seminal studies to suggest instead that the bipolar factor has generally polarised depression and anxiety, and that no such entity or symptom complex of "neurotic depression" has been isolated. Instead "neurotic depression" has been defined principally by features of anxiety and personality style. We argue that the suggested entity is, in fact, a pseudo-entity, being no more than a residual group of non-depressive features without any significant intrinsic depressive characteristics. We support our interpretation by showing comparable solutions in published studies of depressives alone, contrasted with separate analyses of anxious and depressed patients. We also report two studies in which the "neurotic depressive" pole is made to appear and disappear by the inclusion and exclusion of anxiety items. As factor analytic studies have defined the "residual" pole so variably, we argue that some features held to distinguish neurotic depression are of no utility and that such a diagnosis is meaningless. We suggest that the clinician should not proceed (after excluding endogenous depression) to conclude that the default option is necessarily an entity "neurotic depression" and that instead a heterogeneous group of options (e.g. anxiety, personality disorder) require review. If the "neurotic depressive" type of the multivariate analytic studies is a pseudo-entity, then a modified unitary view of depression may be valid.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Mood Disorders Unit, Prince Henry Hospital, Sydney.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Boyce</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hadzi-Pavlovic</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wilhelm</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hickie</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Eyers</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Aust N Z J Psychiatry. 1991 Jun;25(2):160</RefSource><PMID Version="1">1877952</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2049022</ArticleId><ArticleId IdType="doi">10.3109/00048679109077720</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9778606</PMID><DateCompleted><Year>1999</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0302-282X</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>3</Issue><PubDate><Year>1998</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neuropsychobiology</Title><ISOAbbreviation>Neuropsychobiology</ISOAbbreviation></Journal><ArticleTitle>Differential treatment of bipolar disorder with old and new antiepileptic drugs.</ArticleTitle><Pagination><MedlinePgn>181-4</MedlinePgn></Pagination><Abstract><AbstractText>Although lithium remains the preferred medication for bipolar disorders, new investigations suggest that only 60 to 80% of patients have a good response with a classical presentation. The antiepileptics carbamazepine and valproate are important alternatives. Several studies have shown that lithium, carbamazepine and valproate are effective in pure mania. Mixed mania and rapid cycling respond, however, well to valproate. One disadvantage of carbamazepine is its enzyme inducing property with the consequence of a decrease of plasma levels of other psychotropic medications and a worsening of psychopathology. First data indicate a good antimanic and antidepressive efficacy of the new antiepileptic drug lamotrigine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walden</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Universities of Freiburg and Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Normann</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Langosch</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuropsychobiology</MedlineTA><NlmUniqueID>7512895</NlmUniqueID><ISSNLinking>0302-282X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>25</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>10</Month><Day>21</Day><Hour>2</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>16</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>10</Month><Day>21</Day><Hour>2</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9778606</ArticleId><ArticleId IdType="pii">nps38181</ArticleId><ArticleId IdType="doi">10.1159/000026534</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15968806</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-9580</ISSN><JournalIssue CitedMedium="Print"><Volume>46 Suppl 4</Volume><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Epilepsia</Title><ISOAbbreviation>Epilepsia</ISOAbbreviation></Journal><ArticleTitle>Epidemiology of bipolar disorders.</ArticleTitle><Pagination><MedlinePgn>8-13</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Bipolar, or manic-depressive, disorders are frequent and severe mental illnesses associated with considerable morbidity and mortality. Epilepsy and bipolar disorder could probably share some aspects of pathophysiology because manic as well as depressive symptoms are seen in patients with seizures, and a number of antiepileptic drugs are effectively used in the acute and prophylactic treatment of bipolar disorder. Epidemiologic research suggests a dimensional composition of bipolar illness at the population level. Apart from the DSM-IV diagnostic features of bipolar I (mania and depression) and bipolar II (hypomania and depression), the concept of bipolar spectrum disorders comprises a range of bipolar conditions with less obvious manifestations with estimated lifetime prevalence rates ranging from 2.8 to 6.5%. Expanding the definition of bipolar II disorders shows that half of the patients currently diagnosed with a unipolar depressive episode could suffer from unrecognized bipolar II disorder, and about the same number of mild depressive patients could be minor bipolars. Research efforts to refine the diagnostic criteria of bipolar disorder aim at an earlier and complete recognition of the disease to provide appropriate pharmacological and nonpharmacological treatment early in the course of the illness to anticipate individual suffering, suicidal behavior, and increased socioeconomic costs for society. This article also discusses risk factors, comorbid conditions, course of illness, as well as the individual and socioeconomic impact of bipolar disorders.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The findings suggest reconceptualizing bipolar illnesses as highly recurrent, malignant disorders that occur far more frequently than previously thought. Interdisciplinary knowledge transfer could help to increase our understanding of the pathophysiology of these disorders as well as provide grounds for better recognition and treatment of patients with manic and/or depressive symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Charité-University Medicine Berlin, Campus Charité Mitte (CCM), Department of Psychiatry and Psychotherapy, Berlin, Germany. michael.bauer@charite.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfennig</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epilepsia</MedlineTA><NlmUniqueID>2983306R</NlmUniqueID><ISSNLinking>0013-9580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>90</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15968806</ArticleId><ArticleId IdType="doi">10.1111/j.1528-1167.2005.463003.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18849897</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8529</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2008</Year><Month>Sep</Month></PubDate></JournalIssue><Title>CNS spectrums</Title><ISOAbbreviation>CNS Spectr</ISOAbbreviation></Journal><ArticleTitle>Factors associated with rapid cycling in bipolar I manic patients: findings from a French national study.</ArticleTitle><Pagination><MedlinePgn>780-7</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Despite numerous explanatory hypotheses, few studies have involved a large national clinical sample examining risk factors in the occurrence of rapid cycling during the course of bipolar illness.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From 1,090 manic bipolar I disorder inpatients included in a multicenter national study in France, 958 could be classified as rapid or nonrapid cyclers and assessed for demographic, illness course, clinical, psychometric, temperament, comorbidity, and treatment characteristics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Rapid cycling bipolar disorder occurred in 9% (n=86) of the study group. Compared to nonrapid cyclers (n=872), patients with rapid cycling experienced the onset of their illness at a younger age, a higher number of prior episodes, more depression during the first episode, and more suicide attempts. At study entry, they also experienced manic episodes with more depressive and anxious symptoms, but less psychotic features. The following independent variables were associated with rapid cycling: longer duration of illness, antidepressant treatment, episodes with no free intervals, cyclothymic temperament, lower scores on the Scale for Assessment of Positive Symptoms and presence of thyroid disorder. Retrospective study limited to bipolar I disorder inpatients; several factors previously associated with rapid cycling were not assessed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings may confirm previous descriptions, according to which rapid cycling develops later in the course of illness following a sensitization process triggered by antidepressant use or thyroid dysfunction, in patients with a depression-mania-free interval course, and cyclothymic temperament.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>University of Aix-Marseille II, and Department of Adult Psychiatry, Sainte Marguerite Hospital, Marseille Cedex 09, France. jazorin@ap-hm.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaladjian</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Adida</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hantouche</LastName><ForeName>Elie G</ForeName><Initials>EG</Initials></Author><Author ValidYN="Y"><LastName>Hameg</LastName><ForeName>Ahcene</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lancrenon</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Hagop S</ForeName><Initials>HS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CNS Spectr</MedlineTA><NlmUniqueID>9702877</NlmUniqueID><ISSNLinking>1092-8529</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013959" MajorTopicYN="N">Thyroid Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18849897</ArticleId><ArticleId IdType="doi">10.1017/s1092852900013900</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19555719</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-6321</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Brain research reviews</Title><ISOAbbreviation>Brain Res Rev</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder and mechanisms of action of mood stabilizers.</ArticleTitle><Pagination><MedlinePgn>185-209</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.brainresrev.2009.06.003</ELocationID><Abstract><AbstractText>Bipolar disorder (BD) is a major medical and social burden, whose cause, pathophysiology and treatment are not agreed on. It is characterized by recurrent periods of mania and depression (Bipolar I) or of hypomania and depression (Bipolar II). Its inheritance is polygenic, with evidence of a neurotransmission imbalance and disease progression. Patients often take multiple agents concurrently, with incomplete therapeutic success, particularly with regard to depression. Suicide is common. Of the hypotheses regarding the action of mood stabilizers in BD, the "arachidonic acid (AA) cascade" hypothesis is presented in detail in this review. It is based on evidence that chronic administration of lithium, carbamazepine, sodium valproate, or lamotrigine to rats downregulated AA turnover in brain phospholipids, formation of prostaglandin E(2), and/or expression of AA cascade enzymes, including cytosolic phospholipase A(2), cyclooxygenase-2 and/or acyl-CoA synthetase. The changes were selective for AA, since brain docosahexaenoic or palmitic acid metabolism, when measured, was unaffected, and topiramate, ineffective in BD, did not modify the rat brain AA cascade. Downregulation of the cascade by the mood stabilizers corresponded to inhibition of AA neurotransmission via dopaminergic D(2)-like and glutamatergic NMDA receptors. Unlike the mood stabilizers, antidepressants that increase switching of bipolar depression to mania upregulated the rat brain AA cascade. These observations suggest that the brain AA cascade is a common target of mood stabilizers, and that bipolar symptoms, particularly mania, are associated with an upregulated cascade and excess AA signaling via D(2)-like and NMDA receptors. This review presents ways to test these suggestions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rapoport</LastName><ForeName>Stanley I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA. sir@helix.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basselin</LastName><ForeName>Mireille</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyung-Wook</ForeName><Initials>HW</Initials></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Jagadeesh S</ForeName><Initials>JS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z01 AG000145-07</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Brain Res Rev</MedlineTA><NlmUniqueID>101300366</NlmUniqueID><ISSNLinking>0165-0173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>27YG812J1I</RegistryNumber><NameOfSubstance UI="D016718">Arachidonic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016718" MajorTopicYN="N">Arachidonic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019610" MajorTopicYN="N">Cytoprotection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>299</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19555719</ArticleId><ArticleId IdType="pii">S0165-0173(09)00074-5</ArticleId><ArticleId IdType="doi">10.1016/j.brainresrev.2009.06.003</ArticleId><ArticleId IdType="pmc">PMC2757443</ArticleId><ArticleId IdType="mid">NIHMS133490</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Psychiatry. 2002;7(8):845-50</Citation><ArticleIdList><ArticleId IdType="pubmed">12232777</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Nov 1;60(9):1020-2</Citation><ArticleIdList><ArticleId IdType="pubmed">16814257</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2317-21</Citation><ArticleIdList><ArticleId IdType="pubmed">8637870</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 15;62(8):934-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17628508</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1999 Oct 30;846(1):112-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10536218</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Braz J Psychiatry. 2006 Sep;28(3):252-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17063225</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2007;21(9):727-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17696573</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 5;133B(1):110-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15578606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Physiol. 2002 Dec;193(3):275-86</Citation><ArticleIdList><ArticleId IdType="pubmed">12384980</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 May;60(5):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Oct;161(10):1814-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15465978</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2003 Sep;24(9):441-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12967765</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2006 Mar;40(3):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16476148</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2006 Feb;96(3):669-79</Citation><ArticleIdList><ArticleId IdType="pubmed">16405503</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2007;31(6):920-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17499358</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Clin Nutr Metab Care. 2007 Mar;10(2):136-41</Citation><ArticleIdList><ArticleId IdType="pubmed">17285000</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2001 May;77(3):796-803</Citation><ArticleIdList><ArticleId IdType="pubmed">11331408</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Jan 15;61(2):154-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16806101</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1998 Oct 15;335 ( Pt 2):313-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9761729</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2003 May;8(5):546-57</Citation><ArticleIdList><ArticleId IdType="pubmed">12808434</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1977 Mar;34(3):346-51</Citation><ArticleIdList><ArticleId IdType="pubmed">320956</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2004 Jul 29;351(5):476-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15282355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2005 Dec;95(5):1332-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16313514</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 2):256-60</Citation><ArticleIdList><ArticleId IdType="pubmed">11249803</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2001 Apr-Jun;16(2-3):243-61; discussion 279-84</Citation><ArticleIdList><ArticleId IdType="pubmed">11478380</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2002 Mar 8;114(2):177-85</Citation><ArticleIdList><ArticleId IdType="pubmed">11857579</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1980;67(3):297-305</Citation><ArticleIdList><ArticleId IdType="pubmed">6155678</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 1998 Oct;139(10):4073-85</Citation><ArticleIdList><ArticleId IdType="pubmed">9751485</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2001 Oct;21(10):1133-45</Citation><ArticleIdList><ArticleId IdType="pubmed">11598490</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 1999 Mar;24(3):399-406</Citation><ArticleIdList><ArticleId IdType="pubmed">10215514</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2003 Jul;168(3):344-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12684737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1988;546:122-32</Citation><ArticleIdList><ArticleId IdType="pubmed">3073692</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1977 Mar;34(3):355-7</Citation><ArticleIdList><ArticleId IdType="pubmed">320957</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2007 Aug;102(3):761-72</Citation><ArticleIdList><ArticleId IdType="pubmed">17488274</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2006 Feb;11(2):125-33, 115</Citation><ArticleIdList><ArticleId IdType="pubmed">16261167</ArticleId></ArticleIdList></Reference><Reference><Citation>Naunyn Schmiedebergs Arch Pharmacol. 1981 Nov;317(3):209-13</Citation><ArticleIdList><ArticleId IdType="pubmed">7322212</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2007 Sep;102(6):1918-1927</Citation><ArticleIdList><ArticleId IdType="pubmed">17550430</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1993 Nov 1;34(9):641-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8292693</ArticleId></ArticleIdList></Reference><Reference><Citation>Med J Aust. 1949 Sep 3;2(10):349-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18142718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2007 Jan;12(1):36-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16983391</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10237-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12149485</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomics. 1995 Mar 1;26(1):138-41</Citation><ArticleIdList><ArticleId IdType="pubmed">7782073</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Dec;10(12):1104-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16103889</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2000 May;150(1):15-23</Citation><ArticleIdList><ArticleId IdType="pubmed">10867972</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2006 Jun;9(3):267-76</Citation><ArticleIdList><ArticleId IdType="pubmed">15982445</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Feb;52(2):114-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7848047</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychiatry. 2007 Jan;20(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17143074</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Aug 1;58(3):175-89</Citation><ArticleIdList><ArticleId IdType="pubmed">16084838</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Dec;104(1-3):91-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17434599</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2005 Aug;1053:195-204</Citation><ArticleIdList><ArticleId IdType="pubmed">16179524</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 1991 Sep;13(5):345-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1743505</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 1996 Aug;22(2):183-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8883919</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Dev Neurosci. 2000 Nov;18(7):669-77</Citation><ArticleIdList><ArticleId IdType="pubmed">10978845</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1999 Jan 8;274(2):628-37</Citation><ArticleIdList><ArticleId IdType="pubmed">9872996</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 2001;52:503-17</Citation><ArticleIdList><ArticleId IdType="pubmed">11160792</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Aug;9(8):734-55</Citation><ArticleIdList><ArticleId IdType="pubmed">15136794</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2001 Dec;79(5):1090-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11739623</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 2006 Sep;58(3):591-620</Citation><ArticleIdList><ArticleId IdType="pubmed">16968951</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Rev Neurobiol. 2004;16(1-2):83-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15581403</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2000;42 Suppl 1:2-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11093063</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2005 Jul;30(7):1223-37</Citation><ArticleIdList><ArticleId IdType="pubmed">15827567</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 1999 Dec 16;10(18):3887-90</Citation><ArticleIdList><ArticleId IdType="pubmed">10716228</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1996 Jan;57(1):22-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8543543</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2006 Aug 4;1103(1):164-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16806120</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsy Res. 2001 Feb;43(2):153-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11164704</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Jan 15;49(2):97-109</Citation><ArticleIdList><ArticleId IdType="pubmed">11164756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1997 Aug;69(2):704-12</Citation><ArticleIdList><ArticleId IdType="pubmed">9231730</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Jun;7(3):260-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15898963</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2004 Sep;45(9):1471-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15347713</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1989 Nov 3;59(3):411-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2553271</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1997 Dec;69(6):2336-44</Citation><ArticleIdList><ArticleId IdType="pubmed">9375664</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Feb;13(2):197-207</Citation><ArticleIdList><ArticleId IdType="pubmed">17486107</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2001 Jun;107(11):1347-51</Citation><ArticleIdList><ArticleId IdType="pubmed">11390414</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2005 Aug;94(4):1063-76</Citation><ArticleIdList><ArticleId IdType="pubmed">16092947</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 2008 Sep;60(3):358-403</Citation><ArticleIdList><ArticleId IdType="pubmed">18922967</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsy Res Suppl. 1996;11:153-80</Citation><ArticleIdList><ArticleId IdType="pubmed">9294735</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2006 Nov 6;17(16):1739-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17047464</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Jul 21;24(29):6578-89</Citation><ArticleIdList><ArticleId IdType="pubmed">15269270</ArticleId></ArticleIdList></Reference><Reference><Citation>Prostaglandins Other Lipid Mediat. 2005 Sep;77(1-4):65-76</Citation><ArticleIdList><ArticleId IdType="pubmed">16099392</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2007 Sep;32(9):1888-902</Citation><ArticleIdList><ArticleId IdType="pubmed">17299517</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Mar;163(3):478-87</Citation><ArticleIdList><ArticleId IdType="pubmed">16513870</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1999 Mar;72(3):1327-30</Citation><ArticleIdList><ArticleId IdType="pubmed">10037507</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 1999 Feb 15;55(4):401-10</Citation><ArticleIdList><ArticleId IdType="pubmed">10723051</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2007 Feb;61(1):3-19</Citation><ArticleIdList><ArticleId IdType="pubmed">17239033</ArticleId></ArticleIdList></Reference><Reference><Citation>J Lipid Res. 2010 May;51(5):1049-56</Citation><ArticleIdList><ArticleId IdType="pubmed">20040630</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2001;15(11):871-904</Citation><ArticleIdList><ArticleId IdType="pubmed">11700151</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2003 Sep;2(9):527</Citation><ArticleIdList><ArticleId IdType="pubmed">12941571</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Lipidol. 2002 Jun;13(3):267-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12045396</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1990 Mar 1;27(5):555-60</Citation><ArticleIdList><ArticleId IdType="pubmed">2310809</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2006 Dec 7;52(5):897-909</Citation><ArticleIdList><ArticleId IdType="pubmed">17145509</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2001;19(5 Pt 1):483-95</Citation><ArticleIdList><ArticleId IdType="pubmed">11465308</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2008 Sep;49(9):1414-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18703605</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Pharmacol. 2007 Feb;7(1):33-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17129762</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 May;86(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15820265</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1993 Jun;54(6):229-34</Citation><ArticleIdList><ArticleId IdType="pubmed">8331092</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1997 Mar;16(3):238-45</Citation><ArticleIdList><ArticleId IdType="pubmed">9138440</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1982 Sep 15;206(3):587-95</Citation><ArticleIdList><ArticleId IdType="pubmed">7150264</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 May;69(1-3):1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12103447</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2003 Feb;28(2):244-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12589377</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1996 Dec 20;220(3):171-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8994220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Hum Genet. 1967 Aug;31(1):1-20</Citation><ArticleIdList><ArticleId IdType="pubmed">6056557</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Jun;13(6):558-69</Citation><ArticleIdList><ArticleId IdType="pubmed">18317468</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Feb;8(1):65-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16411982</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2005 May 13;76(26):3107-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15850602</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Mar 1;59(5):401-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16182257</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 1990 Jan;23(1):3-17</Citation><ArticleIdList><ArticleId IdType="pubmed">2179972</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1994 Mar 23-30;271(12):918-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8120960</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Jun;84(2-3):214-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16549338</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2005 Oct 14;280(41):35018-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16049015</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Jan;188:46-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16388069</ArticleId></ArticleIdList></Reference><Reference><Citation>Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):251-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18060754</ArticleId></ArticleIdList></Reference><Reference><Citation>Prostaglandins Leukot Essent Fatty Acids. 1997 Oct;57(4-5):353-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9430378</ArticleId></ArticleIdList></Reference><Reference><Citation>J Lipid Res. 2008 Jan;49(1):162-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17957090</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2008 Jul;33(7):1373-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18302021</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiol Clin. 2006 Jun;24(2):341-64</Citation><ArticleIdList><ArticleId IdType="pubmed">16927933</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2008 Mar;34(2):312-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18263882</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2007 Feb 15;34(4):1342-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17196833</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2007 Jun;35(2):208-19</Citation><ArticleIdList><ArticleId IdType="pubmed">17428676</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2006 Jan;184(1):122-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16344985</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2004 Jun 11;1011(1):58-68</Citation><ArticleIdList><ArticleId IdType="pubmed">15140644</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1990 Mar;87(6):2187-91</Citation><ArticleIdList><ArticleId IdType="pubmed">2315313</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hirnforsch. 1999;39(3):391-400</Citation><ArticleIdList><ArticleId IdType="pubmed">10536872</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Apr;15(4):384-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19488045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1989;559:37-55</Citation><ArticleIdList><ArticleId IdType="pubmed">2672943</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Brain Res. 1993;98:309-15</Citation><ArticleIdList><ArticleId IdType="pubmed">8248520</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Nutr. 1986;5(2):183-211</Citation><ArticleIdList><ArticleId IdType="pubmed">2873160</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2008 May;33(5):861-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18080190</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2008 Jan;33(1):110-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17912251</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2009 Aug;1791(8):697-705</Citation><ArticleIdList><ArticleId IdType="pubmed">19327408</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005;7 Suppl 4:13-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15948763</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Lipid Res. 1981;20:523-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6804977</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1996 Aug;67(2):822-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8764612</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2007 Nov;32(11):1857-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17562170</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2004 Jan;29(1):32-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12942141</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2007 Apr;32(4):793-802</Citation><ArticleIdList><ArticleId IdType="pubmed">16936714</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Jan;161(1):163-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14702267</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2004 Mar;88(5):1168-78</Citation><ArticleIdList><ArticleId IdType="pubmed">15009672</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2003 May;85(3):690-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12694395</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Nov;159(11):1841-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12411217</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1995 Mar 31;270(13):7737-44</Citation><ArticleIdList><ArticleId IdType="pubmed">7706322</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 1992;56(1):53-78</Citation><ArticleIdList><ArticleId IdType="pubmed">1297145</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Aug;9(5):513-20</Citation><ArticleIdList><ArticleId IdType="pubmed">17680922</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Jan;35(1):119-22</Citation><ArticleIdList><ArticleId IdType="pubmed">339869</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Jan;66(1):111-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15669897</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2007 Sep;32(5):363-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17823652</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 2003 Mar 13;538(1-3):145-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12633868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Feb;8(1):15-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16411977</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Jan 2;279(1):356-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14561756</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2005 Dec;77(6):1102-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16380920</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Apr;8(2):168-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16542187</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Pharmacol. 2003 Nov;59(8-9):583-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14504851</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2006 Aug 1;32(1):23-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16626973</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1989 May;46(5):421-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2712660</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Metab Dispos. 1986 Nov-Dec;14(6):692-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2877828</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Soc Trans. 1990 Aug;18(4):503-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2177403</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 Jul;12(6):851-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19400979</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 2003 Jul;44(7):917-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12823574</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2005 Apr 30;65(4):331-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15811599</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2001 Sep 28;276(39):36734-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11473107</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1991 Jun 14;65(6):1043-51</Citation><ArticleIdList><ArticleId IdType="pubmed">1904318</ArticleId></ArticleIdList></Reference><Reference><Citation>Naunyn Schmiedebergs Arch Pharmacol. 1999 Dec;360(6):609-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10619176</ArticleId></ArticleIdList></Reference><Reference><Citation>J Lipid Res. 2007 Nov;48(11):2463-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17715424</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurotrauma. 2003 Nov;20(11):1201-13</Citation><ArticleIdList><ArticleId IdType="pubmed">14651807</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2000 Aug 2;274(2):506-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10913368</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2009 Mar;34(3):536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">18719996</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2006 Aug;187(3):303-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16786332</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Dec;66(12):1598-609</Citation><ArticleIdList><ArticleId IdType="pubmed">16401164</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1996 Apr;16(2 Suppl 1):32S-47S</Citation><ArticleIdList><ArticleId IdType="pubmed">8707998</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 1995 Dec;29(6):442-50</Citation><ArticleIdList><ArticleId IdType="pubmed">8787949</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2005 Sep;30(9):1649-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15756305</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2005 Jun;28(2):427-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15826741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):123-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12507745</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2007 Aug;102(3):577-86</Citation><ArticleIdList><ArticleId IdType="pubmed">17403135</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2001 Mar;296(3):1074-84</Citation><ArticleIdList><ArticleId IdType="pubmed">11181943</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 1996 Jun 20;307(1):113-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8831112</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2003 Feb;28(2):300-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12589383</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):375-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11817516</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurocytol. 2005 Dec;34(6):447-58</Citation><ArticleIdList><ArticleId IdType="pubmed">16902765</ArticleId></ArticleIdList></Reference><Reference><Citation>Prostaglandins Other Lipid Mediat. 2000 Jan;60(1-3):15-26</Citation><ArticleIdList><ArticleId IdType="pubmed">10680772</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Apr 15;63(8):759-65</Citation><ArticleIdList><ArticleId IdType="pubmed">17945195</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2004 Nov;4(6 Suppl 2):S27-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16279863</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2005;31(1-3):27-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15953810</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2006 Mar;96(5):1336-48</Citation><ArticleIdList><ArticleId IdType="pubmed">16478526</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2002 Jan 15;57(2):205-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11849827</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Oct;63(10):942-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12416605</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2009 Jul 5;150B(5):638-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19035515</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacogenomics J. 2006 Nov-Dec;6(6):413-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16636684</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1995;56 Suppl 3:25-30</Citation><ArticleIdList><ArticleId IdType="pubmed">7883739</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2009 Jun;34(7):1695-709</Citation><ArticleIdList><ArticleId IdType="pubmed">19145225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2005 Aug;32(1):89-103</Citation><ArticleIdList><ArticleId IdType="pubmed">16077186</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2007 Jan;190(1):103-15</Citation><ArticleIdList><ArticleId IdType="pubmed">17093977</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2006 May-Jun;32(1-2):27-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16531065</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 1991 Mar;111(3):356-61</Citation><ArticleIdList><ArticleId IdType="pubmed">1847879</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Manag Care. 2005 Sep;11(8 Suppl):S235-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16180961</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2003 Jun;85(6):1553-62</Citation><ArticleIdList><ArticleId IdType="pubmed">12787074</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Jul;109(1-2):21-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18037498</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2005 Nov;30(11):2006-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15827566</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurotrauma. 1995 Oct;12(5):791-814</Citation><ArticleIdList><ArticleId IdType="pubmed">8594208</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1997 Apr 1;323 ( Pt 1):281-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9173894</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2007 Jun 7;447(7145):661-78</Citation><ArticleIdList><ArticleId IdType="pubmed">17554300</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jul;59(7):592-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12090811</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Feb 15;57(4):430-2</Citation><ArticleIdList><ArticleId IdType="pubmed">15705360</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Jun;15(6):602-14</Citation><ArticleIdList><ArticleId IdType="pubmed">18982003</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2002 May 1;51(9):762-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11983190</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipids Health Dis. 2007 Sep 18;6:21</Citation><ArticleIdList><ArticleId IdType="pubmed">17877810</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Aug;189:124-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16880481</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):518-30</Citation><ArticleIdList><ArticleId IdType="pubmed">11018224</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2008 May;197(4):557-66</Citation><ArticleIdList><ArticleId IdType="pubmed">18274730</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2005 Jul;180(3):523-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15719218</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Jun;13(6):585-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18347600</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotox Res. 2008 Jan;13(1):63-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18367441</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2007 Sep;193(4):467-74</Citation><ArticleIdList><ArticleId IdType="pubmed">17487474</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Drug Monit. 1998 Feb;20(1):56-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9485555</ArticleId></ArticleIdList></Reference><Reference><Citation>J Proteome Res. 2008 Oct;7(10):4266-77</Citation><ArticleIdList><ArticleId IdType="pubmed">18778095</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1995 Jul;12(4):277-85</Citation><ArticleIdList><ArticleId IdType="pubmed">7576004</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Toxicol Adverse Drug Exp. 1989 Mar-Apr;4(2):127-43</Citation><ArticleIdList><ArticleId IdType="pubmed">2654543</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Jan 15;61(2):246-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16697355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Lipid Res. 2009 Apr;50 Suppl:S237-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19011112</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1997 Jan;54(1):37-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9006398</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Dec;157(12):1925-32</Citation><ArticleIdList><ArticleId IdType="pubmed">11097952</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Jun 2;24(22):5131-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15175382</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2004 Dec;91(6):1389-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15584915</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2003 Jan;44(1):81-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12559124</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Jan;98(1-3):16-28</Citation><ArticleIdList><ArticleId IdType="pubmed">17933495</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2008 Feb;9(2):85-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18209729</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 1997 Jun;22(6):671-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9178949</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1995 Jun;64(6):2765-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7760057</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2007 Feb;12(2):151-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16983392</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2006 Aug;31(8):1659-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16292331</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2004;49(4):185-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15118355</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1996 Sep 1;318 ( Pt 2):701-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8809065</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7 Suppl 1:S57-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11986996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Lipid Res. 2001 May;42(5):678-85</Citation><ArticleIdList><ArticleId IdType="pubmed">11352974</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2007;31(6):832-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17466374</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 Sep 30;160(3):285-99</Citation><ArticleIdList><ArticleId IdType="pubmed">18715653</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2005 Oct;182(1):180-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15986187</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1999 May;4(3):274-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10395219</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1997 Nov;81(1):9-16</Citation><ArticleIdList><ArticleId IdType="pubmed">9300396</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1991 Jan;56(1):352-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1824784</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotherapeutics. 2007 Jan;4(1):130-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17199028</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Rev Clin Lab Sci. 2008;45(1):25-89</Citation><ArticleIdList><ArticleId IdType="pubmed">18293180</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7951-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9653121</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2007 May;101(3):577-99</Citation><ArticleIdList><ArticleId IdType="pubmed">17257165</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1999 Jun;53(3):233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10404709</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychosom Res. 1996 Jan;40(1):53-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8730644</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2006 Sep;1761(9):1050-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16920015</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 1999 Aug;9 Suppl 4:S109-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10524836</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2003 Sep;6(3):269-75</Citation><ArticleIdList><ArticleId IdType="pubmed">12974993</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1990 Jul;55(1):1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">2113081</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Feb;15(2):146-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19078961</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2008 Nov;33(11):2229-40</Citation><ArticleIdList><ArticleId IdType="pubmed">18461450</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 1998 Jul;22(5):787-802</Citation><ArticleIdList><ArticleId IdType="pubmed">9723120</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000;61 Suppl 9:5-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10826655</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Apr 26;356(17):1711-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17392295</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 1992 Sep-Dec;17(3):187-214</Citation><ArticleIdList><ArticleId IdType="pubmed">1467810</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Genet. 2006 Aug;16(4):169-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16829784</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Aug 15;56(4):248-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15312812</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 May;56(5):407-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10232294</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2003 Aug 15;121B(1):21-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12898570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(7):726-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12192617</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2004 Nov;91(4):936-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15525347</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2008 Nov;33(11):2318-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18500552</ArticleId></ArticleIdList></Reference><Reference><Citation>J Lipid Res. 2006 Jan;47(1):172-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16210728</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1987 Mar;48(3):89-93</Citation><ArticleIdList><ArticleId IdType="pubmed">3546274</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacogenet Genomics. 2007 Aug;17(8):605-17</Citation><ArticleIdList><ArticleId IdType="pubmed">17622937</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2000 Dec 29;68(6):669-78</Citation><ArticleIdList><ArticleId IdType="pubmed">11205881</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Jan;164(1):13-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17202538</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 1995 Feb;12(2):146-53</Citation><ArticleIdList><ArticleId IdType="pubmed">7766338</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2000 Sep;106(6):723-31</Citation><ArticleIdList><ArticleId IdType="pubmed">10995780</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Aug;5(4):295-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12895207</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2005 Aug;180(4):735-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16163535</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 Feb;60(2):79-88</Citation><ArticleIdList><ArticleId IdType="pubmed">10084633</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2004 Sep;4(5):759-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15853503</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1999 Jun;38(6):893-907</Citation><ArticleIdList><ArticleId IdType="pubmed">10465693</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Feb;56(2):162-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10025441</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 2003 Oct;143(4 Suppl):S26-34</Citation><ArticleIdList><ArticleId IdType="pubmed">14597911</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1990 Sep;20(1):19-25</Citation><ArticleIdList><ArticleId IdType="pubmed">2147187</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1999 Mar;38(3):403-14</Citation><ArticleIdList><ArticleId IdType="pubmed">10219978</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2005 Mar;30(3):461-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15562295</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Pharmacol. 2005 Nov;16(7):531-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16170230</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2003 Jul;139(5):1014-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12839876</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1998 Jan;70(1):325-34</Citation><ArticleIdList><ArticleId IdType="pubmed">9422378</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Feb;59(2):115-23</Citation><ArticleIdList><ArticleId IdType="pubmed">11825131</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 1999 Mar;24(2):154-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10212559</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2005 Jun;30(6):1064-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15812572</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Dec;160(12):2222-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14638594</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2004 Jul 15;63(6):485-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15249113</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):232-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16449476</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27025465</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2026</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Asian journal of psychiatry</Title><ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Course of illness in comorbid bipolar disorder and obsessive-compulsive disorder patients.</ArticleTitle><Pagination><MedlinePgn>12-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2016.01.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1876-2018(15)30111-8</ELocationID><Abstract><AbstractText>Psychiatric comorbidity is extremely common. One of the most common and difficult to manage comorbid conditions is the co-occurrence of bipolar disorder (BD) and obsessive compulsive disorder (OCD). We updated our recent systematic review searching the electronic databases MEDLINE, Embase, and PsycINFO to investigate course of illness in BD-OCD patients. We identified a total of 13 relevant papers which found that the majority of comorbid OCD cases appeared to be related to mood episodes. OC symptoms in comorbid patients appeared more often during depressive episodes, and comorbid BD and OCD cycled together, with OC symptoms often remitting during manic/hypomanic episodes. </AbstractText><CopyrightInformation>Copyright © 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amerio</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy; Mood Disorders Program, Tufts Medical Center, Boston, MA, USA. Electronic address: andrea.amerio@studenti.unipr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonna</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Mental Health, Local Health Service, Parma, Italy. Electronic address: mtonna@ausl.pr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odone</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Biotechnological and Translational Sciences, Unit of Public Health, University of Parma, Parma, Italy. Electronic address: anna.odone@mail.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stubbs</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Kings College London, London, UK. Electronic address: brendon.stubbs@kcl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaemi</LastName><ForeName>S N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Mood Disorders Program, Tufts Medical Center, Boston, MA, USA; Tufts University Medical School, Department of Psychiatry and Pharmacology, Boston, MA, USA. Electronic address: nghaemi@tuftsmedicalcenter.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Psychiatr</MedlineTA><NlmUniqueID>101517820</NlmUniqueID><ISSNLinking>1876-2018</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="Y">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar</Keyword><Keyword MajorTopicYN="N">Comorbidity</Keyword><Keyword MajorTopicYN="N">Course of illness</Keyword><Keyword MajorTopicYN="N">Obsessive–compulsive</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>01</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27025465</ArticleId><ArticleId IdType="pii">S1876-2018(15)30111-8</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2016.01.009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16280332</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1461-7285</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>6 Suppl</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of psychopharmacology (Oxford, England)</Title><ISOAbbreviation>J Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Challenges in advancing mental and physical health of patients with serious mental illness.</ArticleTitle><Pagination><MedlinePgn>3-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dursun</LastName><ForeName>Serdar</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dinan</LastName><ForeName>Timothy G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Bushe</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Thakore</LastName><ForeName>Jogin</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D054711">Introductory Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychopharmacol</MedlineTA><NlmUniqueID>8907828</NlmUniqueID><ISSNLinking>0269-8811</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="Y">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="Y">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024821" MajorTopicYN="N">Metabolic Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010809" MajorTopicYN="Y">Physical Fitness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040242" MajorTopicYN="N">Risk Reduction Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16280332</ArticleId><ArticleId IdType="pii">19/6_suppl/3</ArticleId><ArticleId IdType="doi">10.1177/0269881105058969</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15117405</PMID><DateCompleted><Year>2004</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2007</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Resistant bipolar disorder precipitated by Behcet's syndrome.</ArticleTitle><Pagination><MedlinePgn>260-3</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To report a case of a patient with Behcet's syndrome who developed treatment resistant bipolar disorder (BD) several years after the onset of Behcet's syndrome.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 62-year-old woman suffering from Behcet's syndrome since the age of 38, who developed a typical BD 6 years after the first manifestations of the syndrome was described.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Once BD occurred, Behcet's syndrome became milder, while BD deteriorated and evolved into a rapid cycling illness. Lithium and carbamazepine were ineffective in controlling the affective symptoms, while sodium valproate combined with low doses of carbamazepine and olanzapine resulted in sufficient stabilization of her mood state.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Behcet's syndrome may have been the organic substrate for BD in this case. The appearance of BD in the setting of an organic-immune disorder, like Behcet's syndrome, suggests that such disorders may be the neurobiologic substrate or contributor for BD, at least in certain cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alevizos</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Athens, Eginition Hospital, Athens, Greece. valeviz@med.uoa.gr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anagnostara</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Christodoulou</LastName><ForeName>G N</ForeName><Initials>GN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001528" MajorTopicYN="N">Behcet Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="Y">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>8</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15117405</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2004.00114.x</ArticleId><ArticleId IdType="pii">BDI114</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8312984</PMID><DateCompleted><Year>1994</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1040-1237</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>1993</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists</Title><ISOAbbreviation>Ann Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Bupropion and secondary mania. Is there a relationship?</ArticleTitle><Pagination><MedlinePgn>271-4</MedlinePgn></Pagination><Abstract><AbstractText>A 36-year-old woman developed mania in association with bupropion treatment. The literature regarding the etiological relationship of bupropion to secondary mania is reviewed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masand</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, SUNY Health Science Center, Syracuse 13210.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>T A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Psychiatry</MedlineTA><NlmUniqueID>8911021</NlmUniqueID><ISSNLinking>1040-1237</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>01ZG3TPX31</RegistryNumber><NameOfSubstance UI="D016642">Bupropion</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016642" MajorTopicYN="N">Bupropion</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>15</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8312984</ArticleId><ArticleId IdType="doi">10.3109/10401239309148827</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20374145</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2010</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1369-1627</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>International review of psychiatry (Abingdon, England)</Title><ISOAbbreviation>Int Rev Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The structural neuroimaging of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>297-313</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/09540260902962081</ELocationID><Abstract><AbstractText>There is an increasing body of literature fuelled by advances in high-resolution structural MRI acquisition and image processing techniques which implicates subtle neuroanatomical abnormalities in the aetiopathogenesis of bipolar disorder. This account reviews the main findings from structural neuroimaging research into regional brain abnormalities, the impact of genetic liability and mood stabilizing medication on brain structure in bipolar disorder, and the overlapping structural deviations found in the allied disorders of schizophrenia and depression. The manifold challenges extant within neuroimaging research are highlighted with accompanying recommendations for future studies. The most consistent findings include preservation of total cerebral volume with regional grey and white matter structural changes in prefrontal, midline and anterior limbic networks, non-contingent ventriculomegaly and increased rates of white matter hyperintensities, with more pronounced deficits in juveniles suffering from the illness. There is increasing evidence that medication has observable effects on brain structure, whereby lithium status is associated with volumetric increase in the medial temporal lobe and anterior cingulate gyrus. However, research continues to be confounded by the use of highly heterogeneous methodology and clinical populations, in studies employing small scale, low-powered, cross-sectional designs. Future work should investigate larger, clinically homogenous groups of patients and unaffected relatives, combining both categorical and dimensional approaches to illness classification in cross-sectional and longitudinal designs in order to elucidate trait versus state mechanisms, genetic effects and medication/illness progression effects over time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Emsell</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National University of Ireland Galway, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Colm</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Rev Psychiatry</MedlineTA><NlmUniqueID>8918131</NlmUniqueID><ISSNLinking>0954-0261</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038524" MajorTopicYN="Y">Diffusion Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="Y">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>160</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20374145</ArticleId><ArticleId IdType="doi">10.1080/09540260902962081</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11093070</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0302-282X</ISSN><JournalIssue CitedMedium="Print"><Volume>42 Suppl 1</Volume><PubDate><Year>2000</Year></PubDate></JournalIssue><Title>Neuropsychobiology</Title><ISOAbbreviation>Neuropsychobiology</ISOAbbreviation></Journal><ArticleTitle>Periodic motor impairments in a case of 48-hour bipolar ultrarapid cycling before and under treatment with valproate.</ArticleTitle><Pagination><MedlinePgn>38-42</MedlinePgn></Pagination><Abstract><AbstractText>Motor impairments of psychiatric patients can be assessed with digital recordings of handwriting tasks. The investigation of patients with bipolar affective disorders differentiates intraindividual changes related to the patient's fluctuating affective states. An unmedicated 67-year-old male with 48-hour bipolar ultrarapid cycling was investigated during 8 consecutive days of ultrarapid cycling and 4 weeks later, after remission under treatment with valproate. The handwriting skills of the patient followed the same rhythmic changes of the psychopathology in the first part of the study and a steady pattern in the second phase, after remission. Therefore, it can be assumed that the handwriting skills reflect a state marker of the disease. Poorer handwriting skills on the manic days, as compared to the depressive ones, support the hypothesis of a low arousal in manic patients.</AbstractText><CopyrightInformation>Copyright 2000 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tigges</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Section of Clinical Neurophysiology, Ludwig-Maximilians-University, Munich, Germany. tp@psy.med.uni-muenchen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juckel</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Schröter</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Möller</LastName><ForeName>H J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Hegerl</LastName><ForeName>U</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuropsychobiology</MedlineTA><NlmUniqueID>7512895</NlmUniqueID><ISSNLinking>0302-282X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006236" MajorTopicYN="N">Handwriting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>28</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>28</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11093070</ArticleId><ArticleId IdType="pii">54851</ArticleId><ArticleId IdType="doi">10.1159/000054851</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11005060</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1095-0680</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The journal of ECT</Title><ISOAbbreviation>J ECT</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of ECT against delirium during an episode of bipolar disorder: a case report.</ArticleTitle><Pagination><MedlinePgn>316-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hirose</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Horie</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J ECT</MedlineTA><NlmUniqueID>9808943</NlmUniqueID><ISSNLinking>1095-0680</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="Y">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>9</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>9</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11005060</ArticleId><ArticleId IdType="doi">10.1097/00124509-200009000-00019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28110877</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>03</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Vascular Risk Profile and Cognitive Functioning among Patients with Bipolar Disorder: Cause for Concern?</ArticleTitle><Pagination><MedlinePgn>277-278</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1064-7481(16)30350-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jagp.2016.12.019</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weisenbach</LastName><ForeName>Sara L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Utah, Salt Lake City, UT; Research Service, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT. Electronic address: Sara.Weisenbach@hsc.utah.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forester</LastName><ForeName>Brent P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>McLean Hospital, Harvard Medical School, Belmont, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28110877</ArticleId><ArticleId IdType="pii">S1064-7481(16)30350-5</ArticleId><ArticleId IdType="doi">10.1016/j.jagp.2016.12.019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31610086</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>05</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Cognitive enhancement interventions for people with bipolar disorder: A systematic review of methodological quality, treatment approaches, and outcomes.</ArticleTitle><Pagination><MedlinePgn>216-230</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12848</ELocationID><Abstract><AbstractText Label="BACKGROUND">Patients with bipolar disorder (BD) suffer from cognitive deficits across several domains. The association between cognitive performance and psychosocial functioning has led to the emergence of cognition as a treatment target.</AbstractText><AbstractText Label="OBJECTIVE">This study reviews the existing literature on cognitive enhancement interventions for people with BD, focusing on different treatment approaches and methodological quality.</AbstractText><AbstractText Label="METHODS">We conducted a systematic search following the PRISMA guidelines. Sample characteristics and main outcomes for each study and treatment characteristics for each approach were extracted. Study quality was assessed using the Clinical Trials Assessment Measure (CTAM) and Cochrane Collaboration's Risk of Bias tool by independent raters.</AbstractText><AbstractText Label="RESULTS">Eleven articles reporting data from seven original studies were identified encompassing 471 participants. Two treatment approaches were identified, cognitive and functional remediation. For controlled studies, methodological quality was modest (average CTAM score = 60.3), while the overall risk of bias was considered moderate. Beneficial effects on cognitive or functional outcomes were reported in the majority of studies (91%), but these findings were isolated and not replicated across studies. Key methodological limitations included small sample sizes, poor description of randomization process, high attrition rates, and participant exclusion from the analysis.</AbstractText><AbstractText Label="CONCLUSIONS">Findings are promising but preliminary. Quality studies were few and mostly underpowered. Heterogeneity in sample characteristics, outcome measures, and treatment approaches further limit the ability to generalize findings. Adequately powered trials are required to replicate initial findings, while moderators of treatment response and mechanisms of transfer need to be explored.</AbstractText><CopyrightInformation>© 2019 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsapekos</LastName><ForeName>Dimosthenis</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1972-4813</Identifier><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seccomandi</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mantingh</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cella</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South London &amp; Maudsley NHS Foundation Trust, Maudsley Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wykes</LastName><ForeName>Til</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South London &amp; Maudsley NHS Foundation Trust, Maudsley Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Allan H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South London &amp; Maudsley NHS Foundation Trust, Maudsley Hospital, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PB-PG-0614-34075</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Department of Health [UK]</Agency><Country>International</Country></Grant><Grant><Agency>Onassis Foundation</Agency><Country>International</Country></Grant><Grant><Agency>Maudsley Biomedical Research Centre at</Agency><Country>International</Country></Grant><Grant><Agency>National Institute for Health Research</Agency><Country>International</Country></Grant><Grant><Agency>South London and Maudsley NHS Foundation Trust</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072466" MajorTopicYN="Y">Cognitive Remediation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">cognition</Keyword><Keyword MajorTopicYN="Y">cognitive remediation</Keyword><Keyword MajorTopicYN="Y">functional remediation</Keyword><Keyword MajorTopicYN="Y">functioning</Keyword><Keyword MajorTopicYN="Y">methodological quality</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31610086</ArticleId><ArticleId IdType="doi">10.1111/bdi.12848</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Barch DM. Neuropsychological abnormalities in schizophrenia and major mood disorders: Similarities and differences. Curr Psychiatry Rep. 2009;11(4):313-319.</Citation></Reference><Reference><Citation>Bora E, Yucel M, Pantelis C. Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. Br J Psychiatry. 2009;195(6):475-482.</Citation></Reference><Reference><Citation>Bourne C, Aydemir Ö, Balanzá-Martínez V, et al Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand. 2013;128(3):149-162.</Citation></Reference><Reference><Citation>Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand. 2007;116(s434):17-26.</Citation></Reference><Reference><Citation>Demmo C, Lagerberg TV, Kvitland LR, et al Neurocognitive functioning, clinical course and functional outcome in first-treatment bipolar I disorder patients with and without clinical relapse: A 1-year follow-up study. Bipolar Disord. 2018;20(3):228-237.</Citation></Reference><Reference><Citation>Bora E, Ozerdem A. Meta-analysis of longitudinal studies of cognition in bipolar disorder: comparison with healthy controls and schizophrenia. Psychol Med. 2017;47(16):2753-2766.</Citation></Reference><Reference><Citation>Burdick KE, Russo M, Frangou S, et al Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. Psychol Med. 2014;44(14):3083-3096.</Citation></Reference><Reference><Citation>Bora E, Hıdıroğlu C, Özerdem A, et al Executive dysfunction and cognitive subgroups in a large sample of euthymic patients with bipolar disorder. Eur Neuropsychopharmacol. 2016;26(8):1338-1347.</Citation></Reference><Reference><Citation>Depp CA, Mausbach BT, Harmell AL, et al Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord. 2012;14(3):217-226.</Citation></Reference><Reference><Citation>Martino DJ, Marengo E, Igoa A, et al Neurocognitive and symptomatic predictors of functional outcome in bipolar disorders: a prospective 1 year follow-up study. J Affect Disord. 2009;116(1-2):37-42.</Citation></Reference><Reference><Citation>Roux P, Raust A, Cannavo A-S, et al Associations between residual depressive symptoms, cognition, and functioning in patients with euthymic bipolar disorder: results from the FACE-BD cohort. Br J Psychiatry. 2018;211(6):381-387.</Citation></Reference><Reference><Citation>Tse S, Chan S, Ng KL, Yatham LN. Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. Bipolar Disord. 2014;16(3):217-229.</Citation></Reference><Reference><Citation>Miskowiak KW, Carvalho AF, Vieta E, Kessing LV. Cognitive enhancement treatments for bipolar disorder: a systematic review and methodological recommendations. Eur Neuropsychopharmacol. 2016;26(10):1541-1561.</Citation></Reference><Reference><Citation>Bowie CR, Gupta M, Holshausen K. Cognitive remediation therapy for mood disorders: rationale, early evidence, and future directions. Can J Psychiatry. 2013;58(6):319-325.</Citation></Reference><Reference><Citation>Anaya C, Aran AM, Ayuso-Mateos JL, Wykes T, Vieta E, Scott J. A systematic review of cognitive remediation for schizo-affective and affective disorders. J Affect Disord. 2012;142(1):13-21.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.</Citation></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM- 5®). American Psychiatric Pub. 2013.</Citation></Reference><Reference><Citation>World Health Organization. International statistical classification of diseases and related health problems (11th Revision). Retrieved from https://icd.who.int/browse11/l-m/en2018.</Citation></Reference><Reference><Citation>Spitzer R, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35(6):773-782.</Citation></Reference><Reference><Citation>Tarrier N, Wykes T. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? a cautious or cautionary tale? Behav Res Ther. 2004;42(12):1377-1401.</Citation></Reference><Reference><Citation>Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34(3):523-537.</Citation></Reference><Reference><Citation>Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Hoboken, NJ: John Wiley &amp; Sons; 2011.</Citation></Reference><Reference><Citation>Lewandowski KE, Sperry SH, Cohen BM, et al Treatment to enhance cognition in bipolar disorder (TREC-BD): efficacy of a randomized controlled trial of cognitive remediation versus active control. J Clin Psychiatry. 2017;78(9):e1242-e1249.</Citation></Reference><Reference><Citation>Preiss M, Shatil E, Cermakova R, Cimermanova D, Ram I. Personalized cognitive training in unipolar and bipolar disorder: a study of cognitive functioning. Front Hum Neurosci. 2013;14-23.</Citation></Reference><Reference><Citation>Zyto S, Jabben N, Schulte P, Regeer BJ, Kupka RW. A pilot study of a combined group and individual functional remediation program for patients with bipolar I disorder. J Affect Disord. 2016;194:9-15.</Citation></Reference><Reference><Citation>Demant KM, Vinberg M, Kessing LV, Miskowiak KW. Effects of short-term cognitive remediation on cognitive dysfunction in partially or fully remitted individuals with bipolar disorder: results of a randomised controlled trial. PLoS ONE. 2015;10(6):17-24.</Citation></Reference><Reference><Citation>Veeh J, Kopf J, Kittel-Schneider S, Deckert J, Reif A. Cognitive remediation for bipolar patients with objective cognitive impairment: a naturalistic study. Int J Bipolar Disord. 2017;5(1):8-20.</Citation></Reference><Reference><Citation>Deckersbach T, Nierenberg AA, Kessler R, et al Cognitive rehabilitation for bipolar disorder: an open trial for employed patients with residual depressive symptoms. CNS Neurosci Ther. 2010;16(5):298-307.</Citation></Reference><Reference><Citation>Torrent C, Bonnin CD, Martínez-Arán A, et al Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry. 2013;170(8):852-859.</Citation></Reference><Reference><Citation>Bonnin C, Torrent C, Arango C, et al Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome. Br J Psychiatry. 2016;208(1):87-93.</Citation></Reference><Reference><Citation>Bonnin CM, Reinares M, Martínez-Arán A, et al Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. Psychol Med. 2016;46(2):291-301.</Citation></Reference><Reference><Citation>Solé B, Bonnin CM, Mayoral M, et al Functional remediation for patients with bipolar II disorder: improvement of functioning and subsyndromal symptoms. Eur Neuropsychopharmacol. 2015;25(2):257-264.</Citation></Reference><Reference><Citation>Sanchez-Moreno J, Bonnín C, González-Pinto A, et al Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? a 12-month follow-up study. Eur Neuropsychopharmacol. 2017;27(4):350-359.</Citation></Reference><Reference><Citation>Rosa AR, Sánchez-Moreno J, Martínez-Aran A, et al Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol in Ment Health. 2007;3(1):5.</Citation></Reference><Reference><Citation>O'Donnell LA, Deldin PJ, Grogan-Kaylor A, et al Depression and executive functioning deficits predict poor occupational functioning in a large longitudinal sample with bipolar disorder. J Affect Disord. 2017;215:135-142.</Citation></Reference><Reference><Citation>Solé B, Jiménez E, Torrent C, et al Cognitive impairment in bipolar disorder: treatment and prevention strategies. Int J Neuropsychopharmacol. 2017;20(8):670-680.</Citation></Reference><Reference><Citation>Kim EJ, Bahk Y-C, Oh H, Lee W-H, Lee J-S, Choi K-H. Current status of cognitive remediation for psychiatric disorders: a review. Front Psychiatry. 2018;9:461.</Citation></Reference><Reference><Citation>Medalia A, Choi J. Cognitive remediation in schizophrenia. Neuropsychol Rev. 2009;19(3): 353-364.</Citation></Reference><Reference><Citation>Fisher M, Holland C, Merzenich MM, Vinogradov S. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry. 2009;166(7):805-811.</Citation></Reference><Reference><Citation>Wykes T, Spaulding WD. Thinking about the future cognitive remediation therapy-what works and could we do better? Schizophr Bull. 2011;37(Suppl 2):S80-S90.</Citation></Reference><Reference><Citation>Bowie CR, Best MW, Depp C, et al Cognitive and functional deficits in bipolar disorder and schizophrenia as a function of the presence and history of psychosis. Bipolar Disord. 2018;20(7):604-613.</Citation></Reference><Reference><Citation>Biagianti B, Merchant J, Brambilla P, Lewandowski KE. The effects of cognitive remediation in patients with affective psychosis: A systematic review: special section on “translational and neuroscience studies in affective disorders”. Section editor, Maria nobileMD, Phd. This section of jad focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. J Affect Disord. 2019;255:188-194.</Citation></Reference><Reference><Citation>Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord. 2009;113(1-2):1-20.</Citation></Reference><Reference><Citation>Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472-485.</Citation></Reference><Reference><Citation>Twamley EW, Burton CZ, Vella L. Compensatory cognitive training for psychosis: who benefits? who stays in treatment? Schizophr Bull. 2011;37(Suppl 2):S55-62.</Citation></Reference><Reference><Citation>DeTore NR, Mueser KT, Byrd JA, McGurk SR. Cognitive functioning as a predictor of response to comprehensive cognitive remediation. J Psychiatr Res. 2019;113:117-124.</Citation></Reference><Reference><Citation>Lindenmayer J-P, McGurk SR, Mueser KT, et al A Randomized controlled trial of cognitive remediation among inpatients with persistent mental illness. Psychiatr Serv. 2008;59(3):241-247.</Citation></Reference><Reference><Citation>McGurk SR, Mueser KT, Xie H, et al Cognitive enhancement treatment for people with mental illness who do not respond to supported employment: a randomized controlled trial. Am J Psychiatry. 2015;172(9):852-861.</Citation></Reference><Reference><Citation>Martínez-Arán A, Torrent C, Solé B, et al Functional remediation for bipolar disorder. Clinl Pract Epidemiol Ment Health. 2011;7:112-116.</Citation></Reference><Reference><Citation>Bowie CR, Grossman M, Gupta M, Holshausen K, Best MW. Action-based cognitive remediation for individuals with serious mental illnesses: effects of real-world simulations and goal setting on functional and vocational outcomes. Psychiatr Rehabil J. 2017;40(1):53-60.</Citation></Reference><Reference><Citation>Bonnín CM, Martínez-Arán A, Torrent C, et al Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study. J Affect Disord. 2010;121(1-2):156-160.</Citation></Reference><Reference><Citation>Jensen JH, Knorr U, Vinberg M, Kessing LV, Miskowiak KW. Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: associations with functional abilities. J Affect Disord. 2016;205:378-386.</Citation></Reference><Reference><Citation>Burdick KE, Braga RJ, Nnadi CU, Shaya Y, Stearns WH, Malhotra AK. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry. 2012;73(1):103-112.</Citation></Reference><Reference><Citation>Burdick KE, Ketter TA, Goldberg JF, Calabrese JR. Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design. J Clin Psychiatry. 2015;76(3):e342-e350.</Citation></Reference><Reference><Citation>Miskowiak KW, Burdick KE, Martinez-Aran A, et al Methodological recommendations for cognition trials in bipolar disorder by the International Society for bipolar disorders targeting cognition task force. Bipolar Disord. 2017;19(8):614-626.</Citation></Reference><Reference><Citation>Strawbridge R, Fish J, Halari R, et al The Cognitive Remediation in Bipolar (CRiB) pilot study: study protocol for a randomised controlled trial. Trials. 2016;17:9.</Citation></Reference><Reference><Citation>Gomes BC, Rocca CC, Belizario GO, Lafer B. Cognitive-behavioral rehabilitation vs. treatment as usual for bipolar patients: study protocol for a randomized controlled trial. Trials. 2017;18(1): 142.</Citation></Reference><Reference><Citation>Ott CV, Vinberg M, Bowie CR, et al Effect of action-based cognitive remediation on cognition and neural activity in bipolar disorder: study protocol for a randomized controlled trial. Trials. 2018;19(1):487.</Citation></Reference><Reference><Citation>Thomas KR, Puig O, Twamley EW. Age as a moderator of change following compensatory cognitive training in individuals with severe mental illnesses. Psychiatr Rehabil J. 2017;40(1):70-78.</Citation></Reference><Reference><Citation>Ramsay IS, Ma S, Fisher M, et al Model selection and prediction of outcomes in recent onset schizophrenia patients who undergo cognitive training. Schizophr Res Cogn. 2018;11:1-5.</Citation></Reference><Reference><Citation>Kollmann B, Yuen K, Scholz V, Wessa M. Cognitive variability in bipolar I disorder: a cluster-analytic approach informed by resting-state data. Neuropharmacology. 2019;156:107585.</Citation></Reference><Reference><Citation>Medalia A, Dorn H, Watras-Gans S. Treating problem-solving deficits on an acute care psychiatric inpatient unit. Psychiatry Res. 2000;97(1):79-88.</Citation></Reference><Reference><Citation>Wykes T, Reeder C, Huddy V, et al Developing models of how cognitive improvements change functioning: mediation, moderation and moderated mediation. Schizophr Res. 2012;138(1):88-93.</Citation></Reference><Reference><Citation>Cella M, Wykes T. The nuts and bolts of cognitive remediation: exploring how different training components relate to cognitive and functional gains. Schizophr Res. 2017;203:12-16.</Citation></Reference><Reference><Citation>Crawford MJ, Robotham D, Thana L, et al Selecting outcome measures in mental health: the views of service users. J Ment Health. 2011;20(4):336-346.</Citation></Reference><Reference><Citation>Rose D, Wykes T, Farrier D, Doran A-M, Sporle T, Bogner D. What do clients think of cognitive remediation therapy?: a consumer-led investigation of satisfaction and side effects. Am J Psychiatr Rehabil 2008;11(2):181-204.</Citation></Reference><Reference><Citation>Turner-Stokes L. Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin Rehabil. 2009;23(4):362-370.</Citation></Reference><Reference><Citation>Gruber SA, Dahlgren MK, Sagar KA, et al Decreased cingulate cortex activation during cognitive control processing in bipolar disorder. J Affect Disord. 2017;213:86-95.</Citation></Reference><Reference><Citation>Hajek T, Alda M, Hajek E, Ivanoff J. Functional neuroanatomy of response inhibition in bipolar disorders-combined voxel based and cognitive performance meta-analysis. J Psychiatr Res. 2013;47(12):1955-1966.</Citation></Reference><Reference><Citation>Penades R, Gonzalez-Rodriguez A, Catalan R, Segura B, Bernardo M, Junque C. Neuroimaging studies of cognitive remediation in schizophrenia: a systematic and critical review. World J Psychiatry. 2017;7(1):34-43.</Citation></Reference><Reference><Citation>Ramsay IS, MacDonald AW 3rd. Brain correlates of cognitive remediation in schizophrenia: activation likelihood analysis shows preliminary evidence of neural target engagement. Schizophr Bull. 2015;41(6):1276-1284.</Citation></Reference><Reference><Citation>Macoveanu J, Demant KM, Vinberg M, Siebner HR, Kessing LV, Miskowiak KW. Towards a biomarker model for cognitive improvement: no change in memory-related prefrontal engagement following a negative cognitive remediation trial in bipolar disorder. J Psychopharmacology. 2018;32(10):1075-1085.</Citation></Reference><Reference><Citation>Meusel LA, Hall GB, Fougere P, McKinnon MC, MacQueen GM. Neural correlates of cognitive remediation in patients with mood disorders. Psychiatry Res. 2013;214(2):142-152.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17142013</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0924-9338</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European psychiatry : the journal of the Association of European Psychiatrists</Title><ISOAbbreviation>Eur Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Early recognition of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>92-8</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar disorders are frequently not diagnosed until long after their onset, leaving patients with no or correspondingly inadequate treatment. The course of the disorder is all the more severe and the negative repercussions for those affected all the greater. Concerted research effort is therefore going into learning how to recognize bipolar disorders at an early stage. Drawing on current research results, this paper presents considerations for an integrative Early Symptom Scale with which persons at risk can be identified and timely intervention initiated. This will require prospective studies to determine the predictive power of the risk factors integrated into the scale.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Early Recognition Center of Beginning Psychoses, Department of Psychiatry, Charité, Campus Mitte, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfennig</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ozgürdal</LastName><ForeName>Seza</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Heinz</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Juckel</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Psychiatry</MedlineTA><NlmUniqueID>9111820</NlmUniqueID><ISSNLinking>0924-9338</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>27</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>03</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>08</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17142013</ArticleId><ArticleId IdType="pii">S0924-9338(06)00135-0</ArticleId><ArticleId IdType="doi">10.1016/j.eurpsy.2006.08.003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29801445</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>05</Month><Day>25</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Differential mitochondrial DNA copy number in three mood states of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>149</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12888-018-1717-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">Accumulating evidences indicated that mitochondrial abnormalities were associated with bipolar disorder. As a sensitive index of mitochondrial function and biogenesis, Mitochondrial DNA copy number (mtDNAcn) may be involved in the pathophysiology of bipolar disorder.</AbstractText><AbstractText Label="METHODS">Leukocyte relative mtDNAcn was measured by quantitative polymerase chain reaction in subjects with BD (n = 131) in manic, depressive, and euthymic symptoms. Thirty-four healthy individuals were used as comparison control. BD clinical symptomatology was evaluated by Young Mania Rating Scale (YMRS), Hamilton Depression Scale (HAM-D), Clinical Global Impression-Bipolar Disorder-Severity of Illness Scale (CGI-BD-S), and the Positive and Negative Syndrome Scale (PANSS).</AbstractText><AbstractText Label="RESULTS">Compared to healthy controls, BD patients with manic and depressive symptoms presented significantly decreased mtDNAcn levels (p-value = 0.009 and 0.041, respectively). No significant differences were detected in mtDNAcn between euthymic patients and healthy controls. The mtDNAcn was negatively correlated with the number of relapses in manic patients (β = - 0.341, p = 0.044).</AbstractText><AbstractText Label="CONCLUSIONS">Our study described the first evidence of (1) a significant decline of mtDNAcn in manic BD patients, (2) a similar decreased level of mtDNAcn between manic and depressed BD patients, (3) a negative correlation of mtDNAcn with number of relapses in patients suffering from manic states. Alterations of mtDNAcn in manic and depressed patients, which may reflect disturbances of energy metabolism, supported the role of mitochondrial abnormalities in the pathophysiology of BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Health Institute, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zongchang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Weiqing</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Health Institute, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xiaoqian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Health Institute, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Jinsong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Tangjinsong@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Health Institute, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Tangjinsong@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center on Mental Disorders, Changsha, Hunan, China. Tangjinsong@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Technology Institute on Mental Disorders, Changsha, Hunan, China. Tangjinsong@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan, China. Tangjinsong@csu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaogang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Chenxiaogang@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Health Institute, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Chenxiaogang@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center on Mental Disorders, Changsha, Hunan, China. Chenxiaogang@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Technology Institute on Mental Disorders, Changsha, Hunan, China. Chenxiaogang@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan, China. Chenxiaogang@csu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078331" MajorTopicYN="N">Correlation of Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056915" MajorTopicYN="Y">DNA Copy Number Variations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062072" MajorTopicYN="N">Patient Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Depression</Keyword><Keyword MajorTopicYN="Y">Mania</Keyword><Keyword MajorTopicYN="Y">Mitochondrial DNA copy number</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>05</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29801445</ArticleId><ArticleId IdType="doi">10.1186/s12888-018-1717-8</ArticleId><ArticleId IdType="pii">10.1186/s12888-018-1717-8</ArticleId><ArticleId IdType="pmc">PMC5970444</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Psychiatry. 2003 Jun;64(6):663-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12823080</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:10-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26120081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Mar;13(2):198-207</Citation><ArticleIdList><ArticleId IdType="pubmed">21443574</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitochondrion. 2009 Nov;9(6):385-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19563917</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 May 15;53(10):906-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12742678</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Jun;233:15-20</Citation><ArticleIdList><ArticleId IdType="pubmed">28633757</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 May 06;10(5):e0125855</Citation><ArticleIdList><ArticleId IdType="pubmed">25946463</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Res. 2003 Dec;37(12):1307-17</Citation><ArticleIdList><ArticleId IdType="pubmed">14753755</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:32-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24036318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2007;114(5):665-74</Citation><ArticleIdList><ArticleId IdType="pubmed">17195919</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Jul;13(7):685-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17684499</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Cell. 2011 Oct;10(5):824-31</Citation><ArticleIdList><ArticleId IdType="pubmed">21624037</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2013 Jul;13(7):827-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23898853</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2015 Dec 18;5:18553</Citation><ArticleIdList><ArticleId IdType="pubmed">26680692</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2005 Dec;8(4):515-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16202181</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2017 Aug;71(8):518-529</Citation><ArticleIdList><ArticleId IdType="pubmed">27987238</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 2015 May 4;25(9):1146-56</Citation><ArticleIdList><ArticleId IdType="pubmed">25913401</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2014 May;42:157-69</Citation><ArticleIdList><ArticleId IdType="pubmed">24548785</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Cancer Inst. 2008 Aug 6;100(15):1104-12</Citation><ArticleIdList><ArticleId IdType="pubmed">18664653</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2017 Feb;71(2):77-103</Citation><ArticleIdList><ArticleId IdType="pubmed">27800654</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2016 Sep 15;80(6):e41-e42</Citation><ArticleIdList><ArticleId IdType="pubmed">26917357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Aug;15(8):784-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20351717</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(1):e54536</Citation><ArticleIdList><ArticleId IdType="pubmed">23382910</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2013 Mar 19;14(3):6306-44</Citation><ArticleIdList><ArticleId IdType="pubmed">23528859</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2015 Aug 04;5:e614</Citation><ArticleIdList><ArticleId IdType="pubmed">26241352</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2013 Mar;162B(2):213-23</Citation><ArticleIdList><ArticleId IdType="pubmed">23355257</ArticleId></ArticleIdList></Reference><Reference><Citation>Biotech Histochem. 2005 May-Aug;80(3-4):133-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16298898</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2014 Jul;68(7):551-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24447331</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2017 Mar;18(2):151-156</Citation><ArticleIdList><ArticleId IdType="pubmed">27739340</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2016 Sep;68:694-713</Citation><ArticleIdList><ArticleId IdType="pubmed">27377693</ArticleId></ArticleIdList></Reference><Reference><Citation>J Genet Genomics. 2009 Mar;36(3):125-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19302968</ArticleId></ArticleIdList></Reference><Reference><Citation>Xenobiotica. 2016;46(4):369-78</Citation><ArticleIdList><ArticleId IdType="pubmed">26364812</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2010 Aug;177(2):575-85</Citation><ArticleIdList><ArticleId IdType="pubmed">20566748</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitochondrion. 2013 Sep;13(5):481-92</Citation><ArticleIdList><ArticleId IdType="pubmed">23085537</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2006 Jul;11(7):615, 663-79</Citation><ArticleIdList><ArticleId IdType="pubmed">16636682</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Dev Neurosci. 2011 May;29(3):311-24</Citation><ArticleIdList><ArticleId IdType="pubmed">20833242</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 Jul;12(6):805-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19149911</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2010 Jan;1802(1):92-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19751828</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 May 08;9(5):e96869</Citation><ArticleIdList><ArticleId IdType="pubmed">24809340</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28044944</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8529</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>S1</Issue><PubDate><Year>2016</Year><Month>12</Month></PubDate></JournalIssue><Title>CNS spectrums</Title><ISOAbbreviation>CNS Spectr</ISOAbbreviation></Journal><ArticleTitle>A pragmatic approach to the diagnosis and treatment of mixed features in adults with mood disorders.</ArticleTitle><Pagination><MedlinePgn>25-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S109285291600078X</ELocationID><Abstract><AbstractText>Mixed features specifier (MFS) is a new nosological entity defined and operationalized in the Diagnostic and Statistical Manual of Mental Disorders (DSM), 5th Edition. The impetus to introduce the MFS and supplant mixed states was protean, including the lack of ecological validity, high rates of misdiagnosis, and guideline discordant treatment for mixed states. Mixed features specifier identifies a phenotype in psychiatry with greater illness burden, as evidenced by earlier age at onset, higher episode frequency and chronicity, psychiatric and medical comorbidity, suicidality, and suboptimal response to conventional antidepressants. Mixed features in psychiatry have historical, conceptual, and nosological relevance; MFS according to DSM-5, is inherently neo-Kraepelinian insofar as individuals with either Major Depressive Disorder (MDD) or Bipolar Disorder (BD) may be affected by MFS. Clinicians are encouraged to screen all patients presenting with a major depressive episode (or hypomanic episode) for MFS. Although "overlapping symptoms" were excluded from the diagnostic criteria (eg, agitation, anxiety, irritability, insomnia), clinicians are encouraged to probe for these nonspecific symptoms as a possible proxy of co-existing MFS. In addition to conventional antidepressants, second generation antipsychotics and/or conventional mood stabilizers (eg, lithium) may be considered as first-line therapies for individuals with a depressive episode as part of MDD or BD with mixed features.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>1Mood Disorders Psychopharmacology Unit,University Health Network,Toronto,Ontario,Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yena</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>1Mood Disorders Psychopharmacology Unit,University Health Network,Toronto,Ontario,Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansur</LastName><ForeName>Rodrigo B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>1Mood Disorders Psychopharmacology Unit,University Health Network,Toronto,Ontario,Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CNS Spectr</MedlineTA><NlmUniqueID>9702877</NlmUniqueID><ISSNLinking>1092-8529</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>6UKA5VEJ6X</RegistryNumber><NameOfSubstance UI="C092292">ziprasidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="Y">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">bipolar spectrum</Keyword><Keyword MajorTopicYN="Y">depression spectrum</Keyword><Keyword MajorTopicYN="Y">major depressive disorder</Keyword><Keyword MajorTopicYN="Y">mixed features</Keyword><Keyword MajorTopicYN="Y">mixed states</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28044944</ArticleId><ArticleId IdType="pii">S109285291600078X</ArticleId><ArticleId IdType="doi">10.1017/S109285291600078X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1673076</PMID><DateCompleted><Year>1991</Year><Month>05</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>158</Volume><PubDate><Year>1991</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Bipolar affective disorder following head injury.</ArticleTitle><Pagination><MedlinePgn>117-9</MedlinePgn></Pagination><Abstract><AbstractText>A patient developed distinct episodes of major depressive illness, schizophreniform psychoses and mania as well as focal epilepsy following head injury. Head injury may be directly causative in the development of affective psychoses, in this case secondary bipolar (mixed) disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bamrah</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Withington Hospital, Didsbury, Manchester.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1673076</ArticleId><ArticleId IdType="pii">S0007125000048169</ArticleId><ArticleId IdType="doi">10.1192/bjp.158.1.117</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">22464937</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><Issue>2-3</Issue><PubDate><Year>2012</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Pediatric bipolar disorder and ADHD: family history comparison in the LAMS clinical sample.</ArticleTitle><Pagination><MedlinePgn>382-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2012.03.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(12)00203-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Transgenerational association of bipolar spectrum disorder (BPSD) and attention deficit/hyperactivity disorder (ADHD) has been reported, but inconclusively.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Children ages 6-12 were systematically recruited at first outpatient visit at 9 clinics at four universities and reliably diagnosed; 621 had elevated symptoms of mania (&gt;12 on the Parent General Behavior Inventory 10-Item Mania Scale); 86 had scores below 12. We analyzed baseline data to test a familial association hypothesis: compared to children with neither BPSD nor ADHD, those with either BPSD or ADHD would have parents with higher rates of both bipolar and ADHD symptoms, and parents of comorbid children would have even higher rates of both.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 707 children, 421 had ADHD without BPSD, 45 BPSD without ADHD, 117 comorbid ADHD+BPSD, and 124 neither. The rate of parental manic symptoms was similar for the comorbid and BPSD-alone groups, significantly greater than for ADHD alone and "neither" groups, which had similar rates. ADHD symptoms in parents of children with BPSD alone were significantly less frequent than in parents of children with ADHD (alone or comorbid), and no greater than for children with neither diagnosis. Family history of manic symptoms, but not ADHD symptoms, was associated with parent-rated child manic-symptom severity over and above child diagnosis.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The sample was not epidemiologic, parent symptoms were based on family history questions, and alpha was 0.05 despite multiple tests.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results do not support familial linkage of BPSD and ADHD; they are compatible with heritability of each disorder separately with coincidental overlap.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>L Eugene</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Division of Child and Adolescent Psychiatry, Department of Psychiatry, Ohio State University, Columbus, OH, United States. L.Arnold@osumc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mount</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Frazier</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Demeter</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Youngstrom</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Fristad</LastName><ForeName>Mary A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Birmaher</LastName><ForeName>Boris</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Horwitz</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Findling</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Kowatch</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Axelson</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH073801</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH073816</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH073953</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH073967</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="N">Child of Impaired Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>02</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22464937</ArticleId><ArticleId IdType="pii">S0165-0327(12)00203-0</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2012.03.015</ArticleId><ArticleId IdType="pmc">PMC3574899</ArticleId><ArticleId IdType="mid">NIHMS437049</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Oct;36(10):1378-87; discussion 1387-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9334551</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Jul;66(7):738-47</Citation><ArticleIdList><ArticleId IdType="pubmed">19581565</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Aug-Sep;13(5-6):509-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22017220</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Nov;51(2):177-87</Citation><ArticleIdList><ArticleId IdType="pubmed">10743850</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 May;69(5):831-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18452343</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Jul;34(7):867-76</Citation><ArticleIdList><ArticleId IdType="pubmed">7649957</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet C Semin Med Genet. 2003 Nov 15;123C(1):48-58</Citation><ArticleIdList><ArticleId IdType="pubmed">14601036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Aug;8(4):373-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16879138</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortex. 2006 Aug;42(6):838-45</Citation><ArticleIdList><ArticleId IdType="pubmed">17131588</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Apr;99(1-3):51-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17045657</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2001 Apr;40(4):450-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11314571</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1139-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17015816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Dec;9(8):828-38</Citation><ArticleIdList><ArticleId IdType="pubmed">18076532</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Methods. 2009 Nov;41(4):1149-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19897823</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):454-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7751259</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):325-46, viii-ix</Citation><ArticleIdList><ArticleId IdType="pubmed">18295149</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Psychiatry. 1984 Mar;23(2):191-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6715741</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Nov 1;60(9):951-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16730333</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Jul;57(7):675-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10891038</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2007 Feb;61(1):3-19</Citation><ArticleIdList><ArticleId IdType="pubmed">17239033</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Oct;68(10):1012-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21969459</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Nov;71(11):1511-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21034684</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Mar;167(3):321-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20080982</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):483-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16403174</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2010 Apr;49(4):388-96</Citation><ArticleIdList><ArticleId IdType="pubmed">20410731</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1992 Jan;31(1):68-77</Citation><ArticleIdList><ArticleId IdType="pubmed">1537784</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Sep;36(9):1168-76</Citation><ArticleIdList><ArticleId IdType="pubmed">9291717</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2005 Jan 5;132B(1):109-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15700344</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2011 Oct;21(5):407-15</Citation><ArticleIdList><ArticleId IdType="pubmed">22040186</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Oct 1;58(7):554-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16112654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Aug;7(4):344-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16026487</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Apr;64(1):19-26</Citation><ArticleIdList><ArticleId IdType="pubmed">11292516</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2011 Oct;21(5):399-405</Citation><ArticleIdList><ArticleId IdType="pubmed">22040185</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2003 Jul;42(7):786-96</Citation><ArticleIdList><ArticleId IdType="pubmed">12819438</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1996 Aug;35(8):997-1008</Citation><ArticleIdList><ArticleId IdType="pubmed">8755796</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Mar;66(3):287-96</Citation><ArticleIdList><ArticleId IdType="pubmed">19255378</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Dec;71(12):1664-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21034685</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):507-17</Citation><ArticleIdList><ArticleId IdType="pubmed">16403176</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2006 Dec 7;145(2-3):155-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17083985</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 May 30;177(3):299-304</Citation><ArticleIdList><ArticleId IdType="pubmed">20452063</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol (New York). 2010 Dec 1;17(4):350-359</Citation><ArticleIdList><ArticleId IdType="pubmed">21278822</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Nov;51(2):93-100</Citation><ArticleIdList><ArticleId IdType="pubmed">10743842</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">33037692</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>02</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Prevention of suicidal behavior in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>14-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.13017</ELocationID><Abstract><AbstractText Label="BACKGROUND">Excess mortality is a critical hallmark of bipolar disorder (BD) due to co-occurring general medical disorders and especially from suicide. It is timely to review of the status of suicide in BD and to consider the possibility of limiting suicidal risk.</AbstractText><AbstractText Label="METHODS">We carried out a semi-systematic review of recent research reports pertaining to suicide in BD.</AbstractText><AbstractText Label="FINDINGS">Suicide risk in BD is greater than with most other psychiatric disorders. Suicide rates (per 100,000/year) are approximately 11 and 4 in the adult and juvenile general populations, but over 200 in adults, and 100 among juveniles diagnosed with BD. Suicide attempt rates with BD are at least 20 times higher than in the adult general population, and over 50 times higher among juveniles. Notable suicidal risk factors in BD include: previous suicidal acts, depression, mixed-agitated-dysphoric moods, rapid mood-shifts, impulsivity, and co-occurring substance abuse. Suicide-preventing therapeutics for BD remain severely underdeveloped. Evidence favoring lithium treatment is stronger than for other measures, although encouraging findings are emerging for other treatments.</AbstractText><AbstractText Label="CONCLUSIONS">Suicide is a leading clinical challenge for those caring for BD patients. Improved understanding of risk and protective factors combined with knowledge and close follow-up of BD patients should limit suicidal risk. Ethically appropriate and scientifically sound studies of plausible medicinal, physical, and psychosocial treatments aimed at suicide prevention specifically for BD patients are urgently needed.</AbstractText><CopyrightInformation>© 2020 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tondo</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1624-0522</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Consortium for Mood &amp; Psychotic Disorder Research, McLean Hospital, Belmont, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lucio Bini Mood Disorder Centers, Cagliari and Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vázquez</LastName><ForeName>Gustavo H</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>International Consortium for Mood &amp; Psychotic Disorder Research, McLean Hospital, Belmont, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Queen's University School of Medicine, Kingston, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>Ross J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0001-9718-8211</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Consortium for Mood &amp; Psychotic Disorder Research, McLean Hospital, Belmont, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="Y">Depressive Disorder, Major</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059020" MajorTopicYN="N">Suicidal Ideation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">attempts</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">lethality</Keyword><Keyword MajorTopicYN="Y">prevention</Keyword><Keyword MajorTopicYN="Y">suicide</Keyword><Keyword MajorTopicYN="Y">treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>09</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>10</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33037692</ArticleId><ArticleId IdType="doi">10.1111/bdi.13017</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Naghavi M; (Global Burden of Disease Self-Harm Collaborators). Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. BMJ. 2019;364(6 Feb):l94.</Citation></Reference><Reference><Citation>Turecki G, Brent DA, Gunnell D, et al. Suicide and suicidal risk: a primer. Nature Rev Dis Prim. 2019;5(1):74-95.</Citation></Reference><Reference><Citation>WHO (World Health Organization). Suicide rates in 183 countries, 2020. https://www.who.int/mental_health/prevention/suicide/estimate/en. Accessed 21 Apr 2020</Citation></Reference><Reference><Citation>CDC (US Centers for Disease Control and Prevention). Estimated rate of suicide attempts in the US, 2020. www.cdc.gov/violenceprevention/pdf/suicides-datasheet-1.pdf. Accessed 21 Apr 2020</Citation></Reference><Reference><Citation>Wang J, Sumner SA, Simon TR, et al. Trends in the incidence and lethality of suicidal acts in the United States, 2006 to 2015. JAMA Psychiatry. 2020;77(7):1-10.</Citation></Reference><Reference><Citation>Hoffmann JA, Farrell CA, Monuteaux MC, Fleegler EW, Lee LK. Association of pediatric suicide with county-level poverty in the United States, 2007-2016. JAMA Pediatrics. 2020;174(3):287-294.</Citation></Reference><Reference><Citation>Tondo L, Albert MJ, Baldessarini RJ. Suicide rates in relation to health-care access in the United States: an ecological study. J Clin Psychiatry. 2006;67(4):517-523.</Citation></Reference><Reference><Citation>Conner A, Azrael D, Miller M. Suicide case-fatality rates in the United States, 2007 to 2014: nationwide population-based study. Ann Intern Med. 2019;171(12):885-895.</Citation></Reference><Reference><Citation>Crosby AE, Ortega L, Melanson C. Self-directed violence surveillance: uniform definitions and recommended data elements, Version 1.0. Atlanta: US National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (CDC), 2011.</Citation></Reference><Reference><Citation>Kessler RC, Berglund P, Borges G, Nock M, Wang PS. Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003. JAMA. 2005;293(20):2487-2495.</Citation></Reference><Reference><Citation>Park-Lee E, Hedden SL, Lipari RN. Suicidal thoughts and behavior in 33 metropolitan statistical areas update: 2013 to 2015. CBHSQ Report. Rockville, MD: US Substance Abuse and Mental Health Services Administration; 2018. https://www.samhsa.gov/data/sites/default/files/report_3452/ShortReport-3452.html; Accessed 22 Jan 2020</Citation></Reference><Reference><Citation>Tondo L, Lepri B, Baldessarini RJ. Suicidal risks among 2826 major affective disorder patients. Acta Psychiatr Scand. 2007;116(6):419-428.</Citation></Reference><Reference><Citation>Tondo L, Lepri B, Baldessarini RJ. Suicidal status during antidepressant treatment in 789 Sardinian patients with major affective disorder. Acta Psychiatr Scand. 2008;118(2):106-115.</Citation></Reference><Reference><Citation>Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173(7):11-53.</Citation></Reference><Reference><Citation>Baldessarini RJ, Tondo L, Pinna M, Nuñez N, Vázquez GH. Suicidal risk factors in major affective disorders. Br J Psychiatry. 2019;215(7):621-626.</Citation></Reference><Reference><Citation>Baldessarini RJ, Tondo L. Suicidal risks in psychiatric disorders. J Affect Disord. 2020;271(4):66-73.</Citation></Reference><Reference><Citation>Schaffer A, Isometsä ET, Tondo L, et al. International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord. 2015;17(1):1-16.</Citation></Reference><Reference><Citation>Tondo L, Pompili M, Forte A, Baldessarini RJ. Suicide attempts in bipolar disorders: comprehensive review of 101 reports. Acta Psychiatr Scand. 2016;133(3):174-186.</Citation></Reference><Reference><Citation>Geulayov G, Casey D, McDonald KC, et al. Incidence of suicide, hospital-presenting non-fatal self-harm, and community-occurring non-fatal self-harm in adolescents in England (the iceberg model of self-harm): retrospective study. Lancet Psychiatry. 2018;5(2):167-174.</Citation></Reference><Reference><Citation>Döme P, Rihmer Z, Gonda X. Suicide risk in bipolar disorder: brief review. Medicina (Kaunas). 2019;55(8):403-410.</Citation></Reference><Reference><Citation>Spiller HA, Ackerman JP, Spiller NE, Casavant MJ. Sex- and age-specific increased in suicide attempts by self-poisoning in the United States among youth and young adults from 2000 to 2018. J Pediatrics. 2019;210(7):201-208.</Citation></Reference><Reference><Citation>Glenn CR, Kleiman EM, Kelerman J, et al. Annual research review: meta-analytic review of worldwide suicide rates in adolescents. J Child Psychol Psychiatry. 2020;61(3):294-308.</Citation></Reference><Reference><Citation>Baldessarini RJ. Chemotherapy in Psychiatry, (3rd edn). New York: Springer Press; 2013.</Citation></Reference><Reference><Citation>Baldessarini RJ, Tondo L, Vázquez GH. Treatment of bipolar disorder. Mol Psychiatry. 2019;24(2):196-217.</Citation></Reference><Reference><Citation>Jones S, Riste L, Barrowclough C, et al. Reducing relapse and suicide in bipolar disorder: practical clinical approaches to identifying risk, reducing harm and engaging service users in planning and delivery of care. Chapter 5 in the PARADES (Psychoeducation, Anxiety, Relapse, Advance Directive Evaluation and Suicidality) program. Southampton (UK): NIHR Journals Library, 2018; pp 149-181.</Citation></Reference><Reference><Citation>Malhi GS, Outhred T, Das P, Morris G, Hamilton A, Mannie Z. Modeling suicide in bipolar disorders. Bipolar Disord. 2018;20(4):334-348.</Citation></Reference><Reference><Citation>Tondo L, Baldessarini RJ, Barbuti M, Colombini P, Angst J, Azorin J-M. Factors associated with single versus multiple suicide attempts in depressive disorders. J Affect Disord. 2020; in press. 28.</Citation></Reference><Reference><Citation>Carroll R, Metcalfe C, Gunnell D. Hospital presenting self-harm and risk of fatal and non-fatal repetition: systematic review and meta-analysis. PLoS One. 2014;9(2):e89944-e89953.</Citation></Reference><Reference><Citation>Dong M, Lu L, Zhang L, et al. Prevalence of suicide attempts in bipolar disorder: systematic review and meta-analysis of observational studies. Epidemiol Psychiatr Sci. 2019;29(10):e63.</Citation></Reference><Reference><Citation>Tondo L, Baldessarini RJ. Suicide in bipolar disorder. Chapt 37 in Yildiz A, Nemeroff C, Ruiz P (editors). The Bipolar Book: History, Neurobiology, and Treatment. New York: Oxford University Press, 2015, pp 509-528.</Citation></Reference><Reference><Citation>Forte A, Baldessarini RJ, Tondo L, Vázquez GH, Pompili M, Girardi P. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Affect Disord. 2015;178(6):71-78.</Citation></Reference><Reference><Citation>Pallaskorpi S, Suominen K, Rosenström T, et al. Predominant polarity in bipolar I and II disorders: five-year follow-up study. J Affect Disord. 2019;246(3):806-813.</Citation></Reference><Reference><Citation>Tondo L, Vázquez GH, Baldessarini RJ. Suicidal behavior associated with mixed features in major mood disorders. Psychiatr Clin No Am. 2020;43(1):83-93.</Citation></Reference><Reference><Citation>Vázquez GH, Lolich M, Cabrera C, et al. Mixed symptoms in mood disorders: systematic review. J Affect Disord. 2018;225(1):756-760.</Citation></Reference><Reference><Citation>Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. International Society for Bipolar Disorders (ISBD) task force report on antidepresant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249-1262.</Citation></Reference><Reference><Citation>Blasco-Fontecilla H, Baca-Garcia E, Dervic K, et al. Specific features of suicidal behavior in patients with narcissistic personality disorder. J Clin Psychiatry. 2009;70(11):1583-1587.</Citation></Reference><Reference><Citation>Ansell EB, Markowitz JC, Sanislow CA, et al. Personality disorder risk factors for suicide attempts over 10 years of follow-up. Personal Disord. 2015;6(2):161-167.</Citation></Reference><Reference><Citation>Coleman D, Lawrence R, Parekh A, et al. Narcissistic personality and suicidal behavior in mood disorders. J Psychiatr Res. 2017;85(2):24-28.</Citation></Reference><Reference><Citation>Zimmerman M, Balling C, Chelminski I, Dalrymple K. Patients with borderline personality disorder and bipolar disorder: a descriptive and comparative study. Psychol Med. 2020: [published online ahead of print March 17, 12 pp].</Citation></Reference><Reference><Citation>Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV. Sheehan Suicidality Tracking Scale (Sheehan-STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder. Psychiatry (Edgmont). 2009;6(1):26-31.</Citation></Reference><Reference><Citation>Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035-1043.</Citation></Reference><Reference><Citation>Miller JN, Black DW. Bipolar disorder and suicide: review. Curr Psychiatry Rep. 2020;22(2):6.</Citation></Reference><Reference><Citation>Tondo L, Baldessarini RJ. Suicide in psychiatric disorders: rates, risk factors and therapeutics. In Vázquez GH, Zarate CAJr, Brietzke E (editors). Ketamine in Treatment Resistant Depression: Neurobiology and Applications. New York: Elsevier-Academic Press, 2020, in press.</Citation></Reference><Reference><Citation>Baldessarini RJ, Tondo L, Strombom I, et al. Analysis of ecological studies of relationships between antidepressant utilization and suicidal risk. Harv Rev Psychiatry. 2007;15(4):133-145.</Citation></Reference><Reference><Citation>Braun C, Bschor T, Franklin J, Baethge C. Suicides and suicide attempts during long-term treatment with antidepressants: meta-analysis of 29 placebo-controlled studies including 6934 patients with major depressive disorder. Psychother Psychosomat. 2016;85(3):171-179.</Citation></Reference><Reference><Citation>Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol. 2006;26(2):203-207.</Citation></Reference><Reference><Citation>Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: systematic review of observational studies. CMAJ. 2009;180(3):291-297.</Citation></Reference><Reference><Citation>Tondo L, Baldessarini RJ, Hennen J, Floris G, Silvetti F, Tohen M. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry. 1998;59(8):405-414.</Citation></Reference><Reference><Citation>Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: 40 to 44 years’ follow-up. Arch Suicide Res. 2005;9(3):279-300.</Citation></Reference><Reference><Citation>Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: meta-analytic review. Bipolar Disord. 2006;8(5:2):625-639.</Citation></Reference><Reference><Citation>Müller-Oerlinghausen B, Ahrens B, Felber W. Suicide-preventive and mortality-reducing effect of lithium. In: Bauer M, Grof P, Müller-Oerlinghausen B, eds. Lithium in Neuropsychiatry. London: Informa Healthcare; 2006:79-192.</Citation></Reference><Reference><Citation>Lewitzka U, Bauer M, Felber W, Müller-Oerlinghausen B. Anti-suicidal effect of lithium: current state of research and its clinical implications for the long-term treatment of affective disorders (German). Nervenarzt. 2013;84(3):294-306.</Citation></Reference><Reference><Citation>Del Matto L, Muscas M, Murru A, et al. Lithium and suicide prevention in mood disorders and the general population: systematic review. Neurosci Biobehav Rev. 2020;116(6):142-153.</Citation></Reference><Reference><Citation>Tondo L, Alda M, Bauer M, et al. Clinical use of lithium salts: guide for users and prescribers. Int J Bipolar Disord. 2019;7(1):16-25.</Citation></Reference><Reference><Citation>Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91.</Citation></Reference><Reference><Citation>Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: mini-review. Neuropsychobiology. 2010;62:43-49.</Citation></Reference><Reference><Citation>Manchia M, Hajek T, O'Donovan C, et al. Genetic risk of suicidal behavior in bipolar spectrum disorder: analysis of 737 pedigrees. Bipolar Disord. 2013;15(5):496-506.</Citation></Reference><Reference><Citation>Oquendo MA, Galfalvy HC, Currier D, et al. Treatment of suicide attempters with bipolar disorder: randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry. 2011;168(10):1050-1056.</Citation></Reference><Reference><Citation>Søndergård L, Lopez AG, Andersen PK, Kessing LV. Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord. 2013;10(1):87-94.</Citation></Reference><Reference><Citation>Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry. 1996;29(3):103-107.</Citation></Reference><Reference><Citation>Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290(11):1467-1473.</Citation></Reference><Reference><Citation>Baldessarini RJ, Tondo L. Meta-analytic comparison of antisuicidal effects of lithium versus anticonvulsants. Pharmacopsychiatry. 2009;42(2):72-75.</Citation></Reference><Reference><Citation>Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry. 2009;66(12):1354-1360.</Citation></Reference><Reference><Citation>Smith EG, Søndergård L, Lopez AG, Andersen PK, Kessing LV. Association between consistent purchase of anticonvulsants or lithium and suicide risk: longitudinal cohort study from Denmark, 1995-2001. J Affect Disord. 2009;117(3):162-167.</Citation></Reference><Reference><Citation>Yerevanian BI, Choi YM. Impact of psychotropic drugs on suicide and suicidal behaviors. Bipolar Disord. 2013;15(5):594-621.</Citation></Reference><Reference><Citation>Fontoulakis KN, Gonda X, Baghai TC, et al. Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. Int J Psychiatry Clin Pract. 2015;19(3):158-167.</Citation></Reference><Reference><Citation>Mula M. Do anti-epileptic drugs increase suicide in epilepsy? 10 years after the FDA alert. Expert Rev Neurother. 2018;18(3):177-178.</Citation></Reference><Reference><Citation>Wimberley T, MacCabe JH, Laursen TM, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry. 2017;174(10):990-998.</Citation></Reference><Reference><Citation>Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61-68.</Citation></Reference><Reference><Citation>Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutterland AL, Correll CU, de Haan L. Clozapine and long-term mortality risk in patients with schizophrenia: systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull. 2019;45(2):315-329.</Citation></Reference><Reference><Citation>Haukka J, Tiihonen J, Härkänen T, Lönnqvist J. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol Drug Saf. 2008;17(7):686-696.</Citation></Reference><Reference><Citation>Lindström L, Lindström E, Nilsson M, Höistat M. Maintenance therapy with second generation antipsychotics for bipolar disorder: systematic review and meta-analysis. J Affect Disord. 2017;213(4):138-150.</Citation></Reference><Reference><Citation>Seemüller F, Schennach R, Mayr A, et al. Akathisia and suicidal ideation in first-episode schizophrenia. J Clin Psychopharmacol. 2012;32(5):694-698.</Citation></Reference><Reference><Citation>Gaertner I, Gilot C, Heidrich P, Gaertner HJ. Case control study on psychopharmacotherapy before suicide committed by 61 psychiatric inpatients. Pharmacopsychiatry. 2002;35(2):37-43.</Citation></Reference><Reference><Citation>D'Anci KE, Uhl S, Girardi G, Martin C. Treatments for prevention and management of suicide: systematic review. Ann Int Med. 2019;171(5):334-342.</Citation></Reference><Reference><Citation>Gardner DL, Cowdry RW. Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry. 1985;142(1):98-100.</Citation></Reference><Reference><Citation>Molero P, Pamos-Quiroga JA, Martin-Santos R, Calvalo-Sánchez E, Gutiérrez-Rojas L, Meana JJ. Antidepressant efficacy and tolerability of ketamine and esketamine: critical review. CNS Drugs. 2018;32(5):411-420.</Citation></Reference><Reference><Citation>Fu D-J, Ionescu DF, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptom in patients who have active suicidal ideation with intent: double-blind, randomized study. J Clin Psychiatry. 2020;81(3):19m13191-19m13198.</Citation></Reference><Reference><Citation>McIntyre RS, Lipsitz O, Rodrigues NB, et al. Effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disord. 2020. [published online ahead of print, May12].</Citation></Reference><Reference><Citation>Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry. 2020;54(1):29-45.</Citation></Reference><Reference><Citation>Hawton K, Witt KG, Salisbury TLT, et al. Psychosocial interventions following self-harm in adults: systematic review and meta-analysis. Lancet Psychiatry. 2016;3(8):740-750.</Citation></Reference><Reference><Citation>Méndez-Bustos P, Calati R, Rubio-Ramírez F, Olié E, Courtet P, Lopez-Castroman J. Effectiveness of psychotherapy on suicidal risk: systematic review of observational studies. Front Psychol. 2019;10(2):277-286.</Citation></Reference><Reference><Citation>Meyer EC, Walser R, Hermann B, et al. Acceptance and commitment therapy for co-occurring posttraumatic stress disorder and alcohol use disorders in veterans: pilot treatment outcomes. J Trauma Stress. 2018;31(5):781-789.</Citation></Reference><Reference><Citation>Forte A, Buscajoni A, Fiorillo A, Pompili M, Baldessarini RJ. Suicidal risk following hospital discharge: a review. Harv Rev Psychiatry. 2019;27(4):209-216.</Citation></Reference><Reference><Citation>Liang CS, Chung CH, Ho PS, Tsai CK, Chien WC. Superior antisuicidal effects of electroconvulsive therapy in unipolar disorder and bipolar depression. Bipolar Disord. 2018;20(6):539-546.</Citation></Reference><Reference><Citation>Jørgensen MB, Rozing MP, Kellner CH, Osler M. Electroconvulsive therapy, depression severity and mortality: data from the Danish National Patient Registry. J Psychopharmacol. 2020;34(3):273-279.</Citation></Reference><Reference><Citation>McGirr A, Karmani S, Arsappa R, et al. Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression. World Psychiatry. 2016;15(1):85-86.</Citation></Reference><Reference><Citation>Tavares DF, Myczkowski ML, Alberto RL, et al. Treatment of bipolar depression with deep TMS: results from a double-blind, randomized, parallel group, sham-controlled clinical trial. Neuropsychopharmacology. 2017;42(13):2593-2601.</Citation></Reference><Reference><Citation>Gold AK, Ornelas AC, Cirillo P, et al. Clinical applications of transcranial magnetic stimulation in bipolar disorder. Brain Behav. 2019;9(10):e01419.</Citation></Reference><Reference><Citation>McAllister-Williams RH, Sousa S, Kumar A, et al. Effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: 5-year prospective registry. Int J Bipolar Disord. 2020;8(1):13-23.</Citation></Reference><Reference><Citation>Gippert SM, Switala C, Bewernick BH, et al. Deep brain stimulation for bipolar disorder-review and outlook. CNS Spectr. 2017;22(3):254-257.</Citation></Reference><Reference><Citation>Saunders KEA, Hawton K. Clinical assessment and crisis intervention for the suicidal bipolar disorder patient. Bipolar Disord. 2013;15(5):575-583.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22711881</PMID><DateCompleted><Year>2013</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1614</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development.</ArticleTitle><Pagination><MedlinePgn>26-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0004867412449303</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Bipolar patients frequently relapse within 12 months of their previous mood episode, even in the context of adequate treatment, suggesting that better continuation and maintenance treatments are needed. Based on recent research of the pathophysiology of bipolar disorder, we review the evidence for mitochondrial dysregulation and selected mitochondrial modulators (MM) as potential treatments.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed the literature about mitochondrial dysfunction and potential MMs worthy of study that could improve the course of bipolar disorder, reduce subsyndromal symptoms, and prevent subsequent mood episodes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">MM treatment targets mitochondrial dysfunction, oxidative stress, altered brain energy metabolism and the dysregulation of multiple mitochondrial genes in patients with bipolar disorder. Several tolerable and readily available candidates include N-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), S-adenosylmethionine (SAMe), coenzyme Q(10) (CoQ10), alpha-lipoic acid (ALA), creatine monohydrate (CM), and melatonin. The specific metabolic pathways by which these MMs may improve the symptoms of bipolar disorder are discussed and combinations of selected MMs could be of interest as well.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Convergent data implicate mitochondrial dysfunction as an important component of the pathophysiology of bipolar disorder. Clinical trials of individual MMs as well as combinations are warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA 02114, USA. anierenberg@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kansky</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Brennan</LastName><ForeName>Brian P</ForeName><Initials>BP</Initials></Author><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Perlis</LastName><ForeName>Roy</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Iosifescu</LastName><ForeName>Dan V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050259" MajorTopicYN="N">Genes, Mitochondrial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22711881</ArticleId><ArticleId IdType="pii">0004867412449303</ArticleId><ArticleId IdType="doi">10.1177/0004867412449303</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2912286</PMID><DateCompleted><Year>1989</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>146</Volume><Issue>2</Issue><PubDate><Year>1989</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Effects of diagnosis and context on dangerousness.</ArticleTitle><Pagination><MedlinePgn>289-90</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003134" MajorTopicYN="N">Commitment of Mentally Ill</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003617" MajorTopicYN="Y">Dangerous Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014754" MajorTopicYN="Y">Violence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2912286</ArticleId><ArticleId IdType="doi">10.1176/ajp.146.2.289</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32598093</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-6394</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>02</Month></PubDate></JournalIssue><Title>Depression and anxiety</Title><ISOAbbreviation>Depress Anxiety</ISOAbbreviation></Journal><ArticleTitle>Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials.</ArticleTitle><Pagination><MedlinePgn>114-123</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/da.23069</ELocationID><Abstract><AbstractText Label="BACKGROUND">Adjunctive antidepressants are frequently used for bipolar depression but their clinical efficacy has been studied in few trials and little is known about how co-occurring manic symptoms affect treatment response.</AbstractText><AbstractText Label="METHODS">Bipolar Clinical Health Outcomes Initiative in Comparative Effectiveness (N = 482) and Lithium Treatment Moderate-Dose Use Study (N = 281) were similar comparative effectiveness trials on outpatients with bipolar disorder comparing four different randomized treatment arms with adjunctive personalized guideline-based treatment for 24 weeks. Adjunctive antidepressant treatment could be used if clinically indicated and was assessed at every study visit. Adjusted mixed effects linear regression analyses compared users of antidepressants to nonusers overall and in different subcohorts.</AbstractText><AbstractText Label="RESULTS">Of the 763 patients, 282 (37.0%) used antidepressant drugs during the study. Antidepressant users had less improvement compared to nonusers on the Clinical Global Impression Scale for Bipolar Disorder and on measures of depression. This was particularly true among patients with co-occurring manic symptoms. Exclusion of individuals begun on antidepressants late in the study (potentially due to overall worse response) resulted in no differences between users and nonusers. We found no differences in treatment effects on mania scales.</AbstractText><AbstractText Label="CONCLUSIONS">In this large cohort of outpatients with bipolar disorder, clinically indicated and guideline-based adjunctive antidepressant treatment was not associated with lower depressive symptoms or higher mania symptoms. The treatment-by-indication confounding due to the nonrandomized design of the trials complicates causal interpretations, but no analyses indicated better treatment effects of adjunctive antidepressants.</AbstractText><CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Köhler-Forsberg</LastName><ForeName>Ole</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-5121-1287</Identifier><AffiliationInfo><Affiliation>Psychosis Research Unit and the Department of Affective Disorders, Aarhus University Psychiatry Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sylvia</LastName><ForeName>Louisa G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fung</LastName><ForeName>Vicki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Policy Research Center, Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Overhage</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Policy Research Center, Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deckersbach</LastName><ForeName>Thilo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowden</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Health Science Center, San Antonio, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McInnis</LastName><ForeName>Melvin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kocsis</LastName><ForeName>James H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Weill Cornell Medical College, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Edward S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ketter</LastName><ForeName>Terence A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Lindner Center of HOPE, Mason, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Alabama at Birmingham, Birmingham, Alabama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostacher</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-0353-7535</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iosifescu</LastName><ForeName>Dan V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01HS019371-01</GrantID><Agency>Agency for Healthcare Research and Quality</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Depress Anxiety</MedlineTA><NlmUniqueID>9708816</NlmUniqueID><ISSNLinking>1091-4269</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">adjunctive</Keyword><Keyword MajorTopicYN="Y">antidepressant</Keyword><Keyword MajorTopicYN="Y">bipolar depression</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">depression</Keyword><Keyword MajorTopicYN="Y">treatment-emergent mania</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>02</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32598093</ArticleId><ArticleId IdType="doi">10.1002/da.23069</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Baldessarini, R. J., Tondo, L., &amp; Vazquez, G. H. (2019). Pharmacological treatment of adult bipolar disorder. Molecular Psychiatry, 24(2), 198-217. https://doi.org/10.1038/s41380-018-0044-2</Citation></Reference><Reference><Citation>Bjorklund, L. B., Horsdal, H. T., Mors, O., Gasse, C., &amp; Ostergaard, S. D. (2017). Psychopharmacological treatment of psychotic mania and psychotic bipolar depression compared to non-psychotic mania and non-psychotic bipolar depression. Bipolar Disorders, 19(6), 505-512. https://doi.org/10.1111/bdi.12504</Citation></Reference><Reference><Citation>Bjorklund, L., Horsdal, H. T., Mors, O., Ostergaard, S. D., &amp; Gasse, C. (2016). Trends in the psychopharmacological treatment of bipolar disorder: A nationwide register-based study. Acta Neuropsychiatrica, 28(2), 75-84. https://doi.org/10.1017/neu.2015.52</Citation></Reference><Reference><Citation>Bowden, C. L., Singh, V., Thompson, P., Gonzalez, J. M., Katz, M. M., Dahl, M., … Chang, X. (2007). Development of the bipolar inventory of symptoms scale. Acta Psychiatrica Scandinavica, 116(3), 189-194.</Citation></Reference><Reference><Citation>Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., … Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet, 391, 1357-1366.</Citation></Reference><Reference><Citation>Frye, M. A., Helleman, G., McElroy, S. L., Altshuler, L. L., Black, D. O., Keck, P. E., Jr, … Suppes, T. (2009). Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. The American Journal of Psychiatry, 166(2), 164-172. https://doi.org/10.1176/appi.ajp.2008.08030322</Citation></Reference><Reference><Citation>Gijsman, H. J., Geddes, J. R., Rendell, J. M., Nolen, W. A., &amp; Goodwin, G. M. (2004). Antidepressants for bipolar depression: A systematic review of randomized, controlled trials. The American Journal of Psychiatry, 161(9), 1537-1547. https://doi.org/10.1176/appi.ajp.161.9.1537</Citation></Reference><Reference><Citation>Goldberg, J. F., Perlis, R. H., Ghaemi, S. N., Calabrese, J. R., Bowden, C. L., Wisniewski, S., … Thase, M. E. (2007). Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: Findings from the STEP-BD. The American Journal of Psychiatry, 164(9), 1348-1355.</Citation></Reference><Reference><Citation>Gonzalez, J. M., Bowden, C. L., Katz, M. M., Thompson, P., Singh, V., Prihoda, T. J., &amp; Dahl, M. (2008). Development of the bipolar inventory of symptoms scale: Concurrent validity, discriminant validity and retest reliability. International Journal of Methods in Psychiatric Research, 17(4), 198-209. https://doi.org/10.1002/mpr.262</Citation></Reference><Reference><Citation>Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., … Zernig, G. (2011). AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry, 44(6), 195-235.</Citation></Reference><Reference><Citation>Kauer-Sant'Anna, M., Frey, B. N., Fijtman, A., Loredo-Souza, A. C., Dargel, A. A., Pfaffenseller, B., … Kapczinski, F. (2019). Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trial. Journal of Psychopharmacology, 33(4), 502-510. https://doi.org/10.1177/0269881119826602</Citation></Reference><Reference><Citation>Kupka, R. W., Altshuler, L. L., Nolen, W. A., Suppes, T., Luckenbaugh, D. A., Leverich, G. S., … Post, R. M. (2007). Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disorders, 9(5), 531-535.</Citation></Reference><Reference><Citation>Malhi, G. S., Outhred, T., Morris, G., Boyce, P. M., Bryant, R., Fitzgerald, P. B., … Fritz, K. (2018). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary. The Medical Journal of Australia, 208(5), 219-225. https://doi.org/10.5694/mja17.00658</Citation></Reference><Reference><Citation>Mauer, S., Alahmari, R., Vohringer, P. A., Vergne, D. E., Lovdahl, H., Correa, E., … Ghaemi, S. N. (2014). International prescribing patterns for mood illness: The international mood network (IMN). Journal of Affective Disorders, 167, 136-139. https://doi.org/10.1016/j.jad.2014.05.049</Citation></Reference><Reference><Citation>McGirr, A., Vohringer, P. A., Ghaemi, S. N., Lam, R. W., &amp; Yatham, L. N. (2016). Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: A systematic review and meta-analysis of randomised placebo-controlled trials. The Lancet.Psychiatry, 3(12), 1138-1146.</Citation></Reference><Reference><Citation>Montgomery, S. A., &amp; Asberg, M. (1979). A new depression scale designed to be sensitive to change. The British Journal of Psychiatry, The Journal of Mental Science, 134, 382-389.</Citation></Reference><Reference><Citation>Nierenberg, A. A., Friedman, E. S., Bowden, C. L., Sylvia, L. G., Thase, M. E., Ketter, T., … Calabrese, J. R. (2013). Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: A randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. The American Journal of Psychiatry, 170(1), 102-110. https://doi.org/10.1176/appi.ajp.2012.12060751</Citation></Reference><Reference><Citation>Nierenberg, A. A., McElroy, S. L., Friedman, E. S., Ketter, T. A., Shelton, R. C., Deckersbach, T., … Thase, M. E. (2016). Bipolar CHOICE (clinical health outcomes initiative in comparative effectiveness): A pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. The Journal of Clinical Psychiatry, 77(1), 90-99. https://doi.org/10.4088/JCP.14m09349</Citation></Reference><Reference><Citation>Nierenberg, A. A., Sylvia, L. G., Leon, A. C., Reilly-Harrington, N. A., Ketter, T. A., Calabrese, J. R., … Litmus Study Group (2009). Lithium treatment-moderate dose use study (LiTMUS) for bipolar disorder: Rationale and design. Clinical Trials, 6(6), 637-648. https://doi.org/10.1177/1740774509347399</Citation></Reference><Reference><Citation>Nierenberg, A. A., Sylvia, L. G., Leon, A. C., Reilly-Harrington, N. A., Shesler, L. W., McElroy, S. L., … Bipolar CHOICE Study Group (2014). Clinical and health outcomes initiative in comparative effectiveness for bipolar disorder (bipolar CHOICE): A pragmatic trial of complex treatment for a complex disorder. Clinical Trials, 11(1), 114-127. https://doi.org/10.1177/1740774513512184</Citation></Reference><Reference><Citation>Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., … Vieta, E. (2013). The international society for bipolar disorders (ISBD) task force report on antidepressant use in bipolar disorders. The American Journal of Psychiatry, 170(11), 1249-1262. https://doi.org/10.1176/appi.ajp.2013.13020185</Citation></Reference><Reference><Citation>Pacchiarotti, I., Valenti, M., Colom, F., Rosa, A. R., Nivoli, A. M., Murru, A., … Vieta, E. (2011). Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. Journal of Affective Disorders, 129(1-3), 321-326. https://doi.org/10.1016/j.jad.2010.07.036</Citation></Reference><Reference><Citation>Post, R. M., Altshuler, L. L., Leverich, G. S., Frye, M. A., Nolen, W. A., Kupka, R. W., … Mintz, J. (2006). Mood switch in bipolar depression: Comparison of adjunctive venlafaxine, bupropion and sertraline. The British Journal of Psychiatry, The Journal of Mental Science, 189, 124-131.</Citation></Reference><Reference><Citation>Reilly-Harrington, N. A., Sylvia, L. G., Leon, A. C., Shesler, L. W., Ketter, T. A., Bowden, C. L., … Nierenberg, A. A. (2013). The medication recommendation tracking form: A novel tool for tracking changes in prescribed medication, clinical decision making, and use in comparative effectiveness research. Journal of Psychiatric Research, 47(11), 1686-1693. https://doi.org/10.1016/j.jpsychires.2013.07.009</Citation></Reference><Reference><Citation>Sachs, G. S., Lafer, B., Stoll, A. L., Banov, M., Thibault, A. B., Tohen, M., &amp; Rosenbaum, J. F. (1994). A double-blind trial of bupropion versus desipramine for bipolar depression. The Journal of Clinical Psychiatry, 55(9), 391-393.</Citation></Reference><Reference><Citation>Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., … Thase, M. E. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. The New England Journal of Medicine, 356(17), 1711-1722.</Citation></Reference><Reference><Citation>Schaffer, A., Zuker, P., &amp; Levitt, A. (2006). Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. Journal of Affective Disorders, 96(1-2), 95-99.</Citation></Reference><Reference><Citation>Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., … Dunbar, G. C. (1998). The mini-international neuropsychiatric interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The Journal of Clinical Psychiatry, 59(Suppl. 20), 22-33.</Citation></Reference><Reference><Citation>Shelton, R. C., &amp; Stahl, S. M. (2004). Risperidone and paroxetine given singly and in combination for bipolar depression. The Journal of Clinical Psychiatry, 65(12), 1715-1719.</Citation></Reference><Reference><Citation>Shvartzman, Y., Krivoy, A., Valevski, A., Gur, S., Weizman, A., &amp; Hochman, E. (2018). Adjunctive antidepressants in bipolar depression: A cohort study of six- and twelve-months rehospitalization rates. European Neuropsychopharmacology, The Journal of the European College of Neuropsychopharmacology, 28(3), 353-360.</Citation></Reference><Reference><Citation>Sidor, M. M., &amp; Macqueen, G. M. (2011). Antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis. The Journal of Clinical Psychiatry, 72(2), 156-167. https://doi.org/10.4088/JCP.09r05385gre</Citation></Reference><Reference><Citation>Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., &amp; Nolen, W. (1997). Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP): The CGI-BP. Psychiatry Research, 73(3), 159-171.</Citation></Reference><Reference><Citation>Vazquez, G. H., Tondo, L., Undurraga, J., &amp; Baldessarini, R. J. (2013). Overview of antidepressant treatment of bipolar depression. The International Journal of Neuropsychopharmacology, 16(7), 1673-1685. https://doi.org/10.1017/S1461145713000023</Citation></Reference><Reference><Citation>Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., … Berk, M. (2018). Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97-170. https://doi.org/10.1111/bdi.12609</Citation></Reference><Reference><Citation>Young, R. C., Biggs, J. T., Ziegler, V. E., &amp; Meyer, D. A. (1978). A rating scale for mania: Reliability, validity and sensitivity. The British Journal of Psychiatry, 133, 429-435.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6883496</PMID><DateCompleted><Year>1983</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0008-9176</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>1983</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Central African journal of medicine</Title><ISOAbbreviation>Cent Afr J Med</ISOAbbreviation></Journal><ArticleTitle>The laboratory and clinical monitoring of lithium treatment in manic-depressive patients.</ArticleTitle><Pagination><MedlinePgn>86-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Field</LastName><ForeName>S P</ForeName><Initials>SP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Zimbabwe</Country><MedlineTA>Cent Afr J Med</MedlineTA><NlmUniqueID>0372566</NlmUniqueID><ISSNLinking>0008-9176</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1983</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1983</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1983</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6883496</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1540777</PMID><DateCompleted><Year>1992</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>160</Volume><PubDate><Year>1992</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Post-stroke rapid cycling bipolar affective disorder.</ArticleTitle><Pagination><MedlinePgn>283</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berthier</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Br J Psychiatry. 1991 Aug;159:279-80</RefSource><PMID Version="1">1773247</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1540777</ArticleId><ArticleId IdType="pii">S0007125000035844</ArticleId><ArticleId IdType="doi">10.1192/bjp.160.2.283a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1498960</PMID><DateCompleted><Year>1992</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN><JournalIssue CitedMedium="Print"><Volume>15 Suppl 1 Pt A</Volume><PubDate><Year>1992</Year></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Association and linkage studies in bipolar affective disorder.</ArticleTitle><Pagination><MedlinePgn>580A-581A</MedlinePgn></Pagination><AuthorList CompleteYN="N"><Author ValidYN="Y"><LastName>Lanczik</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dept. Psychiatry, Univ. Würzburg, FRG.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nöthen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Körner</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rietschel</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Erdmann</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Stratmann</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cichon</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lichtermann</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Propping</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1498960</ArticleId><ArticleId IdType="doi">10.1097/00002826-199201001-00301</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27855308</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1778-3585</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><PubDate><Year>2017</Year><Month>02</Month></PubDate></JournalIssue><Title>European psychiatry : the journal of the Association of European Psychiatrists</Title><ISOAbbreviation>Eur Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A longitudinal mirror-image assessment of morbidity in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>55-59</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0924-9338(16)30075-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eurpsy.2016.06.010</ELocationID><Abstract><AbstractText Label="BACKGROUND">Evidence about the clinical course of bipolar disorder is inconsistent and limited. The aim of this study was to assess changes in morbidity in patients with bipolar disorder along a mean follow-up period of 80months.</AbstractText><AbstractText Label="METHODS">Based on a mirror-image design, the follow-up period of each patient was divided into two halves. Then, three measures of morbidity - number of affective episodes, time spent ill, and cycle length - were recorded and compared between each half of the follow-up period.</AbstractText><AbstractText Label="RESULTS">On average, there was a trend to a smaller amount of time spent with subclinical symptomatology during the second half of the follow-up period. In contrast, there were no differences in terms of number of episodes, time spent with clinical symptoms, or cycle length between the first and second half of the follow-up period. A subgroup analysis identified 21.9% of patients with consistent data of a worsening during follow-up.</AbstractText><AbstractText Label="CONCLUSIONS">The results suggest that, on average, there is stability or slight improvement of clinical morbidity over the course of BD. Then, worsening of the clinical course may be a feature of a subgroup of patients rather than an inherent characteristic of the disorder. These subgroups or patient profiles could represent an opportunity for further studies to assess clinical, pathophysiologic, and therapeutic features associated with them.</AbstractText><CopyrightInformation>Copyright Â© 2016 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martino</LastName><ForeName>D J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Neuroscience Institute, Favaloro University, Solís 461, Buenos Aires, Argentina; National Council of Scientific and Technical Research (CONICET), avenue Rivadavia 1917, Buenos Aires, Argentina. Electronic address: diejmartino@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samamé</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Neuroscience Institute, Favaloro University, Solís 461, Buenos Aires, Argentina; National Council of Scientific and Technical Research (CONICET), avenue Rivadavia 1917, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marengo</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Neuroscience Institute, Favaloro University, Solís 461, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Igoa</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Neuroscience Institute, Favaloro University, Solís 461, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scápola</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Neuroscience Institute, Favaloro University, Solís 461, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strejilevich</LastName><ForeName>S A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Neuroscience Institute, Favaloro University, Solís 461, Buenos Aires, Argentina; Institute of Cognitive Neurology (INECO), Pacheco de Melo 1860, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Psychiatry</MedlineTA><NlmUniqueID>9111820</NlmUniqueID><ISSNLinking>0924-9338</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Cycle length</Keyword><Keyword MajorTopicYN="Y">Long-term</Keyword><Keyword MajorTopicYN="Y">Recurrences</Keyword><Keyword MajorTopicYN="Y">Staging</Keyword><Keyword MajorTopicYN="Y">Time spent ill</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>06</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27855308</ArticleId><ArticleId IdType="pii">S0924-9338(16)30075-X</ArticleId><ArticleId IdType="doi">10.1016/j.eurpsy.2016.06.010</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14643095</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>11</Issue><PubDate><Year>2003</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>State and trait influences on mood regulation in bipolar disorder: blood flow differences with an acute mood challenge.</ArticleTitle><Pagination><MedlinePgn>1274-83</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Even in remission, patients with bipolar disorder (BD) remain sensitive to external stressors that can trigger new episodes. Imitating such stressors by the controlled transient exposure to an emotional stimulus may help to identify brain regions modulating this sensitivity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Transient sadness was induced in 9 euthymic and in 11 depressed subjects with BD. Regional blood flow (rCBF) changes were measured using (15)O-water positron emission tomography.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Common changes in both groups were increased rCBF in anterior insula and cerebellum and decreased rCBF in dorsal-ventral-medial frontal cortex, posterior cingulate, inferior parietal, and temporal cortices. Decreases in dorsal ventral medial frontal cortices occurred in both groups, but subjects in remission showed a greater magnitude of change. Unique to remitted subjects with BD were rCBF increases in dorsal anterior cingulate and in premotor cortex. Lateral prefrontal rCBF decreases were unique to depressed subjects with BD. At baseline, remitted subjects showed a unique increase in dorsal anterior cingulate and orbitofrontal cortex.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Common rCBF changes in remitted and depressed subjects identifies potential sites of disease vulnerability. Unique cingulate and orbitofrontal changes both at baseline and with induced sadness seen in the absence of prefrontal rCBF decreases may identify regional interactions important to the euthymic state in this population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krüger</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry (SK), University of Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seminowicz</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Goldapple</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Sidney H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Mayberg</LastName><ForeName>Helen S</ForeName><Initials>HS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010104">Oxygen Radioisotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010104" MajorTopicYN="N">Oxygen Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14643095</ArticleId><ArticleId IdType="pii">S0006322303006917</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(03)00691-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10357029</PMID><DateCompleted><Year>1999</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>1-3</Issue><PubDate><MedlineDate>1999 Jan-Mar</MedlineDate></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder in the latter half of life: symptom presentation, global functioning and age of onset.</ArticleTitle><Pagination><MedlinePgn>161-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Little is known about bipolar disorder in late life. Recent research has been in acute, in-patient, settings, and has focused on late-onset mania, or has produced samples with surprisingly late mean ages of onset. No recent study has used a larger out-patient sample to address late-life outcomes of bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">86 community-residing, middle-aged and older adults who met RDC for bipolar I or II were interviewed using the Schedule for Affective Disorders and Schizophrenia, three times over 8 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants were primarily unmarried and impoverished. Most were living alone or with immediate family members. The majority were in depressive episodes. Depressive symptoms were more common and more predictive of functioning than manic symptoms. Age of onset was related to global functioning. The effect of age of onset was mediated by number of depressive episodes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Most adults in this sample had supports to maintain them in the community in spite of chronic or intermittently cycling manifestations of affective disorder and limited medication. Consistent with prior research, early age of onset was related to poorer functioning, apparently by increasing the number and severity of depressive episodes.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Limitations stem from possible exclusion of those people with the worst and best outcomes. It also is a relatively young sample for a gerontological study.</AbstractText><AbstractText Label="CLINICAL RELEVANCE" NlmCategory="CONCLUSIONS">The study suggests that more attention needs to be paid to diagnosing and treating depressive episodes in later life.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meeks</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Louisville, KY 40292, USA. s0meek01@homer.louisville.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="Y">Social Adjustment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>6</Month><Day>5</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>6</Month><Day>5</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10357029</ArticleId><ArticleId IdType="pii">S0165-0327(98)00069-X</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(98)00069-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3348456</PMID><DateCompleted><Year>1988</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>145</Volume><Issue>4</Issue><PubDate><Year>1988</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Alternative patterns of seasonal affective disorder: three case reports from north India.</ArticleTitle><Pagination><MedlinePgn>515-6</MedlinePgn></Pagination><Abstract><AbstractText>Three cases of seasonal affective disorder in north India are described, illustrating different seasonal patterns: 1) mania in summer and depression in winter, 2) mania in early winter and depression in late winter, and 3) depression in summer and mania in early winter.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Dayanand Medical College and Hospital, Punjab, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005843" MajorTopicYN="N">Geography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013696" MajorTopicYN="N">Temperature</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3348456</ArticleId><ArticleId IdType="doi">10.1176/ajp.145.4.515</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">288468</PMID><DateCompleted><Year>1979</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>1979</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Onset of mania in bipolar manic-depressive patients.</ArticleTitle><Pagination><MedlinePgn>57-61</MedlinePgn></Pagination><Abstract><AbstractText>Onset of mania was evaluated retrospectively in 48 bipolar manic-depressive patients. Mania occurred as the initial episode in 40% of cases. In patients with initial episode of depression, approximately 80% developed mania prior to their third episodes of depression and within 5 years from the onset of this illness. Differences in type of illness onset were related to family history of bipolar illness and sex of the proband. Male patients with a positive family history were significantly more likely to manifest mania at onset of illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>G F</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>G E</ForeName><Initials>GE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">288468</ArticleId><ArticleId IdType="doi">10.3109/00048677909159110</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14654872</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0327-6139</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>54</Issue><PubDate><MedlineDate>2003 Dec-2004 Feb</MedlineDate></PubDate></JournalIssue><Title>Vertex (Buenos Aires, Argentina)</Title><ISOAbbreviation>Vertex</ISOAbbreviation></Journal><ArticleTitle>[Perception of the impact of Bipolar Disorder and its diagnosis in health centers in Argentine and Chile].</ArticleTitle><Pagination><MedlinePgn>245-52</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Early detection and treatment of Bipolar Disorder (BD) determine a significant relief in the considerable burden this disease implies. In order to adequately plan the strategies to guarantee access to treatment, it is useful to consider data which reflect the everyday vicissitudes the people affected by this pathology have to deal with. People on treatment for BD in centres in Argentina and Chile were surveyed, collecting data on their access to diagnosis and treatment. The centre surveyed in Chile, unlike those in Argentina, operates as a specialized unit.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">An anonymous assisted survey was carried out; a random sample of people assisted in the participating centres with a diagnosis of BD type I or II, and stabilized for a period no shorter than 12 months, was assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">100 people were surveyed in Argentina and 69 in Chile (70% women, age 45.2 +/- 14.7, average schooling 12 years). Seventy one percent began symptoms at adult age (28,43 +/- 13 years), 14% during childhood. Age at first consultation was: 30 +/- 12.5; 85% reported having suffered psychotic symptoms, 46.4% suicide attempts, 71% hospitalisations for BD. Sixty-nine percent reported diagnostic delays longer than a year (median 8 years), 75% reported having received other diagnosis prior to their BD diagnosis (62% unipolar depression, 41% schizophrenia). Forty-one percent reported being unemployed. Delays and diagnostic errors were associated to a significant increase in the functional impact reported.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Approximately 7 out of 10 people report difficulties in the access to a BD diagnosis. These difficulties magnify the already important impact of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strejilevich</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Area de Investigación y Desarrollo en Salud Mental, Buenos Aires, Argentina. sstreji@intramed.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Retamal Carrasco</LastName><ForeName>Pedro</ForeName><Initials>P</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><VernacularTitle>Percepción del impacto y el proceso diagnóstico del trastorno bipolar en personas en tratamiento en centros de Argentina y Chile.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Vertex</MedlineTA><NlmUniqueID>9440528</NlmUniqueID><ISSNLinking>0327-6139</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001118" MajorTopicYN="N" Type="Geographic">Argentina</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002677" MajorTopicYN="N" Type="Geographic">Chile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14654872</ArticleId><ArticleId IdType="pii">040579197</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16260043</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>89</Volume><Issue>1-3</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The use of the GBI as predictor of bipolar disorder in a population of adolescent offspring of parents with a bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>147-55</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the usefulness of the General Behavior Inventory (GBI) to predict the development of mood disorders in the offspring of parents with bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The GBI and the K-SADS (first measurement) and the SCID (last measurement) were used to assess psychopathology among 129 adolescent and young adult offspring of a bipolar parent with an interval of 5 years. Based on the SCID results at the last measurement, the offspring were assigned to one of four groups: with bipolar mood disorder, with unipolar mood disorders, with non-mood disorders and without disorders and GBI-scores at the first measurement were compared across the four groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The scores on the Depression scale of the GBI for the offspring who later developed a bipolar or any mood disorder were significantly higher than for the offspring who did not develop a mood disorder across a 5-year interval. For the offspring with a unipolar mood disorder at the first measurement, the scores on the Depression scale were significantly higher for those who switched to bipolar disorder versus those who remained unipolar.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The GBI can be used in a high-risk sample of offspring of parents with bipolar disorder as a self-report measure as an aid to detect those who will develop bipolar disorder across a 5-year interval.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reichart</LastName><ForeName>Catrien G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Erasmus Medical Center Rotterdam/Department of Child and Adolescent Psychiatry, Sophia Children's Hospital, Rotterdam, The Netherlands. C.Reichart@Accare.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Ende</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wals</LastName><ForeName>Marjolein</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hillegers</LastName><ForeName>Manon H J</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Ormel</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Verhulst</LastName><ForeName>Frank C</ForeName><Initials>FC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="N">Child of Impaired Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="N">Psychopathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>01</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16260043</ArticleId><ArticleId IdType="pii">S0165-0327(05)00288-0</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2005.09.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8295640</PMID><DateCompleted><Year>1994</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2162</ISSN><JournalIssue CitedMedium="Print"><Volume>138</Volume><Issue>3</Issue><PubDate><Year>1994</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Nederlands tijdschrift voor geneeskunde</Title><ISOAbbreviation>Ned Tijdschr Geneeskd</ISOAbbreviation></Journal><ArticleTitle>[Rapid cycling in bipolar disorders].</ArticleTitle><Pagination><MedlinePgn>145-8</MedlinePgn></Pagination><Abstract><AbstractText>Two patients, a woman aged 32 and a man aged 27 years, were suffering from rapid cycling bipolar disorder (i.e. a course with four or more episodes a year). Hypothyroidism and the use of antidepressants may be involved in the development of such a disease course. Treatment with carbamazepine was successful in both patients. Patients suffering from rapid cycling bipolar disorder should be treated with lithium or carbamazepine, or a combination of these. Antidepressants should only be used with great caution.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Knoppert-van der Klein</LastName><ForeName>E A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Psychiatrisch Ziekenhuis Endegeest, afd. Jelgersmapolikliniek, Oegstgeest.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoogduin</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>W A</ForeName><Initials>WA</Initials></Author></AuthorList><Language>dut</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>'Rapid cycling' bij bipolaire stoornissen.</VernacularTitle></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ned Tijdschr Geneeskd</MedlineTA><NlmUniqueID>0400770</NlmUniqueID><ISSNLinking>0028-2162</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>1</Month><Day>15</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>1</Month><Day>15</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8295640</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18357846</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Clinical characteristics of bipolar I patients according to their family history of affective disorders].</ArticleTitle><Pagination><MedlinePgn>762-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The familial nature of bipolar disorder has been well described and multiple genes are probably involved in most or all cases. Each gene contributes equally to a bipolar phenotype and it may contribute to clinical characteristics. However, the genetic transmission of bipolar disorder remained undetermined up to now, partly due to clinical and genetically heterogeneity. In Tunisia, genetic study will profit from specific interests and advantages: the high rates of consanguinity, the existence of large families, and the relative geographical stability of the population.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to compare clinical characteristics of familial and nonfamilial bipolar I disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">One hundred and thirty subjects met DSM-IV criteria for a bipolar I disorder; they were recruited and divided into groups according to their family history of affective disorders. Group 1 with a familial history group, comporting bipolar I patients with a family history of affective disorders in first and second degree relatives (n = 76; 52 males and 24 females, mean age = 37.2 +/- 10.7 years) was compared to group 2 (nonfamilial history group), comporting bipolar I patients without a family history of affective disorders (n = 54; 29 males and 25 females, mean age = 38.1 +/- 10.9 years). Available information was obtained from a structured clinical interview, collateral history, and medical records. The family investigation permitted completion of genealogies over three generations. The comparison of the two groups was based on the clinical characteristics (age at onset, numbers of affective episodes, nature and severity of the last affective episode,...).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no significant differences between the two groups concerning demographic and social features, with the exception of professional activity. Indeed 30.2% of patients with a family history of affective disorders were unemployed versus 12.9% of patients without a family history of affective disorders (p = 0.02). Bipolar I patients with a family history of affective disorders were characterised by an early age at onset of the first episode (before 20 years) (48.7 versus 24.0%; p = 0.004), a high frequency of affective episodes (8.1 +/- 3.6 versus 6.0 +/- 3.5; p = 0.002) and had been more often hospitalised than patients without a family history of affective disorders (5.7 +/- 3.0 versus 4.7 +/- 3.0; p = 0.06). No significant differences were found concerning the nature of the first affective episode in bipolar I patients with or without a family history of affective disorders. Eleven women had developed their first affective episode during the puerperal period; eight of whom had a family history of affective disorders (p = 0.07). The last affective episode was significantly more severe (94.8 versus 77.8%; p = 0.003) and more often associated with psychotic features (55.3 versus 35.2%; p = 0.02) in patients with a family history of affective disorders. After multiple regression, the high frequency of affective episodes and the severity of last episode were more related with a family history of affective disorders.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results of our study provide evidence of familiality for some clinical characteristics which can be useful as phenotypic measures in future molecular genetic studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mrad</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratoire de recherche vulnérabilité aux psychoses, service de psychiatrie, CHU de Monastir, Monastir, Tunisie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mechri</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rouissi</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Khiari</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gaha</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><VernacularTitle>Caractéristiques cliniques des patients bipolaires type I en fonction de leurs antécédents familiaux thymiques.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18357846</ArticleId><ArticleId IdType="pii">S0013-7006(07)00023-1</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2006.12.002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23088582</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-0619</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>May</Month></PubDate></JournalIssue><Title>Cognitive neuropsychiatry</Title><ISOAbbreviation>Cogn Neuropsychiatry</ISOAbbreviation></Journal><ArticleTitle>Genetic and neurocognitive foundations of emotion abnormalities in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>168-207</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13546805.2012.690938</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Bipolar Disorder (BD) is a serious mood disorder, the aetiology of which is still unclear. The disorder is characterised by extreme mood variability in which patients fluctuate between markedly euphoric, irritable, and elevated states to periods of severe depression. The current research literature shows that BD patients demonstrate compromised neurocognitive ability in addition to these mood symptoms. Viable candidate genes implicated in neurocognitive and socioemotional processes may explain the development of these core emotion abnormalities. Additionally, links between faulty neurocognition and impaired socioemotional ability complement genetic explanations of BD pathogenesis. This review examines associations between cognition indexing prefrontal neural regions and socioemotional impairments including emotion processing and regulation. A review of the effect of COMT and TPH2 on these functions is also explored.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Major computer databases including PsycINFO, Google Scholar, and Medline were consulted in order to conduct a comprehensive review of the genetic and cognitive literature in BD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This review determines that COMT and TPH2 genetic variants contribute susceptibility to abnormal prefrontal neurocognitive function which oversees the processing and regulation of emotion. This provides for greater understanding of some of the emotional and cognitive symptoms in BD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Current findings in this direction show promise, although the literature is still in its infancy and further empirical research is required to investigate these links explicitly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Rheenen</LastName><ForeName>Tamsyn E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Brain and Psychological Sciences Research Centre, Faculty of Life and Social Sciences, Swinburne University, and Cognitive Neuropsychology Laboratory, Monash Alfred Psychiatry Research Center, The Alfred Hospital, Melbourne, Australia. tvanrheenen@swin.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossell</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cogn Neuropsychiatry</MedlineTA><NlmUniqueID>9713497</NlmUniqueID><ISSNLinking>1354-6805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.16.4</RegistryNumber><NameOfSubstance UI="C494784">TPH2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.4</RegistryNumber><NameOfSubstance UI="D014365">Tryptophan Hydroxylase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014365" MajorTopicYN="N">Tryptophan Hydroxylase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23088582</ArticleId><ArticleId IdType="doi">10.1080/13546805.2012.690938</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22079454</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2012</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9572</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>NeuroImage</Title><ISOAbbreviation>Neuroimage</ISOAbbreviation></Journal><ArticleTitle>Genome-wide supported risk variant for bipolar disorder alters anatomical connectivity in the human brain.</ArticleTitle><Pagination><MedlinePgn>3288-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuroimage.2011.10.083</ELocationID><Abstract><AbstractText>Bipolar disorder is a devastating, highly heritable mental disorder related to disturbed connectivity between limbic and frontal brain areas. A meta-analysis of genome-wide association studies as well as independent replications showed ankyrin 3 (ANK3) to be one of the best-supported risk genes for bipolar disorder. Using an imaging genetics approach employing diffusion tensor imaging in 88 healthy volunteers, we show decreased white matter integrity, indicated by lower fractional anisotropy and longitudinal diffusivity, in healthy carriers of the ANK3 rs10994336 risk genotype in the anterior limb of the internal capsule. We are also able to show that the resulting alterations of cortical-striatal-thalamic circuits are related to impaired set-shifting and increased risk-taking. For risk-allele carriers of ANK3 rs9804190 no white matter alterations or neuropsychological impairments were observed. In sum, our findings show that ANK3 rs10994336 or a variant in linkage-disequilibrium is functional in the human brain and also influences behavioral phenotypes related to bipolar disorder.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Linke</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witt</LastName><ForeName>Stephanie H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Andrea V</ForeName><Initials>AV</Initials></Author><Author ValidYN="Y"><LastName>Nieratschker</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Poupon</LastName><ForeName>Cyril</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gass</LastName><ForeName>Achim</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hennerici</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Rietschel</LastName><ForeName>Marcella</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wessa</LastName><ForeName>Michèle</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuroimage</MedlineTA><NlmUniqueID>9215515</NlmUniqueID><ISSNLinking>1053-8119</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="Y">Diffusion Tensor Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>05</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22079454</ArticleId><ArticleId IdType="pii">S1053-8119(11)01253-5</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2011.10.083</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12776396</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>May</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Influence of season and latitude in a community sample of subjects with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>277-80</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To report on the prevalence of seasonal bipolar disorder (BD) and the impact of latitude in a community sample in the province of Ontario.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">This study used the telephone-administered Depression and Seasonality Interview. Exact latitude was determined for each participant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 14 of 62 (22.6%) subjects with BD had the seasonal subtype of BD. Latitude did not appear to influence the proportion of subjects with the seasonal subtype.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We identified a seasonal pattern of illness in a proportion of subjects with BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schaffer</LastName><ForeName>Ayal</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Mood Disorders Program, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario. ayal.schaffer@swchsc.on.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levitt</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Boyle</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>6</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>6</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12776396</ArticleId><ArticleId IdType="doi">10.1177/070674370304800413</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27111134</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1749-6632</ISSN><JournalIssue CitedMedium="Internet"><Volume>1366</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>02</Month></PubDate></JournalIssue><Title>Annals of the New York Academy of Sciences</Title><ISOAbbreviation>Ann N Y Acad Sci</ISOAbbreviation></Journal><ArticleTitle>Innovative approaches to bipolar disorder and its treatment.</ArticleTitle><Pagination><MedlinePgn>76-89</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/nyas.13048</ELocationID><Abstract><AbstractText>All psychiatric disorders have suffered from a dearth of truly novel pharmacological interventions. In bipolar disorder, lithium remains a mainstay of treatment, six decades since its effects were serendipitously discovered. The lack of progress reflects several factors, including ignorance of the disorder's pathophysiology and the complexities of the clinical phenotype. After reviewing the current status, we discuss some ways forward. First, we highlight the need for a richer characterization of the clinical profile, facilitated by novel devices and new forms of data capture and analysis; such data are already promoting a reevaluation of the phenotype, with an emphasis on mood instability rather than on discrete clinical episodes. Second, experimental medicine can provide early indications of target engagement and therapeutic response, reducing the time, cost, and risk involved in evaluating potential mood stabilizers. Third, genomic data can inform target identification and validation, such as the increasing evidence for involvement of calcium channel genes in bipolar disorder. Finally, new methods and models relevant to bipolar disorder, including stem cells and genetically modified mice, are being used to study key pathways and drug effects. A combination of these approaches has real potential to break the impasse and deliver genuinely new treatments.</AbstractText><CopyrightInformation>© 2016 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals Inc. on behalf of The New York Academy of Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Health NHS Foundation Trust, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cipriani</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Health NHS Foundation Trust, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harmer</LastName><ForeName>Catherine J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Health NHS Foundation Trust, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nobre</LastName><ForeName>Anna C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Health NHS Foundation Trust, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Centre for Human Brain Activity, Warneford Hospital, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Health NHS Foundation Trust, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>Guy M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Health NHS Foundation Trust, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geddes</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Health NHS Foundation Trust, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>104571</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann N Y Acad Sci</MedlineTA><NlmUniqueID>7506858</NlmUniqueID><ISSNLinking>0077-8923</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035703" MajorTopicYN="N">Therapies, Investigational</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">clinical</Keyword><Keyword MajorTopicYN="Y">genetics</Keyword><Keyword MajorTopicYN="Y">mood</Keyword><Keyword MajorTopicYN="Y">therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>02</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>03</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27111134</ArticleId><ArticleId IdType="doi">10.1111/nyas.13048</ArticleId><ArticleId IdType="pmc">PMC4850752</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neuropharmacology. 2016 Feb;101:439-48</Citation><ArticleIdList><ArticleId IdType="pubmed">26476274</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Oct;21(10):1324-32</Citation><ArticleIdList><ArticleId IdType="pubmed">27240535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Adv Chronic Dis. 2011 May;2(3):209-26</Citation><ArticleIdList><ArticleId IdType="pubmed">23251751</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2014 Dec;2(1):11</Citation><ArticleIdList><ArticleId IdType="pubmed">26092397</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2015 Apr;51:243-54</Citation><ArticleIdList><ArticleId IdType="pubmed">25662294</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2011 Aug;41(8):1567-77</Citation><ArticleIdList><ArticleId IdType="pubmed">20836910</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2015 Dec;72(12):1167-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26536621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2015 Mar;20(3):388-97</Citation><ArticleIdList><ArticleId IdType="pubmed">24821222</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2015 Mar;25(3):283-94</Citation><ArticleIdList><ArticleId IdType="pubmed">25595029</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Aug;17(5):543-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25846854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Mar;16(2):199-203</Citation><ArticleIdList><ArticleId IdType="pubmed">24372835</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 May 30;159(1-2):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18295902</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2015 May 21;5(5):e007504</Citation><ArticleIdList><ArticleId IdType="pubmed">25998036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Gen Psychiatry. 2015 Jul 07;14:19</Citation><ArticleIdList><ArticleId IdType="pubmed">26155299</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Jun;2(2):108-19</Citation><ArticleIdList><ArticleId IdType="pubmed">11252650</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2014 Jul;44(9):1793-808</Citation><ArticleIdList><ArticleId IdType="pubmed">24074230</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2015 Feb;25(2):151-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25661911</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1992 Jun 6;339(8806):1397-400</Citation><ArticleIdList><ArticleId IdType="pubmed">1350815</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley Interdiscip Rev Membr Transp Signal. 2014 Mar 1;3(2):15-38</Citation><ArticleIdList><ArticleId IdType="pubmed">24683526</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2003 Oct;23(5):484-95</Citation><ArticleIdList><ArticleId IdType="pubmed">14520126</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16783-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21930901</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Aug;15(5):457-90</Citation><ArticleIdList><ArticleId IdType="pubmed">23755739</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2007;31(6):850-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17307253</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2015 Mar 20;15:52</Citation><ArticleIdList><ArticleId IdType="pubmed">25884824</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 May;15(3):253-63</Citation><ArticleIdList><ArticleId IdType="pubmed">23551755</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2016 Jun;41(7):1768-78</Citation><ArticleIdList><ArticleId IdType="pubmed">26593266</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Apr 1;73(7):683-90</Citation><ArticleIdList><ArticleId IdType="pubmed">23237312</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2015 Sep;21(9):979-88</Citation><ArticleIdList><ArticleId IdType="pubmed">26340119</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Jan 15;190:162-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26519636</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 May 15;148(1):28-36</Citation><ArticleIdList><ArticleId IdType="pubmed">23561484</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2015 May;76(5):614-24</Citation><ArticleIdList><ArticleId IdType="pubmed">26035191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Nov;17(7):705-14</Citation><ArticleIdList><ArticleId IdType="pubmed">26394555</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2015 Jul;207(1):46-51</Citation><ArticleIdList><ArticleId IdType="pubmed">25614530</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2011 Jul;21(7):495-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21684455</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Tissue Res. 2014 Aug;357(2):477-92</Citation><ArticleIdList><ArticleId IdType="pubmed">24577622</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2015 Jan;172(1):41-51</Citation><ArticleIdList><ArticleId IdType="pubmed">25219389</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2013 Jul;162B(5):439-51</Citation><ArticleIdList><ArticleId IdType="pubmed">23728906</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Mar 26;9(3):e90169</Citation><ArticleIdList><ArticleId IdType="pubmed">24670976</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2015 Oct;72(10):1029-36</Citation><ArticleIdList><ArticleId IdType="pubmed">26332608</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Jul;149(1-3):46-55</Citation><ArticleIdList><ArticleId IdType="pubmed">23141630</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Feb;191:88-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26655117</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2015 Sep 19;370(1677):20140213</Citation><ArticleIdList><ArticleId IdType="pubmed">26240428</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2010 Aug;11(8):552-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20631711</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Biol Sci. 2012 Mar 7;279(1730):916-24</Citation><ArticleIdList><ArticleId IdType="pubmed">21849316</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2015 Apr;76(4):398-405</Citation><ArticleIdList><ArticleId IdType="pubmed">25844756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Behav Ther Exp Psychiatry. 2015 Mar;46:14-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25164093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Feb;15(2):146-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19078961</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2014 Nov;205(5):337-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25368357</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3131-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22323591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2011 Oct 8;378(9799):1306-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21851976</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2014 Oct;57:1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">25016347</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2014 Jul;17(7):1039-52</Citation><ArticleIdList><ArticleId IdType="pubmed">23449044</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2014 Dec;130(6):452-69</Citation><ArticleIdList><ArticleId IdType="pubmed">25283309</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2011 Sep;21 Suppl 4:S683-93</Citation><ArticleIdList><ArticleId IdType="pubmed">21835596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2015 Dec;2(12):1045-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26613842</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2014 May;129(5):328-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24289821</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2016 Mar 1;173(3):271-81</Citation><ArticleIdList><ArticleId IdType="pubmed">26541814</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 Sep;128(3):149-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23617548</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2010 Feb;196(2):92-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20118450</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Feb;161(2):217-22</Citation><ArticleIdList><ArticleId IdType="pubmed">14754766</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Internet Res. 2015 Aug 17;17(8):e198</Citation><ArticleIdList><ArticleId IdType="pubmed">26283290</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2014 Oct 22;84(2):399-415</Citation><ArticleIdList><ArticleId IdType="pubmed">25374361</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2015 Jul;207(1):55-63</Citation><ArticleIdList><ArticleId IdType="pubmed">25953891</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Aug 1;181:87-91</Citation><ArticleIdList><ArticleId IdType="pubmed">25933099</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2013;4:1332</Citation><ArticleIdList><ArticleId IdType="pubmed">23299882</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2015 Jun;131(6):417-25</Citation><ArticleIdList><ArticleId IdType="pubmed">25735195</ArticleId></ArticleIdList></Reference><Reference><Citation>Evid Based Ment Health. 2015 May;18(2):40-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25908686</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 Apr 20;381(9875):1371-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23453885</ArticleId></ArticleIdList></Reference><Reference><Citation>Pract Neurol. 2014 Oct;14(5):336-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24647614</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2014 Jun;13(2):153-60</Citation><ArticleIdList><ArticleId IdType="pubmed">24890068</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 May 11;381(9878):1663-71</Citation><ArticleIdList><ArticleId IdType="pubmed">23663952</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 2013 Jan 08;65(1):105-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23300133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2012 Feb 25;379(9817):721-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22265699</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 2016 Feb;36:1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26210959</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Jan;21(1):89-93</Citation><ArticleIdList><ArticleId IdType="pubmed">25560756</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2015 Oct;98(4):417-41</Citation><ArticleIdList><ArticleId IdType="pubmed">26044279</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Jul;171(7):712-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24980165</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Jul;165(7):820-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18519522</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Nov 5;527(7576):95-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26524527</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2010 Jan 30;375(9712):385-95</Citation><ArticleIdList><ArticleId IdType="pubmed">20092882</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Sep 15;184:36-50</Citation><ArticleIdList><ArticleId IdType="pubmed">26070045</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Dec;169 Suppl 1:S3-11</Citation><ArticleIdList><ArticleId IdType="pubmed">25533912</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2013 Aug;18(8):922-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22850628</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 2010;43(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19893338</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2015 Sep 29;(9):CD011611</Citation><ArticleIdList><ArticleId IdType="pubmed">26415966</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Aug;189:118-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16880480</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2015 Dec;49(12):1087-206</Citation><ArticleIdList><ArticleId IdType="pubmed">26643054</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2012 Aug 1;62(1):530-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22569064</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2014 Sep 25;349:g5673</Citation><ArticleIdList><ArticleId IdType="pubmed">25258392</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Sep 1;54(5):573-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12946886</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2011 Sep;25(9):1148-58</Citation><ArticleIdList><ArticleId IdType="pubmed">20530590</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Jul;171(7):785-94</Citation><ArticleIdList><ArticleId IdType="pubmed">24781368</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 May 11;381(9878):1654-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23663951</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2014 Nov;16(11):493</Citation><ArticleIdList><ArticleId IdType="pubmed">25194313</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Nov 7;503(7474):72-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24153177</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Mar;17(2):139-49</Citation><ArticleIdList><ArticleId IdType="pubmed">25118155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2015 Feb;20(2):162-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25403839</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2015 Dec;2(12):1075-83</Citation><ArticleIdList><ArticleId IdType="pubmed">26453408</ArticleId></ArticleIdList></Reference><Reference><Citation>Trials. 2016 Mar 02;17 (1):116</Citation><ArticleIdList><ArticleId IdType="pubmed">26936776</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2014 Mar 25;4:e375</Citation><ArticleIdList><ArticleId IdType="pubmed">25116795</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Assess. 2009 Sep;21(3):425-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19719353</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2014 Mar 11;5:3339</Citation><ArticleIdList><ArticleId IdType="pubmed">24618891</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2016 Jun;41(7):1691-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26818126</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2015 Jun;20(6):661-70</Citation><ArticleIdList><ArticleId IdType="pubmed">25687772</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2016 Feb 1;173(2):117-27</Citation><ArticleIdList><ArticleId IdType="pubmed">26514657</ArticleId></ArticleIdList></Reference><Reference><Citation>Elife. 2014 Mar 25;3:e01867</Citation><ArticleIdList><ArticleId IdType="pubmed">24668169</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2015 Apr;19(4):183-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25727774</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2016 Mar 12;387(10023):1085-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26806518</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2007 Sep;191:189-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17766755</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2015 Jun;14(2):119-36</Citation><ArticleIdList><ArticleId IdType="pubmed">26043321</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2014 Mar;29(3):117-24</Citation><ArticleIdList><ArticleId IdType="pubmed">24075633</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2015 May 22;:null</Citation><ArticleIdList><ArticleId IdType="pubmed">26010130</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2014 Aug 26;4:e428</Citation><ArticleIdList><ArticleId IdType="pubmed">25158003</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2014 Dec;16(12):523</Citation><ArticleIdList><ArticleId IdType="pubmed">25308392</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2012 Oct 23;2:e180</Citation><ArticleIdList><ArticleId IdType="pubmed">23092984</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2014 Oct;1(5):351-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26360999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2013 Jul 16;159(2):130-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23856683</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Jul;167(7):748-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20595427</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Aug;171(8):829-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24626773</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2013 Jul;162B(5):431-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23780892</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2012 Nov 08;345:e7085</Citation><ArticleIdList><ArticleId IdType="pubmed">23137820</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3576-81</Citation><ArticleIdList><ArticleId IdType="pubmed">25730879</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(1):e53804</Citation><ArticleIdList><ArticleId IdType="pubmed">23326512</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2010 Sep;67(9):939-45</Citation><ArticleIdList><ArticleId IdType="pubmed">20819988</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2016 Jul 1;173(7):695-704</Citation><ArticleIdList><ArticleId IdType="pubmed">26892940</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2015 Oct;45(13):2691-704</Citation><ArticleIdList><ArticleId IdType="pubmed">26220802</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2015 Oct;207(4):283-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26429679</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2002 Sep;1(9):727-30</Citation><ArticleIdList><ArticleId IdType="pubmed">12209152</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2009 Jun;23(4):346-88</Citation><ArticleIdList><ArticleId IdType="pubmed">19329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2015 Aug 1;386(9992):461-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26003379</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2015 Jan;45(2):299-317</Citation><ArticleIdList><ArticleId IdType="pubmed">25036226</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2012 Oct;99(1):1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">22705413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Gen Psychiatry. 2015 Dec 01;14:42</Citation><ArticleIdList><ArticleId IdType="pubmed">26628905</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2013 Jun 27;346:f3646</Citation><ArticleIdList><ArticleId IdType="pubmed">23814104</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Pharmacother. 2012 Jun;13(8):1213-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22594849</ArticleId></ArticleIdList></Reference><Reference><Citation>J R Soc Interface. 2015 Nov 6;12(112):null</Citation><ArticleIdList><ArticleId IdType="pubmed">26577592</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2015 Jun;20(6):703-17</Citation><ArticleIdList><ArticleId IdType="pubmed">25733313</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Dec;169 Suppl 1:S17-23</Citation><ArticleIdList><ArticleId IdType="pubmed">25533910</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2015 Sep;68:76-82</Citation><ArticleIdList><ArticleId IdType="pubmed">26228404</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 May 8;157(4):858-68</Citation><ArticleIdList><ArticleId IdType="pubmed">24813609</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2015 Aug;47(8):856-60</Citation><ArticleIdList><ArticleId IdType="pubmed">26121088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2016 Feb 27;387(10021):823-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26972063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2016 Jan;3(1):31-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26687300</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 May;147(1-3):44-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23122529</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2015 Feb;29(2):85-96</Citation><ArticleIdList><ArticleId IdType="pubmed">25315827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 May 11;381(9878):1672-82</Citation><ArticleIdList><ArticleId IdType="pubmed">23663953</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2015 Nov;20(11):1406-19</Citation><ArticleIdList><ArticleId IdType="pubmed">25560763</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 Sep;128(3):194-202</Citation><ArticleIdList><ArticleId IdType="pubmed">23331090</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2015 Dec;72(12):1182-91</Citation><ArticleIdList><ArticleId IdType="pubmed">26535805</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2012 Jan;35(1):36-46</Citation><ArticleIdList><ArticleId IdType="pubmed">22217451</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2005 May 29;360(1457):1001-13</Citation><ArticleIdList><ArticleId IdType="pubmed">16087444</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2013 Aug;12(8):581-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23868113</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):5018-23</Citation><ArticleIdList><ArticleId IdType="pubmed">24639496</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2014 Mar 5;81(5):1203-13</Citation><ArticleIdList><ArticleId IdType="pubmed">24529980</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2016 Jan 1;79(1):62-70</Citation><ArticleIdList><ArticleId IdType="pubmed">26531027</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2016 Jan 15;16:7</Citation><ArticleIdList><ArticleId IdType="pubmed">26769120</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2014 Oct;75(10):1054-61</Citation><ArticleIdList><ArticleId IdType="pubmed">25099397</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Dec;17 (8):836-48</Citation><ArticleIdList><ArticleId IdType="pubmed">26547512</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3661786</PMID><DateCompleted><Year>1987</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>144</Volume><Issue>10</Issue><PubDate><Year>1987</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mania and head trauma.</ArticleTitle><Pagination><MedlinePgn>1378-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>C C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Shakoor</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006259" MajorTopicYN="N">Craniocerebral Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014474" MajorTopicYN="N">Unconsciousness</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3661786</ArticleId><ArticleId IdType="doi">10.1176/ajp.144.10.aj144101378</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">887159</PMID><DateCompleted><Year>1977</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>268</Volume><Issue>5618</Issue><PubDate><Year>1977</Year><Month>Jul</Month><Day>28</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Adoption study supporting genetic transmission in manic--depressive illness.</ArticleTitle><Pagination><MedlinePgn>327-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendlewicz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rainer</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000300" MajorTopicYN="N">Adoption</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012730" MajorTopicYN="N">Sex Chromosomes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1977</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1977</Year><Month>7</Month><Day>28</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1977</Year><Month>7</Month><Day>28</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">887159</ArticleId><ArticleId IdType="doi">10.1038/268327a0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4274803</PMID><DateCompleted><Year>1974</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0043-5384</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>1</Issue><PubDate><Year>1973</Year></PubDate></JournalIssue><Title>Wiener Zeitschrift fur Nervenheilkunde und deren Grenzgebiete</Title><ISOAbbreviation>Wien Z Nervenheilkd Grenzgeb</ISOAbbreviation></Journal><ArticleTitle>[Relationship between psychopathology and genetics in so-called late schizophrenias].</ArticleTitle><Pagination><MedlinePgn>1-11</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berner</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Beziehungen zwischen Psychopathologie und Genetik sogenannter "Spätschizophrenien".</VernacularTitle></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>Wien Z Nervenheilkd Grenzgeb</MedlineTA><NlmUniqueID>0414001</NlmUniqueID><ISSNLinking>0043-5384</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004777" MajorTopicYN="N">Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1973</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1973</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1973</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4274803</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>